From: <Salvato con Microsoft Internet Explorer 5>
Subject: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche : Nature
Date: Tue, 16 May 2006 19:43:23 +0200
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----=_NextPart_000_0048_01C67920.FE3CF540"
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2869

This is a multi-part message in MIME format.

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/nature/journal/v438/n7069/full/nature04186.html

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" =
"http://www.w3c.org/TR/1999/REC-html401-19991224/loose.dtd">
<HTML lang=3Den xml:lang=3D"en" =
xmlns=3D"http://www.w3.org/1999/xhtml"><HEAD><TITLE>VEGFR1-positive =
haematopoietic bone marrow progenitors initiate the pre-metastatic niche =
: Nature</TITLE>
<META http-equiv=3DContent-Style-Type content=3Dtext/css>
<META http-equiv=3DContent-Type content=3D"text/html; =
charset=3Diso-8859-1">
<META content=3Dnoarchive name=3Drobots><LINK=20
href=3D"http://www.nature.com/favicon.ico" rel=3D"shortcut icon"><LINK =
title=3Dhome=20
href=3D"/nature/" rel=3Dhome><LINK title=3Dcopyright =
href=3D"/nature/copyright/"=20
rel=3Dcopyright><LINK title=3Dhelp =
href=3D"/common/accessibility_statement.html"=20
rel=3Dhelp>
<META=20
content=3D"Nature, science, science news, biology, physics, genetics, =
astronomy, astrophysics, quantum physics, evolution, evolutionary =
biology, geophysics, climate change, earth science, materials science, =
interdisciplinary science, science policy, medicine, systems biology, =
genomics, transcriptomics, palaeobiology, ecology, molecular biology, =
cancer, immunology, pharmacology, development, developmental biology, =
structural biology, biochemistry, bioinformatics, computational biology, =
nanotechnology, proteomics, metabolomics, biotechnology, drug discovery, =
environmental science, life, marine biology, medical research, =
neuroscience, neurobiology, functional genomics, molecular interactions, =
RNA, DNA, cell cycle, signal transduction, cell signalling."=20
name=3Dkeywords>
<META=20
content=3D"Nature is the international weekly journal of science: a =
magazine style journal that publishes full-length research papers in all =
disciplines of science, as well as News and Views, reviews, news, =
features, commentaries, web focuses and more, covering all branches of =
science and how science impacts upon all aspects of society and life. "=20
name=3Ddescription><!-- HR: 2005-08-25 Replaced contents of file with =
pointer to master file in /common folder -->
<SCRIPT type=3Dtext/javascript><!--//--><![CDATA[//><!--
	var include =3D '';

	var wp =3D '157';
	if (wp !=3D '') include +=3D 'wp=3D'+wp;
	include +=3D ';';

	var rf =3D '7';
	if (rf !=3D '') include +=3D "rf=3D"+rf;
	include +=3D ';';
=09
	var sp =3D '75';
	if (sp !=3D '') include +=3D "sp=3D"+sp;
	include +=3D ";";
=09
	var ps =3D '10';
	if (ps !=3D '') include +=3D "ps=3D"+ps;
	include +=3D ";";
=09
	var adinf =3D "lg=3Dno;";

	if(include !=3D ";;;;")
	{
		adinf =3D include;
	}

	var time =3D new Date();
	ordval=3D (time.getTime());
//--><!]]></SCRIPT>
<!-- link rel=3D"stylesheet" href=3D"/common/style/no_standards.css" =
type=3D"text/css" media=3D"screen" / -->
<STYLE type=3Dtext/css media=3Dscreen>@import url( =
/common/style/layout.css );
@import url( /common/style/layout_wide_banner.css );
@import url( /common/style/main.css );
@import url( /common/style/header_footer_smallfonts.css );
@import url( /nature/style/site.css );
@import url( /common/style/restrict_width/930px.css );
</STYLE>
<LINK media=3Dprint =
href=3D"http://www.nature.com/common/style/print.css"=20
type=3Dtext/css rel=3Dstylesheet><!-- makes IE understand css =
declarations min/max-width and min/max-height -->
<SCRIPT src=3D"http://www.nature.com/common/scripts/minmax.js"=20
type=3Dtext/javascript></SCRIPT>

<META content=3D"MSHTML 6.00.2900.2873" name=3DGENERATOR></HEAD>
<BODY class=3Dwww-nature-com-nature id=3Darticle>
<DIV class=3Dclearfix id=3Dheader><!-- global links --><!-- header -->
<DIV id=3Dhead-er>
<DIV class=3Dheader-nonad-wrapper id=3Dtop>
<DIV class=3Daccessibility-login-wrap>
<DIV class=3Daccessibility-login><!--<a href=3D"/" =
class=3D"rollover"><img =
src=3D"/common/includes/header/images/nature.com.gif" alt=3D"Nature.com =
homepage" class=3D"nature-logo" /></a>--><A=20
class=3Dnature-link href=3D"http://www.nature.com/">nature.com<SPAN =
class=3Dhidden>=20
homepage</SPAN></A>=20
<UL class=3Djumplinks>
  <LI class=3Dfirst><A=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#content">Jump&nbsp;to&nbsp;main&nbsp;content</A>=20

  <LI><A=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#journalnav">Jump&nbsp;to&nbsp;navigation</A>=20
  </LI></UL>
<DIV class=3Dlogon>
<P>Welcome back: Giovanni Camporeale. <SPAN class=3Dhidden>- </SPAN><A=20
class=3Dlogoff title=3D"log out of Nature.com"=20
href=3D"http://www.nature.com/foxtrot/svc/logout">Logout<SPAN =
class=3Dhidden> of=20
nature.com </SPAN><!-- following space necessary for Mac IE --></A><SPAN =

class=3Donlyformacie>&nbsp;</SPAN></P></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV>
<HR>

<DIV class=3Dimage-user-services-wrap>
<DIV class=3Dimage-user-services><A =
href=3D"http://www.nature.com/nature/"><IMG=20
class=3Djournal-header alt=3D"Nature homepage"=20
src=3D"http://www.nature.com/nature/images/journal_header.gif"></A>=20
<DIV class=3D"user-services div1"><!-- whitespace removed to deal with =
IE 5.0 bug -->
<UL class=3Dlist1>
  <LI class=3Dli1><A href=3D"http://www.nature.com/myaccount/">My =
account</A>
  <LI class=3Dli2><A title=3D"sign up to receive Nature email alerts"=20
  =
href=3D"http://www.nature.com/nams/svc/myaccount/save/ealert?list_id=3D1"=
>E-alert=20
  sign up</A></LI></UL></DIV>
<DIV class=3D"user-services div2"><!-- whitespace removed to deal with =
IE 5.0 bug -->
<UL class=3Dlist2>
  <LI class=3Dli1><A title=3D"Register with Nature.com"=20
  href=3D"http://www.nature.com/register/">Register</A>
  <LI class=3Dli2><A title=3D"Subscribe to Nature"=20
  =
href=3D"https://secure.nature.com/subscribe/nature">Subscribe</A></LI></U=
L></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV>
<HR>

<DIV class=3D"publications-search-wrap clearfix">
<DIV class=3Dpublications-search>
<UL class=3Dpublications>
  <LI class=3Dfirst><A =
href=3D"http://www.nature.com/siteindex/">Publications A-Z=20
  index</A>
  <LI><A href=3D"http://www.nature.com/browse/">Browse by subject</A> =
</LI></UL>
<HR>

<DIV class=3Dsearch>
<FORM class=3Dsearch action=3Dhttp://search.nature.com/search/? =
method=3Dget>
<DIV><LABEL for=3Dsearchtext>Search</LABEL> <INPUT id=3Dsearchtext =
name=3Dsp-q> <INPUT=20
type=3Dhidden value=3Dcat name=3Dsp-x-9> <INPUT type=3Dhidden =
value=3Ddate name=3Dsp-s>=20
<SELECT name=3Dsp-q-9> <OPTION value=3DNature selected>This =
journal</OPTION>=20
  <OPTION value=3D"">All of Nature.com</OPTION></SELECT> <INPUT =
class=3Dbutton title=3D"search now" type=3Dsubmit value=3Dgo =
name=3Dsubmit> <A=20
href=3D"http://search.nature.com/search/?sp-a=3Dsp1001702d&amp;sp-t=3Dadv=
anced&amp;sp-x-1=3Dujournal&amp;sp-q-1=3DNature">Advanced&nbsp;search</A>=
=20
<INPUT type=3Dhidden value=3Dsp1001702d name=3Dsp-a> <INPUT =
type=3Dhidden=20
value=3Dsubject|ujournal name=3Dsp-sfvl-field> <INPUT type=3Dhidden =
value=3Dresults=20
name=3Dsp-t> <INPUT type=3Dhidden value=3Dujournal name=3Dsp-x-1> <INPUT =
type=3Dhidden=20
value=3Dphrase name=3Dsp-p-1> <INPUT type=3Dhidden value=3Dall =
name=3Dsp-p>=20
</DIV></FORM></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV></DIV></DIV><!-- leaderboard =
ad -->
<DIV class=3Dheader-leaderboard-wrap>
<DIV class=3Dheader-leaderboard>
<SCRIPT type=3Dtext/javascript><!--//--><![CDATA[//><!--
	ord=3DMath.random()*10000000000000000;
	document.write('<script type=3D"text/javascript" =
src=3D"http://ad.doubleclick.net/adj/nature.com/article;type=3Daf;artid=3D=
nature04186;date=3D200512;issue=3D7069;prod=3Dyes;subco=3D;chaco=3D;keywd=
=3D;njdis=3D;njreg=3D;crstg=3D;pos=3Dtop;sz=3D728x90;fidid=3D7;posid=3D10=
;plaid=3D157;maact=3D${dcFieldValue};prisp=3D75;secsp=3D${dcFieldValue};p=
roqu=3D${dcFieldValue};abr=3D!webtv;ord=3D' + ord + '?" ><\/script>');

	if ((!document.images && navigator.userAgent.indexOf('Mozilla/2.') >=3D =
0) || (navigator.userAgent.indexOf("WebTV") >=3D 0)) {
		document.write('<a =
href=3D"http://ad.doubleclick.net/jump/nature.com/keywd=3D;sz=3D728x90;or=
d=3D' + ord + '?">');
		document.write('<img =
src=3D"http://ad.doubleclick.net/ad/nature.com/keywd=3D;sz=3D728x90;ord=3D=
' + ord + '?" width=3D"728" height=3D"90" border=3D"0"></a>');
	}
//--><!]]></SCRIPT>
<NOSCRIPT>
<DIV><A=20
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Daf;artid=
=3Dnature04186;date=3D200512;issue=3D7069;prod=3Dyes;subco=3D;chaco=3D;ke=
ywd=3D;njdis=3D;njreg=3D;crstg=3D;pos=3Dtop;sz=3D728x90;fidid=3D7;posid=3D=
10;plaid=3D157;maact=3D${dcFieldValue};prisp=3D75;secsp=3D${dcFieldValue}=
;proqu=3D${dcFieldValue};abr=3D!NN2;ord=3D123456789?"><IMG=20
alt=3DAdvertisement=20
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Daf;artid=3D=
nature04186;date=3D200512;issue=3D7069;prod=3Dyes;subco=3D;chaco=3D;keywd=
=3D;njdis=3D;njreg=3D;crstg=3D;pos=3Dtop;sz=3D728x90;fidid=3D7;posid=3D10=
;plaid=3D157;maact=3D${dcFieldValue};prisp=3D75;secsp=3D${dcFieldValue};p=
roqu=3D${dcFieldValue};abr=3D!NN2;tile=3D1;ord=3D123456789?"></A></DIV></=
NOSCRIPT></DIV></DIV><!-- end leaderboard ad --><IMG=20
style=3D"BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 1px; HEIGHT: 14px; BORDER-RIGHT-WIDTH: =
0px"=20
alt=3D"" =
src=3D"http://www.nature.com/common/images/clear.gif"><BR></DIV><!-- end =
header --><!-- end global links --></DIV>
<DIV id=3Dconstrain>
<DIV class=3Dconstrain>
<DIV id=3Dbreadcrumb>
<DIV><A href=3D"http://www.nature.com/nature/index.html">Journal =
home</A><SPAN=20
class=3Ddivider> &gt; </SPAN><A=20
href=3D"http://www.nature.com/nature/archive/">Archive</A><SPAN =
class=3Ddivider>=20
&gt; </SPAN><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/index.html#af">Ar=
ticle</A><SPAN=20
class=3Ddivider> &gt; </SPAN><SPAN class=3Dthisitem>Full =
Text</SPAN></DIV></DIV>
<DIV id=3Dcontent-journalnav>
<DIV id=3Dcontent>
<H1 class=3Dpage-header>Article</H1>
<P id=3Dcite><I>Nature</I> <B>438</B>, 820-827 (8 December 2005) | <ABBR =

title=3D"Digital Object Identifier">doi</ABBR>:10.1038/nature04186</P>
<H2 id=3Datl>VEGFR1-positive haematopoietic bone marrow progenitors =
initiate the=20
pre-metastatic niche</H2>
<P id=3Daug>Rosandra N. Kaplan<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a6">6</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a10">10</A></SUP>,=20
Rebecca D. Riba<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a10">10</A></SUP>,=20
Stergios Zacharoulis<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a6">6</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a10">10</A></SUP>,=20
Anna H. Bramley<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A></SUP>,=20
Lo=EFc Vincent<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a4">4</A></SUP>,=20
Carla Costa<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A></SUP>,=20
Daniel D. MacDonald<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A></SUP>,=20
David K. Jin<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a4">4</A></SUP>,=20
Koji Shido<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a4">4</A></SUP>,=20
Scott A. Kerns<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A></SUP>,=20
Zhenping Zhu<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a8">8</A></SUP>,=20
Daniel Hicklin<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a8">8</A></SUP>,=20
Yan Wu<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a8">8</A></SUP>,=20
Jeffrey L. Port<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a5">5</A></SUP>,=20
Nasser Altorki<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a5">5</A></SUP>,=20
Elisa R. Port<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a7">7</A></SUP>,=20
Davide Ruggero<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a9">9</A></SUP>,=20
Sergey V. Shmelkov<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a4">4</A></SUP>,=20
Kristian K. Jensen<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A></SUP>,=20
Shahin Rafii<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a3">3</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a4">4</A></SUP>=20
and&nbsp;David Lyden<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a6">6</A></SUP></P>
<DIV id=3Dabs><A class=3D"backtotop hidden"=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3 class=3Dhidden>Abstract</H3>
<P class=3Dlead>The cellular and molecular mechanisms by which a tumour =
cell=20
undergoes metastasis to a predetermined location are largely unknown. =
Here we=20
demonstrate that bone marrow-derived haematopoietic progenitor cells =
that=20
express vascular endothelial growth factor receptor 1 (VEGFR1; also =
known as=20
Flt1) home to tumour-specific pre-metastatic sites and form cellular =
clusters=20
before the arrival of tumour cells. Preventing VEGFR1 function using =
antibodies=20
or by the removal of VEGFR1<SUP>+</SUP> cells from the bone marrow of =
wild-type=20
mice abrogates the formation of these pre-metastatic clusters and =
prevents=20
tumour metastasis, whereas reconstitution with selected Id3 (inhibitor =
of=20
differentiation 3)-competent VEGFR1<SUP>+</SUP> cells establishes =
cluster=20
formation and tumour metastasis in Id3 knockout mice. We also show that=20
VEGFR1<SUP>+</SUP> cells express VLA-4 (also known as integrin <IMG =
alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0><SUB>4</SUB><IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0><SUB>1</SUB>), and that tumour-specific growth factors =
upregulate=20
fibronectin=97a VLA-4 ligand=97in resident fibroblasts, providing a =
permissive niche=20
for incoming tumour cells. Conditioned media obtained from distinct =
tumour types=20
with unique patterns of metastatic spread redirected fibronectin =
expression and=20
cluster formation, thereby transforming the metastatic profile. These =
findings=20
demonstrate a requirement for VEGFR1<SUP>+</SUP> haematopoietic =
progenitors in=20
the regulation of metastasis, and suggest that expression patterns of=20
fibronectin and VEGFR1<SUP>+</SUP>VLA-4<SUP>+</SUP> clusters dictate=20
organ-specific tumour spread.</P></DIV>
<DIV id=3Darticlebody>
<P class=3Dnorm>Bone marrow-derived cells (BMDCs) contribute to =
malignant=20
transformation<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B1">1</A></SUP>,=20
tumour vascularization<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B2">2,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B3">3</A></SUP>=20
and neoplastic cell migration<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B4">4</A></SUP>.=20
Previously, we identified haematopoietic progenitor cells (HPCs) =
expressing=20
VEGFR1 that reside within specified niches of the bone marrow. During =
the=20
angiogenic switch, these cells proliferate and mobilize to the =
bloodstream along=20
with bone marrow-derived endothelial progenitor cells that express =
VEGFR2 (also=20
known as Flk1), and contribute to the vascularization and growth of =
specific=20
primary tumours<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B2">2,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B5">5</A></SUP>.=20
These myelomonocytic VEGFR1<SUP>+</SUP> cells localize to perivascular =
sites,=20
thus stabilizing tumour neo-vessels<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B2">2</A></SUP>.=20
These and other tumour-associated cells enhance primary tumour =
neo-angiogenesis=20
and growth, yet their precise contribution to metastasis is =
unclear<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B6">6,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B7">7,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B8">8</A></SUP>.=20
Therefore, the aim of this study was to determine the role of =
VEGFR1<SUP>+</SUP>=20
HPCs in the temporal and functional generation of metastasis.</P>
<DIV id=3D"BMDCs colonize pre-metastatic sites before tumour cells"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>BMDCs colonize pre-metastatic sites before tumour cells</H3>
<P class=3Dnorm>We analysed the fate of <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-galactosidase-positive (<IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP>) and green fluorescent protein-positive=20
(GFP<SUP>+</SUP>) BMDCs following intradermal primary tumour injection =
in mice.=20
Animals were inoculated with either Lewis lung carcinoma (LLC) cells, =
which=20
metastasize to the lungs and occasionally the liver, or B16 melanoma =
cells,=20
which possess a more widely disseminated metastatic potential. After=20
irradiation, but before tumour implantation, we observed minimal <IMG =
alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> BMDCs (mean <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> s.e.m., 0.01% <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.01 of cells <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field) or GFP<SUP>+</SUP> BMDCs =
in the=20
lungs. (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1a</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">b</A>,=20
left panels). By day 14 after tumour implantation, but before the =
arrival of=20
tumour cells, the extravasation and cluster formation of <IMG alt=3Dbeta =

src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> BMDCs (3.2% <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.2, <I>P</I> &lt; 0.05 by Student's =
<I>t</I>-test) or=20
GFP<SUP>+</SUP> BMDCs were detected near terminal bronchioles and distal =

alveoli, both common sites for future tumour metastasis (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1a</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">b</A>,=20
left middle panels and insets). On day 16, established <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> cell clusters dictated the contours of =
future=20
metastatic lesions (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1a</A>, right middle panel). Individual DsRed-tagged tumour cells, =
associated=20
with pre-existing BMDC clusters, were visible by day 18 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1b</A>, right middle panel) and progressed to micrometastases by day 23 =
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1a</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">b</A>,=20
right panels). <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> BMDCs were maintained within =
well-established tumour=20
metastases (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1a</A>, right panel and inset).</P>
<DIV class=3Dfigure-table id=3Df1>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F1.html">Figure=20
1:&nbsp;<B>Bone marrow-derived cells form the pre-metastatic=20
niche.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F1.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 1 : Bone marrow-derived cells form the pre-metastatic =
niche. Unfortunately we are unable to provide accessible alternative =
text for this. If you require assistance to access this image, or to =
obtain a text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/v438/n7069/images/nature04186=
-f1.0.jpg"></A>
<P class=3D""><B>a</B>, <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> bone marrow cells (left panel) are rarely =
observed in=20
lungs after irradiation and before LLC cell implantation (<I>n</I> =3D =
6). By day=20
14, <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> bone marrow-derived clusters appear in the =
lung=20
parenchyma (left middle panel and magnified inset of the region arrowed; =

<I>n</I> =3D 25) and are associated with micrometastases by day 23 =
(right panel,=20
arrows) and in gross metastases (right panel, inset; <I>n</I> =3D 12). =
Also shown=20
is a cluster with associated stroma between a terminal bronchiole and =
bronchial=20
vein, a common metastatic site (right middle panel). B, terminal =
bronchiole; V,=20
bronchial vein. <B>b</B>, GFP<SUP>+</SUP> bone marrow in the lungs after =

irradiation and before DsRed-tagged B16 cell implantation (left panel; =
<I>n</I>=20
=3D 6). On day 14, GFP<SUP>+</SUP> (green) BMDCs are seen with no=20
DsRed<SUP>+</SUP> (red) tumour cells (left middle panel and inset; =
<I>n</I> =3D=20
12). Beginning on day 18, a few single DsRed<SUP>+</SUP> B16 cells =
adhere to=20
GFP<SUP>+</SUP> bone marrow clusters (right middle panel), and by day =
23,=20
DsRed<SUP>+</SUP> tumour cells proliferate at cluster sites (right =
panel;=20
<I>n</I> =3D 8). DAPI stain (blue) shows cell nuclei. <B>c</B>, A graph =
showing=20
flow cytometric data of bone marrow-derived GFP<SUP>+</SUP> BMDCs and=20
DsRed<SUP>+</SUP> B16 cells in the lung, and two flow diagrams on day 14 =
(left=20
panel) and day 18 (right panel) (<I>n</I> =3D 30; error bars show =
s.e.m.).=20
<B>d</B>, GFP<SUP>+</SUP> BMDCs mobilized with B16 conditioned media, =
then=20
DsRed-tagged tumour cells injected through the tail vein adhere =
24&nbsp;h later=20
(right panel, arrows) compared with animals receiving media alone (left =
panel;=20
<I>P</I> &lt; 0.01). Inset shows proliferating tumour cells in a cluster =
after=20
four days (right panel inset; <I>n</I> =3D 6). <B>e</B>, Number of =
clusters per=20
<IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field in animals with =
intradermal LLC or B16=20
tumours (<I>n</I> =3D 12). Scale bar on top left panel applies to panels =
<B>a</B>=20
(left, left middle, right middle, 80&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; left middle inset, 8&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; right, 20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; right inset, 47&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m), <B>b</B> (left, left middle, 80&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; left middle inset, 8&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; right middle, right, 40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m) and <B>d</B> (40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; right inset, 20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m).</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F1.html">High=20
resolution image and legend (89K) </A>
<DIV class=3Dcleardiv><!-- clearing div --></DIV></DIV><BR =
class=3Dclear>
<P class=3Dnorm>To further define the timing of tumour cell arrival, a =
flow=20
cytometric study of the lungs was undertaken. Before day 8, minimal=20
GFP<SUP>+</SUP> BMDCs were observed in this tissue; however, from day =
12, BMDCs=20
began migrating into the lung (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1c</A>, graph and left flow cytometry panel). These GFP<SUP>+</SUP> =
cells=20
increased in number, and were joined by DsRed-tagged tumour cells by day =
18 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1c</A>, graph and right flow diagram). No tumour cells were detected by =
flow=20
cytometry or microscopy earlier than day 16, and increasing numbers of =
tumour=20
cells were identified over time (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1b</A>, right panels; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1c</A>; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 1a</A>). More than 95% of tumour cells co-clustered with =
GFP<SUP>+</SUP>=20
BMDCs (97% <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.1; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1b</A>, right panels).</P>
<P class=3Dnorm>Although a few tumour cells may have been undetectable =
using these=20
methodologies, further experiments in mice given =
B16-melanoma-conditioned media=20
(MCM) showed that this conditioning alone mobilized BMDCs that were =
capable of=20
forming a pre-metastatic niche. We introduced DsRed-tagged B16 tumour =
cells=20
intravenously into mice with pre-established GFP<SUP>+</SUP> BMDC =
clusters in=20
the lung after challenge with MCM (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1d</A>, right panel) or media alone (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1d</A>, left panel). MCM increased the number of tumour cells in the =
lung one=20
day after tumour injection compared with media alone (141.3 <IMG =
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 10.2 versus 2.7 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.6 tumour cells per section of lung tissue, =
<I>P</I>=20
&lt; 0.01). Four days after tumour injection, the frequency and size of =
the lung=20
nodules were augmented by MCM (207 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 5.6 versus 14 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.7, <I>P</I> &lt; 0.01; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1d</A>, right panel inset). Co-localization of DsRed-tagged tumour cells =
with=20
GFP<SUP>+</SUP> BMDC clusters was &gt;93% at both time points, =
indicating that=20
BMDCs assist tumour cell adhesion and proliferation. Therefore, factors =
provided=20
by the primary tumour induce BMDCs to enter the bloodstream and mobilize =
to=20
organ-specific pre-metastatic sites, and this migration precedes the =
arrival of=20
tumour cells.</P></DIV>
<DIV id=3D"Sites of BMDC clusters are tumour-type specific"><A =
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Sites of BMDC clusters are tumour-type specific</H3>
<P class=3Dnorm>We examined whether the type of tumour cell dictated =
BMDC=20
distribution to specific pre-metastatic sites. Intradermal injection of =
LLC=20
cells resulted in BMDC cluster formation limited to the lung (47.5 <IMG=20
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 2.6 clusters per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field) and liver (10.8 <IMG =
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.1) with no clusters in other organs (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1e</A>, left panel). In contrast, the B16 melanoma tumour cells induced =
the=20
formation of BMDC clusters in multiple tissues such as the lung (103.8 =
<IMG=20
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 6.9), liver (41.8 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 2.4), testis (36.6 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 3.1), spleen (25 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 3.2) and kidney (20.6 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.8), which are all common metastatic sites =
for this=20
tumour (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1e</A>, right panel). Furthermore, melanoma cells, consistent with their =
more=20
aggressive metastatic nature, induced more clusters than LLC cells =
(<I>P</I>=20
&lt; 0.01).</P></DIV>
<DIV id=3D"Recruited BMDCs consist of haematopoietic progenitors"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Recruited BMDCs consist of haematopoietic progenitors</H3>
<P class=3Dnorm>We characterized the cellular and molecular composition =
of=20
incorporated BMDC clusters. Clusters induced by either tumour type =
expressed=20
VEGFR1 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2a</A>, right panel), and GFP<SUP>+</SUP> BMDC clusters coexpressed =
VEGFR1 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2b</A>, left panel), compared with little VEGFR1 in the lung after =
irradiation=20
alone (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2a</A>, left panel and inset). Further characterization revealed that =
subsets of=20
VEGFR1<SUP>+</SUP> BMDCs coexpressed the stem/progenitor cell antigens =
CD133 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2b</A>, right panel), CD34 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 1b</A> and <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Table</A>) and CD117 (also known as c-Kit; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2c</A>), suggesting that these cells may comprise phenotypically marked=20
VEGFR1<SUP>+</SUP> HPCs and precursor cells. After primary tumour =
implantation,=20
CD117-positive progenitor cells arrived in the lung before GFP-tagged =
tumour=20
cells by flow cytometry (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 1c</A>), recapitulating the recruitment of BMDCs described above. =
There is=20
a degree of maturational heterogeneity, with the myelomonocytic marker =
CD11b=20
present on certain incorporated cells (data not shown). Early =
VEGFR1<SUP>+</SUP>=20
bone marrow clusters lacked expression of VEGFR2 and CD31 (also known as =
PECAM1;=20
<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 1d</A>, left and left middle panels, respectively). VEGFR2-positive =

circulating endothelial progenitor cells migrated to fully formed BMDC =
clusters=20
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 1d</A>, right panel), and coincided with the arrival of tumour =
cells (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 1e</A>, graph). Thus bone marrow-derived VEGFR1<SUP>+</SUP> HPCs =
initiate=20
and maintain the pre-metastatic niche.</P>
<DIV class=3Dfigure-table id=3Df2>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F2.html">Figure=20
2:&nbsp;<B>Pre-metastatic clusters are comprised of VEGFR1<SUP>+</SUP>=20
haematopoietic progenitors.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F2.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 2 : Pre-metastatic clusters are comprised of =
VEGFR1|[plus]| haematopoietic progenitors. Unfortunately we are unable =
to provide accessible alternative text for this. If you require =
assistance to access this image, or to obtain a text description, please =
contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/v438/n7069/images/nature04186=
-f2.0.jpg"></A>
<P class=3D""><B>a</B>, VEGFR1 staining in irradiated lung before tumour =

implantation (left panel and inset; <I>n</I> =3D 10) and 14 days after =
LLC cell=20
implantation showing clusters in the lung (right panel, arrows; <I>n</I> =
=3D 18,=20
3.9 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.2% cells with VEGFR1 staining per <IMG =
alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field, <I>P</I> &lt; 0.05). =
<B>b</B>,=20
<B>c</B>, Double immunofluorescence in the lung of an animal with day 14 =
LLC=20
tumour. <B>b</B>, VEGFR1<SUP>+</SUP> (red) and GFP<SUP>+</SUP> (green) =
bone=20
marrow cells (left panel), VEGFR1<SUP>+</SUP> (red) and =
CD133<SUP>+</SUP>=20
(green) (right panel). <B>c</B>, VEGFR1<SUP>+</SUP> (red) and =
CD117<SUP>+</SUP>=20
(green). <B>d</B>, VEGFR1<SUP>+</SUP> clusters in c-Myc transgenic lymph =
node at=20
day 40 of life and before tumorigenesis (middle panel and inset showing=20
VEGFR1<SUP>+</SUP> cells (red)) as compared with wild-type littermate =
lymph node=20
without the transgene (left panel), and day 120 c-Myc transgenic node =
with=20
lymphoma (right panel). In the inset of the right panel, arrows indicate =
the=20
VEGFR1<SUP>+</SUP> clusters (red) surrounded by lymphoma (green) =
(<I>n</I> =3D 6).=20
Scale bar at bottom right applies to panels <B>a</B> (80&nbsp;<IMG =
alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; left inset, 40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m), <B>b</B> (20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m), <B>c</B> (20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m) and <B>d</B> (80&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; insets, 8&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m).</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F2.html">High=20
resolution image and legend (62K) </A>
<DIV class=3Dcleardiv><!-- clearing div --></DIV></DIV><BR =
class=3Dclear></DIV>
<DIV id=3D"BMDC clusters occur in a spontaneous tumour model"><A =
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>BMDC clusters occur in a spontaneous tumour model</H3>
<P class=3Dnorm>We compared these findings to those in a spontaneous =
tumour model=20
using c-Myc transgenic mice. On day 40 of life, prominent =
VEGFR1<SUP>+</SUP>=20
clusters were detected exclusively in the lymph nodes of these animals =
before=20
the onset of lymphoma (145.1 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 16.4 clusters per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2d</A>, middle panel and inset), with no observed clusters in wild-type=20
littermates (0.4 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.3, <I>P</I> &lt; 0.001; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2d</A>, left panel). By 120 days, VEGFR1<SUP>+</SUP> clusters persisted =
in=20
established lymphomas (67.8 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 9.5 versus 0.7 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.5 in c-Myc mice versus littermates, =
<I>P</I> &lt;=20
0.001; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2d</A>, right panel and inset). The lymphoma cells, which surrounded the =

VEGFR1<SUP>+</SUP> HPCs, did not express VEGFR1 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f2">Fig.=20
2d</A>, right panel inset).</P></DIV>
<DIV id=3D"BMDC clusters are recruited to pre-metastasic human =
tissue"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>BMDC clusters are recruited to pre-metastasic human tissue</H3>
<P class=3Dnorm>To validate the mouse data showing tumour-specific =
formation of=20
VEGFR1<SUP>+</SUP> cellular clusters, we analysed human tissues from =
patients=20
with malignancy. VEGFR1<SUP>+</SUP> clusters were observed in both =
primary=20
tumours and metastatic tissue (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f3">Fig.=20
3</A>, showing breast carcinoma in an axillary lymph node, lung =
carcinoma and=20
oesophageal carcinoma). There were increased cellular clusters in common =
sites=20
of metastasis before tumour spread, suggesting the potential of this =
tissue as a=20
future site for metastasis (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f3">Fig.=20
3</A>, showing axillary lymph node (21 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 5 clusters per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field), lung (19 <IMG =
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 4) and gastro-oesophageal junction (25 <IMG =
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 4)). In patients without malignancy, lymph =
nodes and lung=20
tissue did not show VEGFR1<SUP>+</SUP> clusters (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f3">Fig.=20
3b</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f3">d</A>,=20
insets). VEGFR1<SUP>+</SUP> cellular clusters expressed the =
haematopoietic=20
progenitor marker c-Kit (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f3">Fig.=20
3e</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f3">f</A>,=20
insets).</P>
<DIV class=3Dfigure-table id=3Df3>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F3.html">Figure=20
3:&nbsp;<B>Expression of VEGFR1 in pre-metastatic human =
tissue.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F3.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 3 : Expression of VEGFR1 in pre-metastatic human tissue. =
Unfortunately we are unable to provide accessible alternative text for =
this. If you require assistance to access this image, or to obtain a =
text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/v438/n7069/images/nature04186=
-f3.0.jpg"></A>
<P class=3D""><B>a</B>=96<B>f</B>, Cellular clusters stained with VEGFR1 =
in=20
malignant and non-malignant tissues in individuals with breast (<I>n</I> =
=3D 15),=20
lung (<I>n</I> =3D 15) and gastrointestinal (<I>n</I> =3D 3) cancers. =
Lymph node=20
with evidence of breast adenocarcinoma metastasis (<B>a</B>, red arrows =
indicate=20
tumour) and lymph node without malignancy from same patient (<B>b</B>). =
Primary=20
lung adenocarcinoma (<B>c</B>) and adjacent 'normal' lung without =
neoplasm=20
(<B>d</B>, red arrows indicate VEGFR1<SUP>+</SUP> cells). No =
VEGFR1<SUP>+</SUP>=20
clusters were seen in lymph node (<B>b</B>, inset; <I>n</I> =3D 6) and =
lung tissue=20
(<B>d</B>, inset; <I>n</I> =3D 3) from individuals without cancer. Also =
shown is a=20
primary adenosquamous carcinoma of the gastro-oesophageal junction =
(<B>e</B>),=20
and a hepatic lymph node without carcinoma (<B>f</B>). Insets in =
<B>e</B>,=20
<B>f</B>, show co-immunofluorescence of VEGFR1 (red) and c-Kit (green). =
Scale=20
bar at bottom right applies to all panels (40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; insets, 40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m).</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F3.html">High=20
resolution image and legend (183K) </A>
<DIV class=3Dcleardiv><!-- clearing div --></DIV></DIV><BR =
class=3Dclear></DIV>
<DIV id=3D"Functional role for VEGFR1|[plus]| BMDCs in directing =
metastasis"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Functional role for VEGFR1<SUP>+</SUP> BMDCs in directing =
metastasis</H3>
<P class=3Dnorm>We assessed the potential of purified VEGFR1<SUP>+</SUP> =
bone=20
marrow cells to initiate pre-metastatic clusters by selectively =
transplanting=20
these progenitors into irradiated mice. By day 24 after LLC tumour cell=20
implantation, control mice that received wild-type bone marrow showed =
prominent=20
lung metastases and established blood vessels (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4a</A>, left panel and inset). However, mice transplanted with purified=20
VEGFR1<SUP>+</SUP> cells formed numerous micrometastases throughout the =
lungs=20
(25 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 9 micrometastases per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4a</A>, middle panel) with aberrant vasculature (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4a</A>, middle panel inset). In contrast, bone marrow depleted of=20
VEGFR1<SUP>+</SUP> cells failed to produce pre-metastatic clusters (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4a</A>, right panel; <I>P</I> &lt; 0.01 by analysis of variance =
(ANOVA)). These=20
results suggest that the VEGFR1<SUP>+</SUP> HPCs initiating the =
pre-metastatic=20
cluster can attract tumour cells.</P>
<DIV class=3Dfigure-table id=3Df4>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F4.html">Figure=20
4:&nbsp;<B>Inhibition of homing of bone marrow cells prevents=20
metastasis.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F4.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 4 : Inhibition of homing of bone marrow cells prevents =
metastasis. Unfortunately we are unable to provide accessible =
alternative text for this. If you require assistance to access this =
image, or to obtain a text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/v438/n7069/images/nature04186=
-f4.0.jpg"></A>
<P class=3D""><B>a</B>, VEGFR1<SUP>+</SUP>-selected bone marrow (R1-pos) =
permits=20
micrometastasis (red arrows, middle panel) but prevents =
well-vascularized large=20
metastases as seen in wild types (left panel), 24 days after LLC =
implantation.=20
Insets show CD31 (endothelial marker) expression. Bone marrow depleted =
of=20
VEGFR1<SUP>+</SUP> cells (non-R1) abrogates both clusters and metastases =
(right=20
panel) (<I>P</I> &lt; 0.01 by ANOVA). The table shows the number of =
clusters and=20
micrometastases per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field. *denotes that the =
metastasis filled=20
the lung. (R1-pos, <I>n</I> =3D 4; non-R1, <I>n</I> =3D 4; wild type, =
<I>n</I> =3D 6;=20
non-R1 plus wild type, <I>n</I> =3D 4). <B>b</B>, Treatment with =
antibodies to=20
VEGFR1 (anti-R1) and VEGFR2 (anti-R2) in mice with LLC tumours prevents =
both=20
clusters and metastases (<I>P</I> &lt; 0.01 by ANOVA; for all groups, =
<I>n</I> =3D=20
5). Arrows in the lung of the wild type denote a large LLC metastasis. =
Arrows in=20
anti-R2 show a cluster, inset shows a micrometastasis within a cluster. =
T,=20
tumour cells. The table shows the number of clusters and LLC =
micrometastases in=20
lung per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field. *denotes that the =
metastasis filled=20
the tissue. Scale bar at bottom right applies to panels <B>a</B> =
(20&nbsp;<IMG=20
alt=3Dmicro =
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>m; wild type inset, 26&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; R1-pos inset, 32&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m) and <B>b</B> (40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; anti-R2 inset, 20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m).</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F4.html">High=20
resolution image and legend (69K) </A>
<DIV class=3Dcleardiv><!-- clearing div --></DIV></DIV><BR =
class=3Dclear>
<P class=3Dnorm>To address whether disruption of VEGFR1<SUP>+</SUP> =
cellular=20
cluster formation could block the metastasis of well-established =
tumours, mice=20
inoculated with LLC or B16 tumour cells were treated with monoclonal =
antibodies=20
against VEGFR1 and/or VEGFR2. This approach allows for selective =
targeting of=20
the BMDCs, as the tumour cells do not express either VEGFR1 or VEGFR2. =
By day=20
24, widespread metastases were evident in untreated mice with LLC =
tumours in the=20
lung (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4b</A>, left panel) or B16 tumours in the spleen (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 2</A>, left panel and inset). Anti-VEGFR1 antibody treatment =
eliminated the=20
initiating clusters and completely prevented metastasis (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4b</A>, left middle panel; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 3</A>; <I>P</I> &lt; 0.01 by ANOVA), whereas anti-VEGFR2 antibody =
did not=20
prevent the formation of VEGFR1<SUP>+</SUP> clusters but limited =
metastatic=20
progression (15 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 11 micrometastases per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective field; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f4">Fig.=20
4b</A>, right middle panel and inset; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 3</A>). The two antibodies combined blocked cluster formation to an =
extent=20
similar to anti-VEGFR1 therapy; however, we did observe an isolated LLC =
lesion=20
in the lung of one animal (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 3b</A>, inset). Collectively, these results suggest that targeting =
the=20
VEGFR1<SUP>+</SUP> cell cluster can prevent tumour cell adhesion, =
proliferation=20
and metastatic spread.</P></DIV>
<DIV id=3D"VLA-4, MMP9 and Id3 mediate the pre-metastatic niche"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>VLA-4, MMP9 and Id3 mediate the pre-metastatic niche</H3>
<P class=3Dnorm>We investigated the cellular and molecular mechanisms by =
which=20
migratory HPCs, through interaction with the microenvironment, form =
permissive=20
pre-metastatic niches. The interaction of VLA-4 (integrin <IMG =
alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0><SUB>4</SUB><IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0><SUB>1</SUB>) with its ligand fibronectin is essential for =
the=20
migration of haematopoietic cells within the bone marrow<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B9">9,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B10">10</A></SUP>=20
and of circulating leukocytes<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B4">4,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B11">11</A></SUP>.=20
We assessed whether VEGFR1<SUP>+</SUP> cells express integrins, which =
may=20
facilitate the interaction of this cell type with the pre-metastatic =
niche. We=20
found that VEGFR1<SUP>+</SUP> HPCs at the pre-metastatic cluster express =
VLA-4=20
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5a</A>, and inset showing coexpression with VEGFR1), suggesting that =
VLA-4=20
allows for the adhesion of the BMDCs that form the pre-metastatic niche. =

Following cluster formation, <IMG alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0><SUB>4</SUB><IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0><SUB>7</SUB> and <IMG alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0><SUB>6</SUB><IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0><SUB>4</SUB> integrins were prominently expressed within the =
metastatic=20
niche (data not shown). Proteinases including matrix metalloproteinase 9 =
(MMP9),=20
produced by haematopoietic cells, can serve to break down basement =
membranes,=20
thus altering the local microenvironments by releasing soluble =
Kit-ligand and=20
VEGF-A to support newly introduced cells that express c-Kit<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B12">12,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B13">13</A></SUP>.=20
In addition, metalloproteinase expression can be enhanced through <IMG =
alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0><SUB>4</SUB><IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0><SUB>1</SUB> signalling after fibronectin binding<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B14">14,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B15">15</A></SUP>.=20
MMP9 was expressed in pre-metastatic clusters, and this upregulation of =
MMP9=20
expression may be a result of integrin binding and activation in=20
VEGFR1<SUP>+</SUP> HPCs (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5b</A>). These findings expand upon previous work demonstrating that=20
VEGFR1-mediated induction of MMP9 directed metastasis to the =
lungs<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B7">7</A></SUP>.</P>
<DIV class=3Dfigure-table id=3Df5>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F5.html">Figure=20
5:&nbsp;<B>The VLA-4/fibronectin pathway mediates cluster=20
formation.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F5.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 5 : The VLA-4/fibronectin pathway mediates cluster =
formation. Unfortunately we are unable to provide accessible alternative =
text for this. If you require assistance to access this image, or to =
obtain a text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/v438/n7069/images/nature04186=
-f5.0.jpg"></A>
<P class=3D""><B>a</B>=96<B>c</B>, Wild-type mice 14 days after tumour =
implantation=20
develop clusters expressing VLA-4 (inset, VEGFR1 (red) and VLA-4 =
(green)), MMP9=20
and Id3 (inset, VEGFR1 (red) and Id3 (green)). <B>d</B>, Lung tissue in =
Id3=20
knockout (KO) mice with LLC tumours given =
VEGFR1<SUP>+</SUP>GFP<SUP>+</SUP>=20
BMDCs (<I>P</I> &lt; 0.01 by ANOVA; <I>n</I> =3D 6). Green arrows show =
region in=20
upper inset. Red arrows (lower inset) show the site of metastasis with=20
GFP<SUP>+</SUP>VEGFR1<SUP>+</SUP> cells. <B>e</B>, Baseline fibronectin=20
expression in the wild-type lung (<I>n</I> =3D 6) (left panel). =
Increased stromal=20
fibronectin in the peribronchial region of the pre-metastatic lung at =
day three=20
(middle panel, arrows), with maximal expression on day 14 (right panel). =
Insets,=20
PDGRF<IMG alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0> expression indicates resident fibroblasts laying down =
fibronectin.=20
<B>f</B>, Quantitative RT=96PCR reveals increased fibronectin expression =
in the=20
lungs of mice with LLC tumours compared with wild type (*<I>P</I> &lt; =
0.05 by=20
ANOVA; <I>n</I> =3D 6), and a similar earlier trend in lungs from =
animals with B16=20
melanoma. Scale bar at top right applies to panels <B>a</B>, <B>b</B>, =
<B>c</B>=20
(40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; insets, 8&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m), <B>d</B> (80&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; top right inset, 20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; bottom right inset 80&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m) and <B>e</B> (40&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; insets, 20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m).</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F5.html">High=20
resolution image and legend (57K) </A>
<DIV class=3Dcleardiv><!-- clearing div --></DIV></DIV><BR =
class=3Dclear>
<P class=3Dnorm>We previously showed that upregulation of Id gene =
expression is=20
critical for the mobilization of progenitors that aid the growth of =
primary=20
tumours<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B15">15</A></SUP>.=20
Id3 expression was also seen within the clusters (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5c</A>, and inset showing coexpression with VEGFR1). Id3 may facilitate =
the=20
mobilization of VEGFR1<SUP>+</SUP> cells to the pre-metastatic niche. In =

addition, expression of specific integrins is regulated by Id genes, and =
may be=20
responsible for BMDC and stromal cell interactions, motility and=20
recruitment<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B16">16</A></SUP>.</P>
<P class=3Dnorm>To confirm the functional roles of these proteins in =
establishing=20
the pre-metastatic niche, we either inhibited the expression of VLA-4 =
(with=20
anti-integrin <IMG alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0>4 antibodies) or studied VEGFR1<SUP>+</SUP> cell cluster =
formation in=20
MMP9 and Id3 knockout mice. In these models, we found reduced cluster =
formation=20
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 3a=96c</A>) and metastatic spread three weeks after tumour =
implantation. We=20
also found impaired mobilization of VEGFR1<SUP>+</SUP> HPCs into the =
circulation=20
of Id3 knockout mice compared to wild type (654 versus 3,283=20
VEGFR1<SUP>+</SUP>CD11b<SUP>+</SUP> cells&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>l<SUP>-1</SUP>) in response to tumour inoculation (<I>P</I> =
&lt; 0.01=20
by Student's <I>t</I>-test; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Table</A>). Decreased mobilization of HPCs may explain the reduced =
metastatic=20
phenotype seen in these animals<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B2">2,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B17">17</A></SUP>.</P>
<P class=3Dnorm>To formally examine the potential of wild-type =
VEGFR1<SUP>+</SUP>=20
cells to restore the metastatic defect in Id3 knockout mice, =
Id3-competent=20
GFP<SUP>+</SUP>VEGFR1<SUP>+</SUP> HPCs were injected intravenously into =
Id3=20
knockout tumour-bearing mice. VEGFR1<SUP>+</SUP> HPCs alone =
re-established=20
cluster formation and micrometastases by day 21 after tumour =
implantation (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5d</A>, and upper inset; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 3c</A>). Notably, the LLC metastatic lesions were associated with=20
GFP<SUP>+</SUP> BMDCs (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5d</A>, lower inset). These findings further emphasize the functional =
role of=20
VEGFR1<SUP>+</SUP> BMDCs in the establishment of clusters and=20
metastasis.</P></DIV>
<DIV id=3D"Fibronectin upregulation supports adhesion of VLA-4|[plus]| =
BMDCs"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Fibronectin upregulation supports adhesion of VLA-4<SUP>+</SUP> =
BMDCs</H3>
<P class=3Dnorm>We next investigated the potential of tissue-specific =
ligands to=20
support the adhesion and formation of BMDC clusters. Following the =
implantation=20
of LLC tumour cells, but before the homing of the=20
VLA-4<SUP>+</SUP>VEGFR1<SUP>+</SUP> BMDCs, increased fibronectin =
expression was=20
observed from day 3 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5e</A>, middle panel; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5f</A>) to day 14 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5e</A>, right panel; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5f</A>) in the vicinity of the future metastatic niche, compared with =
the=20
baseline level of fibronectin expression in wild-type lung (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5e</A>, left panel; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5f</A>). Furthermore, resident fibroblast-like stromal cells (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5e</A>, left panel inset), which proliferate in response to primary =
tumour (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f5">Fig.=20
5e</A>, right panel inset), may contribute to the localized deposition =
of=20
fibronectin. Melanoma cells also induced fibronectin expression in the =
lung in a=20
similar fashion to that of LLC cells (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 3d</A>). Moreover, increased fibronectin expression was notable in =
multiple=20
tissues exposed to MCM, such as the intestine and oviduct, consistent =
with the=20
more aggressive metastatic nature of B16 cells (fibronectin expression: =
<I>P</I>=20
&lt; 0.05 days 3=965 and <I>P</I> &lt; 0.001 days 7=969 (by ANOVA) in =
oviducts (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6a</A>) and intestines (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6b</A>) with MCM treatment compared with mice treated with =
LLC-conditioned media=20
(LCM) or wild-type mice).</P>
<DIV class=3Dfigure-table id=3Df6>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F6.html">Figure=20
6:&nbsp;<B>Redirection of LLC metastases to atypical =
sites.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F6.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 6 : Redirection of LLC metastases to atypical sites. =
Unfortunately we are unable to provide accessible alternative text for =
this. If you require assistance to access this image, or to obtain a =
text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/v438/n7069/images/nature04186=
-f6.0.jpg"></A>
<P class=3D""><B>a</B>, <B>b</B>, By quantitative RT=96PCR analysis, =
increased=20
fibronectin expression was seen in the oviduct (<B>a</B>) and intestine=20
(<B>b</B>) in mice given MCM compared with wild-type and LCM-treatment. =
For=20
oviduct, *<I>P</I> &lt; 0.05 at days 3=965 and **<I>P</I> &lt; 0.001 for =
days 7=969=20
compared with wild type, and for intestine, *<I>P</I> &lt; 0.001 at days =
7=969=20
compared with wild type by ANOVA (<I>n</I> =3D 6)<B>.</B> <B>c</B>, =
ELISA assay=20
(in triplicate) for VEGF and PlGF levels in the conditioned media =
(*<I>P</I>=20
&lt; 0.05 when compared with L-LCM, **<I>P</I> &lt; 0.01 when compared =
with=20
media alone, by ANOVA). <B>d</B>, Transwell migration assays (in =
triplicate)=20
demonstrate enhanced migration of VEGFR1<SUP>+</SUP> cells to LCM and =
MCM=20
(**<I>P</I> &lt; 0.001 by ANOVA). <B>e</B>, Treatment with MCM redirects =
the=20
metastatic spread of LLC to B16 melanoma metastatic sites, such as the =
spleen=20
(left panel), kidney (left middle panel), intestine (right middle panel) =
and=20
oviduct (right panel). Arrows denote the regions of metastatic borders, =
which=20
are shown in the insets (<I>n</I> =3D 6). T, LLC tumour cells. Scale bar =
at bottom=20
right applies to panel <B>e</B> (200&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m; insets, 20&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m).</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_F6.html">High=20
resolution image and legend (40K) </A>
<DIV class=3Dcleardiv><!-- clearing div --></DIV></DIV><BR =
class=3Dclear></DIV>
<DIV id=3D"VEGFR1|[plus]| cells promote tumour adherence and growth"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>VEGFR1<SUP>+</SUP> cells promote tumour adherence and growth</H3>
<P class=3Dnorm>To confirm that VEGFR1<SUP>+</SUP> progenitors promote =
the=20
chemoattraction and attachment of circulating tumour cells, we isolated =
and red=20
fluorescence-labelled (PKH26-Gl) VEGFR1<SUP>+</SUP> cells from mice with =

malignancy (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 4</A>). Within one hour of <I>in vitro</I> co-incubation with green =

fluorescence-labelled (PKH2-GL) B16 or LLC cells, the HPCs aggregated,=20
proliferated (150% increase) and promoted the attachment and =
proliferation of=20
the tumour cells. In contrast, preculturing VEGFR1<SUP>+</SUP> HPCs with =
either=20
anti-VEGFR1 or anti-VLA-4 antibodies blocked this binding affinity and =
expansion=20
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 4a</A>, middle and right panels). Using a transwell migration =
assay, tumour=20
cells manifested enhanced mobility in response to bone marrow-derived=20
VEGFR1<SUP>+</SUP> cells (29.6 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.4 tumour cells per <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>200 objective field) as compared to cells that =
do not=20
express VEGFR1 (11.2 <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.4) and media alone (9.9 <IMG =
alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.9, <I>P</I> &lt; 0.001 by ANOVA; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 4b</A>). The SDF-1/CXCR4 chemokine axis participates in homing and=20
retention of HPCs within the bone marrow<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B18">18</A></SUP>.=20
Specific tumour cell types, which express CXCR4, may also migrate in =
this=20
fashion in response to local chemokine gradients<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B19">19,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B20">20,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B21">21</A></SUP>.=20
Within the fully formed pre-metastatic cluster containing =
VEGFR1<SUP>+</SUP>=20
cells, fibroblasts and fibronectin (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f1">Fig.=20
1a</A>, left middle panel), SDF-1 (also known as CXCL12) became highly =
expressed=20
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 4c</A>). We also observed CXCR4 expression in B16 melanoma and LLC =
tumours=20
(<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 4d</A>). These data suggest that SDF-1 may provide one pathway for=20
attracting CXCR4<SUP>+</SUP> tumour cells to the pre-metastatic =
niche.</P></DIV>
<DIV id=3D"Tumour-derived conditioned media dictate metastatic =
patterns"><A=20
class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Tumour-derived conditioned media dictate metastatic patterns</H3>
<P class=3Dnorm>To delineate the mechanism of the organ-specific =
metastatic=20
potential of LLC and B16 cells, we collected culture-derived conditioned =
media.=20
Similarly, but more rapidly than primary LLC cells, the intraperitoneal=20
injection of LCM generated fibronectin expression, possibly from =
resident=20
fibroblasts, and BMDC cluster formation (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5a</A>) compared with media alone (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5a</A>, insets). MCM stimulated fibronectin expression to a greater =
extent=20
in liver than LCM (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5b</A>). MCM caused enhanced fibroblast proliferation (data not =
shown) and=20
fibronectin expression with cluster formation in a wide range of organs, =
as=20
shown for intestine (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6a</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">b</A>;=20
<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5b</A>) in comparison to media (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5b</A>, inset). We analysed LCM and MCM for variations in growth =
factors to=20
account for the distinct metastatic potentials and profiles of LLC and =
B16 (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6c</A>). We found high levels of VEGF in both conditioned media, more =
than in=20
plasma from tumour-bearing mice (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5c</A>). However, in MCM and melanoma-derived plasma we =
specifically=20
detected higher levels of placental growth factor (PlGF), which signals =
though=20
VEGFR1 alone, as compared with LCM- and LLC-derived plasma (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6c</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5c</A>). Furthermore, in the low-metastatic-variant of LLC, levels =
of both=20
VEGF and PlGF were much lower in the conditioned media (L-LCM) and =
plasma=20
compared with its more aggressive counterpart (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6c</A>, <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Fig. 5c</A>). In a transwell assay, LCM and MCM enhanced the migration =
of=20
VEGFR1<SUP>+</SUP> BMDCs most effectively when compared with the other =
growth=20
factor conditions (LCM 55% <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 0.4, MCM 68.1% <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 5, media 10.8% <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> 1.7, <I>P</I> &lt; 0.001 by ANOVA; <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6d</A>). Considering these results, we questioned whether cytokines such =
as PlGF=20
present in MCM were capable of redirecting LLC metastases to =
non-conventional=20
metastatic sites for this tumour. MCM given before intradermal LLC =
implantation,=20
and daily thereafter, resulted in the redirection of LLC metastasis from =
lung to=20
those sites frequently observed in melanoma including kidney, spleen, =
intestine=20
and oviduct (<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#f6">Fig.=20
6e</A>). Our results demonstrate that tumour-specific chemokines and/or=20
cytokines present in conditioned media, along with the =
VEGFR1<SUP>+</SUP>=20
cellular clusters, are another determinant in the multidimensional =
programme=20
driving metastatic spread.</P>
<P class=3Dnorm>The precise cellular and molecular mechanisms that =
dictate=20
metastasis of a specific tumour to a predetermined metastatic location =
are not=20
known. Many tumours have a predilection for metastasis to specific =
organs. Based=20
on the current dogma, metastatic predisposition is believed to reflect =
inherent=20
molecular differences in tumour cells themselves and the potential =
influence by=20
surrounding stromal cells, which include the vasculature, connective =
tissue and=20
immune cells<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B22">22,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B23">23,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B24">24,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B25">25,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B26">26</A></SUP>.=20
Our results introduce the concept that tumour metastasis is initiated by =
a=20
well-defined sequence of events dependent on cellular 'bookmarking' =
through=20
site-specific delivery of VEGFR1<SUP>+</SUP> cells to form permissive =
niches=20
within target organs. Our data suggest that differences in =
tumour-secreted=20
humoral factors promote metastatic spread in specific distant organs. =
Within=20
days following tumour implantation, fibronectin becomes upregulated in =
certain=20
locations by resident fibroblast and fibroblast-like cells within target =
organs=20
that are conventional sites of metastasis, corresponding to the =
particular=20
primary tumour. Simultaneously, HPCs exit the bone marrow into the =
peripheral=20
circulation as previously described<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B11">11</A></SUP>.=20
As a result of the niche-specific directional cues from fibronectin,=20
VEGFR1<SUP>+</SUP> HPCs, expressing VLA-4 and Id3, can traverse =
established=20
endothelium to form a pre-metastatic niche before the arrival of=20
CXCR4<SUP>+</SUP> tumour cells and VEGFR2<SUP>+</SUP> endothelial cells. =
These=20
clusters, with MMP9 production altering the microenvironment and =
enhanced=20
expression of SDF-1 creating a chemokine gradient, permit the attraction =
of=20
tumour cells and their incorporation into the niche, thereby developing =
a=20
complete metastatic lesion. We show that inhibition by a VEGFR1 antibody =
or=20
depletion of VEGFR1<SUP>+</SUP> cells from the bone marrow prevents the=20
formation of pre-metastatic clusters and, therefore, metastases. =
Moreover,=20
blocking either VEGFR1 or VLA-4 inhibits the binding and establishment =
of the=20
haematopoietic cell clusters and tumour cells. Restoration of the =
pre-metastatic=20
niche and metastasis with the introduction of wild-type =
VEGFR1<SUP>+</SUP> cells=20
into Id3 knockout mice suggests that the expression of Id3 induces =
expression of=20
the necessary elements, including MMP9, integrins and possibly =
chemokines, to=20
provide a road map for the homing of VEGFR1<SUP>+</SUP> cells essential =
for the=20
establishment of the pre-metastatic niche.</P>
<P class=3Dnorm>Much focus has been placed on the role of inflammatory =
cells in=20
aiding in tumour adherence and invasion into distant organs<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B27">27,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B28">28,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B29">29,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B30">30</A></SUP>.=20
The VEGFR1<SUP>+</SUP> HPCs identified in this study show =
characteristics common=20
to physiological pathways of inflammation by providing the necessary =
adhesion=20
molecules, proteinases, chemokines and growth conditions to create a =
conducive=20
microenvironment for engraftment of tumour cells<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B12">12,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B20">20,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B31">31</A></SUP>.=20
The pre-metastatic niche, however, is distinct, introducing an =
undifferentiated=20
state as seen with the VEGFR1<SUP>+</SUP> HPC population. This is the =
first=20
direct evidence that a non-neoplastic cell population can portend a =
future=20
metastatic site. Furthermore, identification of haematopoietic clusters =
in human=20
tissues before evidence of tumour spread demonstrates the applicability =
of=20
targeting VEGFR1 and VLA-4 to identify and prevent metastasis in the =
clinical=20
setting. This concept will have a tremendous impact on tumour staging, =
and may=20
alter the landscape of adjuvant chemotherapy.</P></DIV>
<DIV id=3DMethods><A class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Methods</H3>
<DIV id=3D"Bone marrow transplantation">
<H4 class=3Dnorm>Bone marrow transplantation</H4>
<P class=3Dfollows-h4>Wild-type C57Bl/6 mice were lethally irradiated=20
(950&nbsp;rads) and transplanted with 1 <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 10<SUP>6</SUP> <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal<SUP>+</SUP> bone marrow cells (from Rosa26 mice) or 1 =
<IMG=20
alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 10<SUP>6</SUP> GFP<SUP>+</SUP> bone marrow =
cells (from=20
EGFP-transgenic mice, <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p1">C57Bl/6-TgN(ActbEGFP)1Osb/J</A>;=20
Jackson Laboratory)<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B2">2</A></SUP>.=20
After 4 weeks, mice were injected intradermally in the flank with either =
2 <IMG=20
alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 10<SUP>6</SUP> <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p2">LLC</A>=20
or <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p3">B16</A>=20
cells (American Type Culture Collection).</P></DIV>
<DIV id=3D"Selective bone marrow transplantation">
<H4 class=3Dnorm>Selective bone marrow transplantation</H4>
<P class=3Dfollows-h4>Mice irradiated as described above received a bone =
marrow=20
transplant from purified cell populations obtained as described in the =
<A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Methods</A>.</P></DIV>
<DIV id=3D"|[beta]|-Galactosidase staining">
<H4 class=3Dnorm><IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/bold/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-Galactosidase staining</H4>
<P class=3Dfollows-h4>Tissues and femoral bones were fixed in 4% =
paraformaldehyde=20
for 4&nbsp;h. The samples were stained in =
5-bromo-4-chloro-3-indolyl-<IMG=20
alt=3Dbeta =
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>-<SPAN class=3Dscp>d</SPAN>-galactoside =
(X-gal) solution at=20
37&nbsp;=B0C, as described<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B32">32</A></SUP>,=20
for 36&nbsp;h and then embedded<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B2">2</A></SUP>.</P></DIV>
<DIV id=3D"GFP visualization">
<H4 class=3Dnorm>GFP visualization</H4>
<P class=3Dfollows-h4>Tissues were immediately frozen in <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p4">OCT=20
compound (Tissue-Tek)</A> without fixation. Serial sections (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p5">cryostat</A>,=20
Leica) were mounted with Vectashield containing DAPI=20
(4,6-diamidino-2-phenylindole), and visualized with an ultraviolet =
fluorescent=20
microscope (Nikon <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p6">Eclipse=20
E800</A>) with a <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p7">Retiga=20
camera (QImaging)</A> through <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p8">IPLab=20
version 3.65a imaging software (Scanalytics)</A>.</P></DIV>
<DIV id=3DImmunohistochemistry>
<H4 class=3Dnorm>Immunohistochemistry</H4>
<P class=3Dfollows-h4>Tissues were fixed and embedded in OCT or paraffin =
as=20
previously described<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B16">16</A></SUP>.=20
The following antibodies were used: <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p9">VEGFR1=20
clone MF-1 (ImClone Systems)</A> or <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p10">Flt1=20
clone C-17 (Santa Cruz Biotechnology)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p11">CD31=20
SC-1506 (Santa Cruz Biotechnology)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p12">VEGFR2=20
DC101 (ImClone Systems)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p13">MMP9=20
D19557 (Oncogene)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p14">Id3=20
C-20 (Santa Cruz Biotechnology)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p15">Fibronectin=20
TV-1</A> (Chemicon); <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p16">CD11b=20
CBRM1/5 (eBioscience)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p17">CD34=20
RAM34 (BD Pharmigen)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p18">c-Kit=20
ACK2 (eBioscience)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p19">PDGFR<IMG=20
alt=3Dalpha =
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
align=3Dbottom border=3D0> APA5 (BD Pharmingen)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p20"><IMG=20
alt=3Dalpha =
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
align=3Dbottom border=3D0>V (Chemicon)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p21">CD133=20
13A4 (eBioscience)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p22"><IMG=20
alt=3Dalpha =
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
align=3Dbottom border=3D0>4/VLA-4 PS-2 (Southern Biotech)</A>; <IMG =
alt=3Dalpha=20
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0>5 (CD49e, 5H10-27); <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p23"><IMG=20
alt=3Dalpha =
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
align=3Dbottom border=3D0>6/CD49f GoH3 (BD Pharmingen)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p24"><IMG=20
alt=3Dbeta =
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>1 9EG7 (BD Pharmingen)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p25"><IMG=20
alt=3Dbeta =
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>2 M18/2 (BD Pharmingen)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p26"><IMG=20
alt=3Dbeta =
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>4 (Santa Cruz Biotechnology)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p27"><IMG=20
alt=3Dbeta =
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>7 M293 (BD Pharmingen)</A>; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p28">SDF-1=20
79018.111 (R&amp;D Systems)</A>; and <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p29">CXCR4=20
2B11 (BD Pharmingen)</A>.</P></DIV>
<DIV id=3D"Double immunofluorescence">
<H4 class=3Dnorm>Double immunofluorescence</H4>
<P class=3Dfollows-h4>Tissues in OCT were post-fixed with acetone. A =
double=20
immunofluorescence protocol was performed as described in the <A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
Methods</A>.</P></DIV>
<DIV id=3D"Antibody targeting">
<H4 class=3Dnorm>Antibody targeting</H4>
<P class=3Dfollows-h4>Wild-type mice were inoculated with 2 <IMG =
alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 10<SUP>6</SUP> LLC or B16 cells. For blockade =
of VEGFR1=20
function, mice were injected intraperitoneally every 48&nbsp;h, between =
day=20
7=9622, with <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p30">rat=20
anti-mouse VEGFR1 antibody</A> (MF-1, IgG1, 400&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>g, ImClone Systems) or <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p31">VEGFR2=20
antibody</A> (DC101, IgG1, 800&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>g, ImClone Systems) or both, or with IgG control antibody, =
and then=20
killed on day 24.</P></DIV>
<DIV id=3D"Conditioned media assays">
<H4 class=3Dnorm>Conditioned media assays</H4>
<P class=3Dfollows-h4>Conditioned media was filtered (0.22-<IMG =
alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m filter) from serum-free media cultured on B16 (MCM) or LLC =
(LCM)=20
cells for 18&nbsp;h, as described<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B33">33</A></SUP>.=20
Conditioned media (300&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>l) was injected intraperitoneally daily for nine days into =
wild-type=20
mice that had received Rosa26 bone marrow transplants four weeks =
earlier.=20
Tissues were stained for <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p32">fibronectin=20
TV-1 (Chemicon)</A> and <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal. For tumour redirection studies, intraperitoneal =
injections of MCM=20
(300&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>l) commenced two days before intradermal LLC implantation and =
then=20
daily over the next 21 days. Matched control groups with and without =
tumour were=20
given serum-free media. Wild-type mice were injected with MCM =
(300&nbsp;<IMG=20
alt=3Dmicro =
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>l) daily for seven days before tail vein =
injection of B16=20
tumour cells, and then daily until killed either one or four days after=20
intravenous tumour administration. Lungs were perfused with PBS before =
embedding=20
in OCT.</P></DIV>
<DIV id=3D"Migration assays">
<H4 class=3Dnorm>Migration assays</H4>
<P class=3Dfollows-h4>Migration of VEGFR1<SUP>+</SUP> cells in response =
to=20
conditioned media was measured in a transwell assay. VEGFR1<SUP>+</SUP> =
cells=20
were isolated as above, and 1 <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 10<SUP>5</SUP> cells suspended in serum-free =
media placed=20
in the upper compartment of <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p33">5-<IMG=20
alt=3Dmicro =
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif"=20
align=3Dmiddle border=3D0>m-pore transwells (Costar, Corning)</A>. Cells =
were=20
allowed to migrate for 18&nbsp;h with conditioned media or corresponding =
control=20
media in the lower compartment, with the analysis of cell counts =
assessed every=20
6&nbsp;h using a haemocytometer and trypan blue.</P></DIV>
<DIV id=3D"Quantitative analysis of fibronectin expression">
<H4 class=3Dnorm>Quantitative analysis of fibronectin expression</H4>
<P class=3Dfollows-h4>Lung tissue was homogenized with a tissue =
homogenizer in=20
TriZol reagent, and RNA was extracted as described previously<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B34">34</A></SUP>.=20
Fibronectin gene expression was quantified and normalized to=20
glyceraldehyde-3-phosphate dehydrogenase (<I>Gapdh</I>) expression by =
polymerase=20
chain reaction with reverse transcription (RT=96PCR) using <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p34">TaqMan=20
gene expression assays (Applied Biosystems)</A> as described =
previously<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B35">35</A></SUP></P></DIV>
<DIV id=3D"Chemokine assays">
<H4 class=3Dnorm>Chemokine assays</H4>
<P class=3Dfollows-h4>Conditioned media, serum-free media and plasma =
obtained from=20
mice with day 14 tumours were analysed for VEGF and PlGF concentrations =
by an=20
enzyme-linked immunosorbent assay (ELISA; <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p35">Quantikine</A>,=20
R&amp;D Systems) according to the manufacturer's instructions.</P></DIV>
<DIV id=3D"Flow cytometry">
<H4 class=3Dnorm>Flow cytometry</H4>
<P class=3Dfollows-h4>Flow cytometry was performed on an entire right =
lung after=20
perfusion with PBS by right-ventricular injection. The tissue was minced =
into=20
small pieces, filtered with <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p36">100-=20
and 40-<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>m filters (BD Biosciences)</A> to form a single-cell =
suspension as=20
previously described<SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B35">35,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#B36">36</A></SUP>.</P></DIV>
<DIV id=3D"Human specimens">
<H4 class=3Dnorm>Human specimens</H4>
<P class=3Dfollows-h4>Human specimens include: tumour tissue, adjacent =
normal=20
tissue (beyond tumour margins), distant normal tissue and lymph nodes. =
Tissues=20
were embedded as described above and stained with antibodies to human <A =

href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p37">VEGFR1=20
FB5 (ImClone Systems)</A> or <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p38">Flt1=20
(Calbiochem)</A>. Tissue samples were obtained and handled in accordance =
with an=20
approved Institutional Review Board application.</P></DIV>
<DIV id=3D"Quantitative immunohistochemistry">
<H4 class=3Dnorm>Quantitative immunohistochemistry</H4>
<P class=3Dfollows-h4>Using both IPLab and Adobe Photoshop 7.0, random =
<IMG=20
alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0>100 objective fields were analysed by =
selecting a=20
standardized colour range for <IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-gal or immunohistochemical staining. After boundary =
delineation, the=20
area under the pixelation histogram was calculated, comparing total =
staining=20
area to total tissue area.</P></DIV>
<DIV id=3D"Statistical analyses">
<H4 class=3Dnorm>Statistical analyses</H4>
<P class=3Dfollows-h4>Results are expressed as mean <IMG alt=3Dplusminus =

src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> s.e.m. Data were analysed by Student's =
<I>t</I>-test and=20
one way analysis of variance (ANOVA) using the GraphPad <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04186_=
p_p39">Prism</A>=20
statistical program. <I>P</I> values &lt;0.05 were considered =
significant. Error=20
bars depict s.e.m.</P></DIV></DIV></DIV>
<DIV id=3Dacknowledgements><A class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3>Acknowledgments</H3>
<P class=3Dnorm>We thank M. Barna for critical reading of the manuscript =
and L.=20
Breda, S. Rivella and S. Neustein for discussions. R.N.K. is a recipient =
of the=20
Laura Rosenberg Fellowship award and supported by a grant from the =
American=20
Hellenic Educational Progressive Association (Fifth District) and the =
LTC=20
Foundation. D.L. is supported by the Doris Duke Charitable Foundation, =
the=20
Children's Blood Foundation, the Emerald Foundation, the Theodore A. =
Rapp=20
Foundation and a grant from the National Cancer Institute. S.R. is an=20
investigator of the Howard Hughes Medical Institute and supported by =
grants from=20
the American Cancer Society, the Leukemia and Lymphoma Society, and the =
National=20
Institutes of Health.</P>
<H4 class=3Dinline>Competing interests statement: </H4>
<P class=3Dfollows-h4>The authors declared no competing interests.</P>
<P class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
information</A> accompanies this paper.</P></DIV>
<DIV id=3DReferences><A class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3 class=3Dsectitle1>References</H3>
<OL class=3Dnorm>
  <LI id=3DB1><A name=3DB1><!-- . --></A>Coussens, L. , Tinkle, C. , =
Hanahan, D.=20
  &amp; Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes =
to skin=20
  carcinogenesis. <I>Cell</I> <B>103</B>, 481=96490 =
(2000)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"MMP-9 supplied by bone marrow-derived cells contributes to =
skin carcinogenesis"=20
  href=3D"http://dx.doi.org/10.1016/S0092-8674(00)00139-2"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - MMP-9 supplied by bone marrow-derived =
cells contributes to skin carcinogenesis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11081634&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - MMP-9 supplied by bone marrow-derived cells =
contributes to skin carcinogenesis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000090144100013&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - MMP-9 supplied by bone marrow-derived =
cells contributes to skin carcinogenesis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3cXn=
vF2ksLg%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D7fb7b7e7c07d4=
9792e7942b735c81607"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB2><A name=3DB2><!-- . --></A>Lyden, D. <I>et al.</I> =
Impaired=20
  recruitment of bone-marrow-derived endothelial and hematopoietic =
precursor=20
  cells blocks tumour angiogenesis and growth. <I>Nature Med.</I> =
<B>7</B>,=20
  1194=961201 (2001)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Impaired recruitment of =
bone-marrow-derived endothelial and hematopoietic precursor cells blocks =
tumour angiogenesis and growth"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nm1101-1194"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB3><A name=3DB3><!-- . --></A>Autiero, M. , Luttun, A. , =
Tjwa, M. &amp;=20
  Carmeliet, P. Placental growth factor and its receptor, vascular =
endothelial=20
  growth factor receptor-1: novel targets for stimulation of ischemic =
tissue=20
  revascularization and inhibition of angiogenic and inflammatory =
disorders.=20
  <I>J. Thromb. Haemost.</I> <B>1</B>, 1356=961370 (2003)&nbsp;|&nbsp;<A =

  class=3Dreftxt=20
  title=3D"Placental growth factor and its receptor, vascular =
endothelial growth factor receptor-1: novel targets for stimulation of =
ischemic tissue revascularization and inhibition of angiogenic and =
inflammatory disorders"=20
  href=3D"http://dx.doi.org/10.1046/j.1538-7836.2003.00263.x"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Placental growth factor and its receptor, =
vascular endothelial growth factor receptor-1: novel targets for =
stimulation of ischemic tissue revascularization and inhibition of =
angiogenic and inflammatory disorders"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12871269&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Placental growth factor and its receptor, =
vascular endothelial growth factor receptor-1: novel targets for =
stimulation of ischemic tissue revascularization and inhibition of =
angiogenic and inflammatory disorders"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000184170900005&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Placental growth factor and its =
receptor, vascular endothelial growth factor receptor-1: novel targets =
for stimulation of ischemic tissue revascularization and inhibition of =
angiogenic and inflammatory disorders"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:STN:280:DC%2BD3szj=
vFOhuw%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D986323d3629=
7c763578f0a805103ba37"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB4><A name=3DB4><!-- . --></A>Neeson, P. , Thurlow, P. , =
Jamieson, G.=20
  &amp; Bradley, C. Lymphocyte-facilitated tumour cell adhesion to =
endothelial=20
  cells: the role of high affinity leukocyte integrins. <I>Pathology</I> =

  <B>35</B>, 50=9655 (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Lymphocyte-facilitated tumour cell adhesion to endothelial =
cells: the role of high affinity leukocyte integrins"=20
  href=3D"http://dx.doi.org/10.1080/00313020307517"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Lymphocyte-facilitated tumour cell =
adhesion to endothelial cells: the role of high affinity leukocyte =
integrins"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12701685&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Lymphocyte-facilitated tumour cell adhesion =
to endothelial cells: the role of high affinity leukocyte integrins"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000182333400009&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|
  <LI id=3DB5><A name=3DB5><!-- . --></A>Hattori, K. <I>et al.</I> =
Placental growth=20
  factor reconstitutes hematopoiesis by recruiting VEGFR1<SUP>+</SUP> =
stem cells=20
  from bone-marrow microenvironment. <I>Nature Med.</I> <B>8</B>, =
841=96849=20
  (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Placental growth factor reconstitutes =
hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow =
microenvironment"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nm740"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB6><A name=3DB6><!-- . --></A>Pollard, J. W. Tumour-educated =
macrophages=20
  promote tumour progression and metastasis. <I>Nature Rev. Cancer</I> =
<B>4</B>,=20
  71=9678 (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Tumour-educated macrophages promote =
tumour progression and metastasis"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nrc1256"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB7><A name=3DB7><!-- . --></A>Hiratsuka, S. <I>et al.</I> =
MMP9 induction=20
  by vascular endothelial growth factor receptor-1 is involved in =
lung-specific=20
  metastasis. <I>Cancer Cell</I> <B>2</B>, 289=96300 =
(2002)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"MMP9 induction by vascular endothelial growth factor =
receptor-1 is involved in lung-specific metastasis"=20
  href=3D"http://dx.doi.org/10.1016/S1535-6108(02)00153-8"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - MMP9 induction by vascular endothelial =
growth factor receptor-1 is involved in lung-specific metastasis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12398893&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - MMP9 induction by vascular endothelial =
growth factor receptor-1 is involved in lung-specific metastasis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000178717500008&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - MMP9 induction by vascular endothelial =
growth factor receptor-1 is involved in lung-specific metastasis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xo=
t1Gkt7s%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D78e09cf6392dd=
b5f6788e406f7723238"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB8><A name=3DB8><!-- . --></A>De Palma, M. , Vinneri, M. A. , =
Roca, C.=20
  &amp; Naldini, L. Targeting exogenous genes to tumour angiogenesis by=20
  transplantation of genetically modified hematopoietic cells. <I>Nature =

  Med.</I> <B>9</B>, 789=96795 (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Targeting exogenous genes to tumour =
angiogenesis by transplantation of genetically modified hematopoietic =
cells"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nm871"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB9><A name=3DB9><!-- . --></A>Burger, J. , Spoo, A. , =
Dwenger, A. ,=20
  Burger, M. &amp; Behringer, D. CXCR4 chemokine receptors (CD184) and =
<IMG=20
  alt=3Dalpha =
src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0><SUB>4</SUB><IMG alt=3Dbeta=20
  src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
  border=3D0><SUB>1</SUB> integrins mediate spontaneous migration of =
human=20
  CD34<SUP>+</SUP> progenitors and acute myeloid leukaemia cells beneath =
marrow=20
  stromal cells (pseudoemperipolesis). <I>Br. J. Haematol.</I> =
<B>122</B>,=20
  579=96589 (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"CXCR4 chemokine receptors (CD184) and [alpha]4[beta]1 =
integrins mediate spontaneous migration of human CD34+ progenitors and =
acute myeloid leukaemia cells beneath marrow stromal cells =
(pseudoemperipolesis)"=20
  href=3D"http://dx.doi.org/10.1046/j.1365-2141.2003.04466.x"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - CXCR4 chemokine receptors (CD184) and =
[alpha]4[beta]1 integrins mediate spontaneous migration of human CD34+ =
progenitors and acute myeloid leukaemia cells beneath marrow stromal =
cells (pseudoemperipolesis)"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12899713&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - CXCR4 chemokine receptors (CD184) and =
[alpha]4[beta]1 integrins mediate spontaneous migration of human CD34+ =
progenitors and acute myeloid leukaemia cells beneath marrow stromal =
cells (pseudoemperipolesis)"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000184573300006&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - CXCR4 chemokine receptors (CD184) and =
[alpha]4[beta]1 integrins mediate spontaneous migration of human CD34+ =
progenitors and acute myeloid leukaemia cells beneath marrow stromal =
cells (pseudoemperipolesis)"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXn=
sVCgur0%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3Dc2cfa02f08825=
460cbb3bedffc94e166"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB10><A name=3DB10><!-- . --></A>Scott, L. , Priestly, G. =
&amp;=20
  Papayannopoulou, T. Deletion of <IMG alt=3Dalpha=20
  src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0><SUB>4</SUB> integrins from adult =
hematopoietic cells=20
  reveals roles in homeostasis, regeneration, and homing. <I>Mol. Cell.=20
  Biol.</I> <B>23</B>, 9349=969360 (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Deletion of [alpha]4 integrins from adult hematopoietic cells =
reveals roles in homeostasis, regeneration, and homing"=20
  href=3D"http://dx.doi.org/10.1128/MCB.23.24.9349-9360.2003"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Deletion of [alpha]4 integrins from adult =
hematopoietic cells reveals roles in homeostasis, regeneration, and =
homing"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D14645544&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Deletion of [alpha]4 integrins from adult =
hematopoietic cells reveals roles in homeostasis, regeneration, and =
homing"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000187040400039&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Deletion of [alpha]4 integrins from =
adult hematopoietic cells reveals roles in homeostasis, regeneration, =
and homing"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXp=
slGqtbY%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D031e2f1f908aa=
416ebc96dd365efdfb3"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB11><A name=3DB11><!-- . --></A>Jonjic, N. <I>et al.</I> =
Molecules=20
  involved in the adhesion and cytotoxicity of activated monocytes on=20
  endothelial cells. <I>J. Immunol.</I> <B>148</B>, 2080=962083=20
  (1992)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Molecules involved in the adhesion and =
cytotoxicity of activated monocytes on endothelial cells"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D1347549&amp;dopt=3DAbstract=
"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Molecules involved in the adhesion and =
cytotoxicity of activated monocytes on endothelial cells"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3DA1992HJ59600017&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Molecules involved in the adhesion and =
cytotoxicity of activated monocytes on endothelial cells"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DyaK38XitF=
arsr4%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3Da31bd23a61e73e4=
29eca33ad29feb921"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB12><A name=3DB12><!-- . --></A>Heissig, B. <I>et al.</I> =
Recruitment of=20
  stem and progenitor cells from the bone marrow niche requires MMP-9 =
mediated=20
  release of kit-ligand. <I>Cell</I> <B>109</B>, 625=96637 =
(2002)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"Recruitment of stem and progenitor cells from the bone marrow =
niche requires MMP-9 mediated release of kit-ligand"=20
  href=3D"http://dx.doi.org/10.1016/S0092-8674(02)00754-7"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Recruitment of stem and progenitor cells =
from the bone marrow niche requires MMP-9 mediated release of =
kit-ligand"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12062105&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Recruitment of stem and progenitor cells =
from the bone marrow niche requires MMP-9 mediated release of =
kit-ligand"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000175957900011&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Recruitment of stem and progenitor =
cells from the bone marrow niche requires MMP-9 mediated release of =
kit-ligand"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xk=
sVGgs7w%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D08bba9b8fa7c3=
77581a80152dbe6129e"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB13><A name=3DB13><!-- . --></A>Bergers, G. <I>et al.</I> =
Matrix=20
  Metalloproteinase-9 triggers the angiogenic switch during =
carcinogenesis.=20
  <I>Nature Cell Biol.</I> <B>2</B>, 737=96744 (2000)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Matrix Metalloproteinase-9 triggers the angiogenic switch =
during carcinogenesis"=20
  href=3D"http://dx.doi.org/10.1038/35036374" =
target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB14><A name=3DB14><!-- . --></A>Huhtala, P. <I>et al.</I> =
Cooperative=20
  signalling by <IMG alt=3Dalpha=20
  src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0>5<IMG alt=3Dbeta=20
  src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
  border=3D0>1 and <IMG alt=3Dalpha=20
  src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0>4<IMG alt=3Dbeta=20
  src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
  border=3D0>1 integrins regulates metalloproteinase gene expression in=20
  fibroblasts adhering to fibronectin. <I>J. Cell Biol.</I> <B>129</B>, =
867=96879=20
  (1995)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Cooperative signalling by [alpha]5[beta]1 and [alpha]4[beta]1 =
integrins regulates metalloproteinase gene expression in fibroblasts =
adhering to fibronectin"=20
  href=3D"http://dx.doi.org/10.1083/jcb.129.3.867"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Cooperative signalling by [alpha]5[beta]1 =
and [alpha]4[beta]1 integrins regulates metalloproteinase gene =
expression in fibroblasts adhering to fibronectin"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D7537277&amp;dopt=3DAbstract=
"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Cooperative signalling by [alpha]5[beta]1 =
and [alpha]4[beta]1 integrins regulates metalloproteinase gene =
expression in fibroblasts adhering to fibronectin"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3DA1995QW14200026&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Cooperative signalling by =
[alpha]5[beta]1 and [alpha]4[beta]1 integrins regulates =
metalloproteinase gene expression in fibroblasts adhering to =
fibronectin"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DyaK2MXlt1=
WrsLw%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D569525d6b0d060b=
d910f0aa95c1f3513"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB15><A name=3DB15><!-- . --></A>Yakubenko, V. P. , Lobb, R. =
R. , Plow, E.=20
  F. &amp; Ugarova, T. P. Differential induction of gelatinase B (MMP-9) =
and=20
  gelatinase A (MMP-2) in T lymphocytes upon <IMG alt=3Dalpha=20
  src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0><SUB>4</SUB><IMG alt=3Dbeta=20
  src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
  border=3D0><SUB>1</SUB>-mediated adhesion to VCAM-1 and the CS-1 =
peptide of=20
  fibronectin. <I>Exp. Cell Res.</I> <B>260</B>, 73=9684 =
(2000)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"Differential induction of gelatinase B (MMP-9) and gelatinase =
A (MMP-2) in T lymphocytes upon [alpha]4[beta]1-mediated adhesion to =
VCAM-1 and the CS-1 peptide of fibronectin"=20
  href=3D"http://dx.doi.org/10.1006/excr.2000.5002"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Differential induction of gelatinase B =
(MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon =
[alpha]4[beta]1-mediated adhesion to VCAM-1 and the CS-1 peptide of =
fibronectin"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11010812&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Differential induction of gelatinase B =
(MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon =
[alpha]4[beta]1-mediated adhesion to VCAM-1 and the CS-1 peptide of =
fibronectin"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000089791900008&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Differential induction of gelatinase B =
(MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon =
[alpha]4[beta]1-mediated adhesion to VCAM-1 and the CS-1 peptide of =
fibronectin"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3cXm=
vVeitbs%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D37922d96e41a7=
e99d79ae5154631e6c7"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB16><A name=3DB16><!-- . --></A>Ruzinova, M. B. <I>et al.</I> =
Effect of=20
  angiogenesis inhibition by Id loss and the contribution of =
bone-marrow-derived=20
  endothelial cells in spontaneous murine tumours. <I>Cancer Cell</I> =
<B>4</B>,=20
  277=96289 (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Effect of angiogenesis inhibition by Id loss and the =
contribution of bone-marrow-derived endothelial cells in spontaneous =
murine tumours"=20
  href=3D"http://dx.doi.org/10.1016/S1535-6108(03)00240-X"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Effect of angiogenesis inhibition by Id =
loss and the contribution of bone-marrow-derived endothelial cells in =
spontaneous murine tumours"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D14585355&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Effect of angiogenesis inhibition by Id loss =
and the contribution of bone-marrow-derived endothelial cells in =
spontaneous murine tumours"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000186154200008&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Effect of angiogenesis inhibition by Id =
loss and the contribution of bone-marrow-derived endothelial cells in =
spontaneous murine tumours"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXo=
slequrs%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D50258dc7c541e=
14d78cfcd9d11db9c03"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB17><A name=3DB17><!-- . --></A>Lyden, D. <I>et al.</I> Id1 =
and Id3 are=20
  required for neurogenesis, angiogenesis and vascularization of tumour=20
  xenografts. <I>Nature</I> <B>401</B>, 670=96677 (1999)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"Article on Article - Id1 and Id3 are required for =
neurogenesis, angiogenesis and vascularization of tumour xenografts"=20
  href=3D"http://www.nature.com/doifinder/10.1038/44334"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Id1 and Id3 are required for =
neurogenesis, angiogenesis and vascularization of tumour xenografts"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D10537105&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Id1 and Id3 are required for neurogenesis, =
angiogenesis and vascularization of tumour xenografts"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000083207400048&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Id1 and Id3 are required for =
neurogenesis, angiogenesis and vascularization of tumour xenografts"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DyaK1MXmvF=
2rtbc%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D8e70f80e137fa9b=
0049aa947b8809540"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB18><A name=3DB18><!-- . --></A>Ratajczak, M. Z. <I>et =
al.</I> Stem cell=20
  plasticity revisted: CXCR4-positive cells expressing mRNA for early =
muscle,=20
  liver and neural cells 'hide out' in the bone marrow. <I>Leukemia</I>=20
  <B>18</B>, 29=9640 (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Stem cell plasticity revisted: =
CXCR4-positive cells expressing mRNA for early muscle, liver and neural =
cells /`hide out/' in the bone marrow"=20
  href=3D"http://www.nature.com/doifinder/10.1038/sj.leu.2403184"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Stem cell plasticity revisted: =
CXCR4-positive cells expressing mRNA for early muscle, liver and neural =
cells /`hide out/' in the bone marrow"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D14586476&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Stem cell plasticity revisted: =
CXCR4-positive cells expressing mRNA for early muscle, liver and neural =
cells /`hide out/' in the bone marrow"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000187327500005&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Stem cell plasticity revisted: =
CXCR4-positive cells expressing mRNA for early muscle, liver and neural =
cells /`hide out/' in the bone marrow"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXp=
vVekt7k%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D4fafa421d8060=
3d6959d7962fc166034"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB19><A name=3DB19><!-- . --></A>Lapidot, T. &amp; Petit, I. =
Current=20
  understanding of stem cell mobilization: The roles of chemokines, =
proteolytic=20
  enzymes, adhesion molecules, cytokines and stromal cells. <I>Exp. =
Hematol.</I>=20
  <B>30</B>, 973=96981 (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Current understanding of stem cell mobilization: The roles of =
chemokines, proteolytic enzymes, adhesion molecules, cytokines and =
stromal cells"=20
  href=3D"http://dx.doi.org/10.1016/S0301-472X(02)00883-4"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Current understanding of stem cell =
mobilization: The roles of chemokines, proteolytic enzymes, adhesion =
molecules, cytokines and stromal cells"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12225788&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Current understanding of stem cell =
mobilization: The roles of chemokines, proteolytic enzymes, adhesion =
molecules, cytokines and stromal cells"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000178153200001&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Current understanding of stem cell =
mobilization: The roles of chemokines, proteolytic enzymes, adhesion =
molecules, cytokines and stromal cells"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xm=
vVCqsrY%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D1a74a45006b4c=
d0ee9b3951f7f0def70"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB20><A name=3DB20><!-- . --></A>Balkwill, F. The significance =
of cancer=20
  cell expression of the chemokine receptor CXCR4. <I>Semin. Cancer =
Biol.</I>=20
  <B>14</B>, 171=96179 (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"The significance of cancer cell expression of the chemokine =
receptor CXCR4"=20
  href=3D"http://dx.doi.org/10.1016/j.semcancer.2003.10.003"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - The significance of cancer cell =
expression of the chemokine receptor CXCR4"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15246052&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - The significance of cancer cell expression =
of the chemokine receptor CXCR4"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000221730100005&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - The significance of cancer cell =
expression of the chemokine receptor CXCR4"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXj=
vVemsb0%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D8d6031a15b4e7=
1707fcef724264e4041"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB21><A name=3DB21><!-- . --></A>Muller, A. <I>et al.</I> =
Involvement of=20
  chemokine receptors in breast cancer metastasis. <I>Nature</I> =
<B>410</B>,=20
  50=9656 (2001)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Involvement of chemokine receptors in =
breast cancer metastasis"=20
  href=3D"http://www.nature.com/doifinder/10.1038/35065016"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Involvement of chemokine receptors in =
breast cancer metastasis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11242036&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Involvement of chemokine receptors in breast =
cancer metastasis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000167194300037&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Involvement of chemokine receptors in =
breast cancer metastasis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3MXh=
vVSgu74%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D4cd4f859c9d3a=
e5a03017248606db9f2"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB22><A name=3DB22><!-- . --></A>Hynes, R. O. Metastatic =
potential:=20
  generic predisposition of the primary tumour or rare, metastatic =
variants=97or=20
  both? <I>Cell</I> <B>113</B>, 821=96823 (2003)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Metastatic potential: generic predisposition of the primary =
tumour or rare, metastatic variants[mdash]or both?"=20
  href=3D"http://dx.doi.org/10.1016/S0092-8674(03)00468-9"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Metastatic potential: generic =
predisposition of the primary tumour or rare, metastatic =
variants[mdash]or both?"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12837240&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Metastatic potential: generic predisposition =
of the primary tumour or rare, metastatic variants[mdash]or both?"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000183817900006&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Metastatic potential: generic =
predisposition of the primary tumour or rare, metastatic =
variants[mdash]or both?"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXl=
sVSjtb8%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3Da1c69c42ab4db=
3bf66c620209eeedcb7"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB23><A name=3DB23><!-- . --></A>Bergers, G. , Song, S. , =
Meyer-Morse, N.=20
  , Bergsland, E. &amp; Hanahan, D. Benefits of targeting both pericytes =
and=20
  endothelial cells in the tumour vasculature with kinase inhibitors. =
<I>J.=20
  Clin. Invest.</I> <B>111</B>, 1287=961295 (2003)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Benefits of targeting both pericytes and endothelial cells in =
the tumour vasculature with kinase inhibitors"=20
  href=3D"http://dx.doi.org/10.1172/JCI200317929"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Benefits of targeting both pericytes and =
endothelial cells in the tumour vasculature with kinase inhibitors"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12727920&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Benefits of targeting both pericytes and =
endothelial cells in the tumour vasculature with kinase inhibitors"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000182605400007&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Benefits of targeting both pericytes =
and endothelial cells in the tumour vasculature with kinase inhibitors"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXj=
sFCrsr4%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D461ac1d911d66=
5935c3dd5dd2cdc261f"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB24><A name=3DB24><!-- . --></A>Fidler, I. The organ =
microenvironment and=20
  cancer metastasis. <I>Differentiation</I> <B>70</B>, 498=96505=20
  (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"The organ microenvironment and cancer metastasis"=20
  href=3D"http://dx.doi.org/10.1046/j.1432-0436.2002.700904.x"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - The organ microenvironment and cancer =
metastasis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12492492&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - The organ microenvironment and cancer =
metastasis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000179946700004&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|
  <LI id=3DB25><A name=3DB25><!-- . --></A>Duda, D. G. <I>et al.</I> =
Differential=20
  transplantability of tumour-associated stromal cells. <I>Cancer =
Res.</I>=20
  <B>64</B>, 5920=965924 (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Differential transplantability of tumour-associated stromal =
cells"=20
  href=3D"http://dx.doi.org/10.1158/0008-5472.CAN-04-1268"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Differential transplantability of =
tumour-associated stromal cells"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15342367&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Differential transplantability of =
tumour-associated stromal cells"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000223603200002&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Differential transplantability of =
tumour-associated stromal cells"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXn=
tFClsr8%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D5702a2002c9d0=
b373e693b7e7db91f59"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB26><A name=3DB26><!-- . --></A>Folkman, J. Role of =
angiogenesis in=20
  tumour growth and metastasis. <I>Semin. Oncol.</I> <B>29</B>, =
515=96518 (2002)
  <LI id=3DB27><A name=3DB27><!-- . --></A>Coussens, L. M. &amp; Werb, =
Z.=20
  Inflammation and cancer. <I>Nature</I> <B>420</B>, 860=96867=20
  (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Inflammation and cancer"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nature01322"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Inflammation and cancer"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12490959&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Inflammation and cancer"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000179897300067&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Inflammation and cancer"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xp=
sFygtb4%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D01248d02dce67=
ff44fd2c84beb681ad9"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB28><A name=3DB28><!-- . --></A>Borsig, L. , Wong, R. , =
Hynes, R. O. ,=20
  Varki, N. M. &amp; Varki, A. Synergistic effects of L- and P-selectin =
in=20
  facilitating tumour metastasis can involve non-mucin ligands and =
implicate=20
  leukocytes as enhancers of metastasis. <I>Proc. Natl Acad. Sci. =
USA</I>=20
  <B>99</B>, 2193=962198 (2000)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Synergistic effects of L- and P-selectin in facilitating =
tumour metastasis can involve non-mucin ligands and implicate leukocytes =
as enhancers of metastasis"=20
  href=3D"http://dx.doi.org/10.1073/pnas.261704098"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB29><A name=3DB29><!-- . --></A>Lin, E. Y. , Ngyuen, A. V. , =
Russell, R.=20
  G. &amp; Pollard, J. W. Colony stimulating factor 1 promoted =
progression of=20
  mammary tumours to malignancy. <I>J. Exp. Med.</I> <B>193</B>, =
727=96740=20
  (2001)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Colony stimulating factor 1 promoted progression of mammary =
tumours to malignancy"=20
  href=3D"http://dx.doi.org/10.1084/jem.193.6.727"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Colony stimulating factor 1 promoted =
progression of mammary tumours to malignancy"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11257139&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Colony stimulating factor 1 promoted =
progression of mammary tumours to malignancy"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000167631100008&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Colony stimulating factor 1 promoted =
progression of mammary tumours to malignancy"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3MXi=
tFKhsLo%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D529f7c4a011fb=
522dcb262c630f40b15"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB30><A name=3DB30><!-- . --></A>Qian, F. , Hanahan, D. &amp; =
Weissman, I.=20
  L. L-selectin can facilitate metastasis to lymph nodes in a transgenic =
mouse=20
  model of carcinogenesis. <I>Proc. Natl Acad. Sci. USA</I> <B>98</B>, =
3976=963981=20
  (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"L-selectin can facilitate metastasis to lymph nodes in a =
transgenic mouse model of carcinogenesis"=20
  href=3D"http://dx.doi.org/10.1073/pnas.061633698"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB31><A name=3DB31><!-- . --></A>Schoppmann, S. <I>et al.</I>=20
  Tumour-associated macrophages express lymphatic endothelial growth =
factors and=20
  are related to peritumoural lymphangiogenesis. <I>Am. J. Pathol.</I>=20
  <B>161</B>, 947=96956 (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Tumour-associated macrophages express =
lymphatic endothelial growth factors and are related to peritumoural =
lymphangiogenesis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12213723&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Tumour-associated macrophages express =
lymphatic endothelial growth factors and are related to peritumoural =
lymphangiogenesis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000177859600024&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Tumour-associated macrophages express =
lymphatic endothelial growth factors and are related to peritumoural =
lymphangiogenesis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xn=
sFOisrs%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3Dd8d1b4575ebc1=
043d07bbdf402f8b750"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB32><A name=3DB32><!-- . --></A>Tam, P. P. , Parameswaran, M. =
, Kinder,=20
  S. J. &amp; Weinberger, R. P. The allocation of epiblast cells to the=20
  embryonic heart and other mesodermal lineages: the role of ingression =
and=20
  tissue movement during gastrulation. <I>Development</I> <B>124</B>, =
1631=961642=20
  (1999)
  <LI id=3DB33><A name=3DB33><!-- . --></A>Kessinger, A. , Mann, S. , =
Murphy, B. O.=20
  , Jackson, J. D. &amp; Sharp, J. G. Circulating factors may be =
responsible for=20
  murine strain-specific responses to mobilizing cytokines. <I>Exp. =
Hematol.</I>=20
  <B>29</B>, 775=96778 (2001)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Circulating factors may be responsible for murine =
strain-specific responses to mobilizing cytokines"=20
  href=3D"http://dx.doi.org/10.1016/S0301-472X(01)00642-7"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Circulating factors may be responsible =
for murine strain-specific responses to mobilizing cytokines"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11378273&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Circulating factors may be responsible for =
murine strain-specific responses to mobilizing cytokines"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000169174900014&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Circulating factors may be responsible =
for murine strain-specific responses to mobilizing cytokines"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3MXj=
vFShsr0%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D5876c8d34744f=
4b575a43f835e6a7cd5"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB34><A name=3DB34><!-- . --></A>Hashimoto, N. , Jin, H. , =
Liu, T. ,=20
  Chensue, S. W. &amp; Phan, S. H. Bone marrow-derived progenitor cells =
in=20
  pulmonary fibrosis. <I>J. Clin. Invest.</I> <B>113</B>, 243=96252=20
  (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Bone marrow-derived progenitor cells in pulmonary fibrosis"=20
  href=3D"http://dx.doi.org/10.1172/JCI200418847"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Bone marrow-derived progenitor cells in =
pulmonary fibrosis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D14722616&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Bone marrow-derived progenitor cells in =
pulmonary fibrosis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000188195600014&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Bone marrow-derived progenitor cells in =
pulmonary fibrosis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXm=
sVyruw%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3Db31b75a1742=
615e27c6c58796b99123f"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB35><A name=3DB35><!-- . --></A>Jensen, K. K. <I>et al.</I> =
The human=20
  herpes virus 8-encoded chemokine receptor is required for =
angioproliferation=20
  in a murine model of Kaposi's sarcoma. <I>J. Immunol.</I> <B>174</B>,=20
  3686=963694 (2005)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - The human herpes virus 8-encoded =
chemokine receptor is required for angioproliferation in a murine model =
of Kaposi's sarcoma"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15749907&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - The human herpes virus 8-encoded chemokine =
receptor is required for angioproliferation in a murine model of =
Kaposi's sarcoma"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000227510900069&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - The human herpes virus 8-encoded =
chemokine receptor is required for angioproliferation in a murine model =
of Kaposi's sarcoma"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2MXi=
tVeht7k%3D&amp;pissn=3D0028-0836&amp;pyear=3D2005&amp;md5=3D87aaf6f6db4a4=
58c9484e4b5427c3ef2"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB36><A name=3DB36><!-- . --></A>Huaux, F. , Tianju, L. , =
McGarry, B. ,=20
  Ullenbruch, M. &amp; Phan, S. H. Dual roles of IL-4 in lung injury and =

  fibrosis. <I>J. Immunol.</I> <B>170</B>, 2083=962092 </LI></OL></DIV>
<DIV class=3Dno-header-art><A class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A></DIV>
<DIV id=3Daffiliations-notes>
<OL>
  <LI id=3Da1>Department of Pediatrics and the Children's Blood =
Foundation=20
  Laboratories,
  <LI id=3Da2>Cell and Developmental Biology,
  <LI id=3Da3>Howard Hughes Medical Institute,
  <LI id=3Da4>Genetic Medicine and
  <LI id=3Da5>Surgery, Weill Cornell Medical College of Cornell =
University, 1300=20
  York Avenue and
  <LI id=3Da6>Department of Pediatrics and
  <LI id=3Da7>Surgery, Memorial Sloan-Kettering Cancer Center, 1233 York =
Avenue,=20
  New York, New York 10021, USA
  <LI id=3Da8>Imclone Systems Incorporated, New York, New York 10014, =
USA
  <LI id=3Da9>Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, =
USA
  <LI id=3Da10>*These authors contributed equally to this work</LI></OL>
<P class=3Dcaff>Correspondence to: Shahin Rafii<SUP><A =
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a3">3</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a4">4</A></SUP>David=20
Lyden<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a2">2</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#a6">6</A></SUP>=20
Correspondence and requests for materials should be addressed to D.L.=20
(Email:&nbsp;<A=20
href=3D"mailto:dcl2001@med.cornell.edu">dcl2001@med.cornell.edu</A>) or =
S.R.=20
(Email:&nbsp;<A=20
href=3D"mailto:srafii@med.cornell.edu">srafii@med.cornell.edu</A>).</P>
<P class=3Dprdates>Received 13 May 2005; Accepted 19 August =
2005</P></DIV>
<DIV class=3Dno-header><A class=3Dbacktotop=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A></DIV></DIV>
<DIV class=3Darchive id=3Djournalnav>
<H1 class=3Dhidden>Main navigation</H1><!-- whitespace removed to deal =
with IE5.0 PC bug. --><MAP=20
class=3Djournal-nav id=3Dmain-journal-nav title=3D"main journal =
navigation">
  <UL>
    <LI class=3Djn-home><A =
href=3D"http://www.nature.com/nature/">Journal home</A><!--<ul =
class=3D"subnav"><li class=3D"jn-about-cover"><a =
href=3D"/nature_CSS/about_cover.html">About the cover</a></li></ul>-->
    <LI class=3Djn-aop><A=20
    =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/index.html">Ad=
vance=20
    online publication</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-about-aop><A=20
      =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/about.html">Ab=
out=20
      AOP</A></LI></UL>
    <LI class=3Djn-issue><A=20
    href=3D"http://www.nature.com/nature/current_issue">Current =
issue</A>
    <LI class=3Djn-archive><A=20
    =
href=3D"http://www.nature.com/nature/archive/">Archive</A></LI></UL></MAP=
><!-- whitespace removed to deal with IE5.0 PC bug. --><MAP=20
class=3D"journal-nav supplementary" id=3Dsupplementary-journal-nav=20
title=3D"supplementary journal navigation">
  <UL>
    <LI class=3Djn-supplements><A=20
    href=3D"http://www.nature.com/nature/supplements/">Supplements</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-insights><A=20
      =
href=3D"http://www.nature.com/nature/supplements/insights/">Insights</A>
      <LI class=3Djn-outlooks><A=20
      =
href=3D"http://www.nature.com/nature/supplements/outlooks/">Outlooks</A>
      <LI class=3Djn-collections><A=20
      =
href=3D"http://www.nature.com/nature/supplements/collections/">Collection=
s</A>
      <LI class=3Djn-tech-features><A=20
      href=3D"http://www.nature.com/nature/supplements/tech/">Technology =

      Features</A></LI></UL>
    <LI class=3Djn-web-focuses><A =
href=3D"http://www.nature.com/nature/focus/">Web=20
    focuses</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-biological-sciences><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_biologicalsciences.html"=
>Biological=20
      sciences</A>
      <LI class=3Djn-earth-environment><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_earthandenvironment.html=
">Earth=20
      and environment</A>
      <LI class=3Djn-physical-sciences><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_physicalsciences.html">P=
hysical=20
      sciences</A>
      <LI class=3Djn-science-politics><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_scienceandpolitics.html"=
>Science=20
      and politics</A>
      <LI class=3Djn-science-culture><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_scicult.html">Science, =
art=20
      and culture</A></LI></UL>
    <LI class=3Djn-multimedia><A=20
    href=3D"http://www.nature.com/nature/multimedia/">Multimedia</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-podcast><A=20
      href=3D"http://www.nature.com/nature/podcast/">Nature podcast</A>
      <LI class=3Djn-video><A=20
      href=3D"http://www.nature.com/nature/videoarchive/">Video =
streaming</A>
      <LI class=3Djn-google><A=20
      =
href=3D"http://www.nature.com/nature/multimedia/googleearth">Google=20
earth</A>
      <LI class=3Djn-blogs><A=20
      =
href=3D"http://www.nature.com/blogs/index.html">Blogs</A></LI></UL><!--<l=
i class=3D"jn-press-releases"><a href=3D"/nature/press_release/">Press =
releases</a></li>-->
    <LI class=3Djn-about-journal><A=20
    href=3D"http://www.nature.com/nature/about/">About the journal</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-contact-journal><A=20
      href=3D"http://www.nature.com/nature/about/contact/">Contact the =
journal</A>
      <LI class=3Djn-about-editors><A=20
      href=3D"http://www.nature.com/nature/about/editors/">About the =
editors</A>
      <LI class=3Djn-nature-family><A=20
      href=3D"http://www.nature.com/nature/about/family/">Nature family =
of=20
      journals</A><!--<li class=3D"jn-first-issue"><a =
href=3D"/nature/about/first/"><span =
class=3D"journalname">Nature</span>'s first issue</a></li>-->
      <LI class=3Djn-for-advertisers><A=20
      href=3D"http://npg.nature.com/media/nature/index.html">For =
advertisers</A>
      <LI class=3Djn-for-librarians><A=20
      =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/07_home.xml&=
amp;style=3Dxml/07_home.xsl">For=20
      librarians</A></LI></UL>
    <LI class=3Djn-for-authors-and-referees><A=20
    href=3D"http://www.nature.com/nature/authors/">For authors and =
referees</A>
    <UL class=3Dsubnav><!--<li class=3D"jn-getting-published"><a =
href=3D"/nature/authors/get_published/">Getting published</a></li>-->
      <LI class=3Djn-guide-authors><A=20
      href=3D"http://www.nature.com/nature/authors/gta/">Formatting =
guide</A>
      <LI class=3Djn-publication-policies><A=20
      href=3D"http://www.nature.com/nature/authors/policy/">Publication=20
      policies</A>
      <LI class=3Djn-submissions><A=20
      =
href=3D"http://www.nature.com/nature/authors/submissions/">Submissions</A=
>
      <LI class=3Djn-for-referees><A=20
      href=3D"http://www.nature.com/nature/authors/referees/">For =
referees</A><!--<li class=3D"jn-scientists"><a href=3D"#">Scientists at =
nature.com</a></li>--></LI></UL>
    <LI class=3Djn-online-submission><A class=3Dsubmission=20
    href=3D"http://www.nature.com/nature/authors/submissions/">Online=20
    submission</A>
    <LI class=3Djn-permissions-and-reprints><A=20
    =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/01_reprints.=
xml&amp;style=3Dxml/01_reprints.xsl">Reprints</A>
    <LI class=3Djn-help><A=20
href=3D"http://www.nature.com/conferences">Conferences</A>
    <LI class=3Djn-help><A=20
    =
href=3D"http://nature.custhelp.com/cgi-bin/nature.cfg/php/enduser/std_alp=
.php">Help</A></LI></UL></MAP>
<H2 class=3Dnpg-resources>Gateways</H2>
<UL class=3Dnpg-resources>
  <LI><A href=3D"http://www.natureasia.com/home.html">Asia gateway</A>
  <LI><A href=3D"http://deutsche.nature.com/">German gateway</A>
  <LI><A href=3D"http://www.nature.com/omics/index.html">Omics =
gateway</A></LI></UL>
<DIV id=3Dglobal-subject-areas>
<H2><ABBR title=3D"Nature Publishing Group">NPG</ABBR> Journals</H2>
<H3 class=3Dview>by Subject Area</H3>
<UL class=3Dcategory-list>
  <LI>
  <H4>Chemistry</H4>
  <UL>
    <LI><A =
href=3D"http://www.nature.com/chemistry/index.html">Chemistry</A>=20
    <LI><A href=3D"http://www.nature.com/drugdisc/index.html">Drug =
discovery</A>=20
    <LI><A =
href=3D"http://www.nature.com/biotech/index.html">Biotechnology</A>=20
    </LI></UL>
  <LI>
  <H4>Clinical Practice &amp; Research</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/cancer/index.html">Cancer</A>=20
    <LI><A =
href=3D"http://www.nature.com/cardio/index.html">Cardiovascular=20
    medicine</A>=20
    <LI><A =
href=3D"http://www.nature.com/dentistry/index.html">Dentistry</A>=20
    <LI><A title=3D""=20
    =
href=3D"http://www.nature.com/endocrinology/index.html">Endocrinology -=20
    NEW</A>=20
    <LI><A =
href=3D"http://www.nature.com/gastrohep/index.html">Gastroenterology=20
    &amp; Hepatology</A>=20
    <LI><A href=3D"http://www.nature.com/pathology/index.html">Pathology =
&amp;=20
    Pathobiology</A>=20
    <LI><A href=3D"http://www.nature.com/urology/index.html">Urology</A> =
</LI></UL>
  <LI>
  <H4>Earth &amp; Environment</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/earthsciences/index.html">Earth =

    sciences</A>=20
    <LI><A href=3D"http://www.nature.com/evoeco/index.html">Evolution =
&amp;=20
    Ecology</A> </LI></UL>
  <LI>
  <H4>Life sciences</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/cancer/index.html">Cancer</A>=20
    <LI><A =
href=3D"http://www.nature.com/development/index.html">Development</A>=20
    <LI><A href=3D"http://www.nature.com/drugdisc/index.html">Drug =
discovery</A>=20
    <LI><A href=3D"http://www.nature.com/evoeco/index.html">Evolution =
&amp;=20
    Ecology</A>=20
    <LI><A =
href=3D"http://www.nature.com/genetics/index.html">Genetics</A>=20
    <LI><A =
href=3D"http://www.nature.com/immuno/index.html">Immunology</A>=20
    <LI><A =
href=3D"http://www.nature.com/medicalresearch/index.html">Medical=20
    research</A>=20
    <LI><A =
href=3D"http://www.nature.com/micro/index.html">Microbiology</A>=20
    <LI><A =
href=3D"http://www.nature.com/molcellbio/index.html">Molecular cell=20
    biology</A>=20
    <LI><A =
href=3D"http://www.nature.com/neurosci/index.html">Neuroscience</A>=20
    <LI><A =
href=3D"http://www.nature.com/pharma/index.html">Pharmacology</A>=20
  </LI></UL>
  <LI>
  <H4>Physics</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/physics/index.html">Physics</A> =

    <LI><A =
href=3D"http://www.nature.com/materials/index.html">Materials</A>=20
  </LI></UL></LI></UL>
<H3 class=3Dview><A title=3D"View A to Z list of Nature Publishing Group =
journals"=20
href=3D"http://www.nature.com/siteindex/index.html">by A - Z=20
Index</A></H3></DIV></DIV></DIV>
<DIV class=3Darchive id=3Dextranav>
<H1 class=3Dhidden>Extra navigation</H1><SPAN =
class=3Dpage-header-spacer>.</SPAN>=20
<DIV class=3Dsubscribe-to-nature>
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.write ('<ilayer id=3D"layer1" visibility=3D"hidden" =
width=3D"158" height=3D"60"></ilayer>');
document.write ('<nolayer>');
document.write ('<iframe =
src=3D"http://ad.doubleclick.net/adi/nature.com/article;type=3Daf;artid=3D=
nature04186;pos=3Dtop;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;=
subco=3D;chaco=3D;keywd=3D;dcopt=3Dist;sz=3D158x60;ord=3D' + ordval + =
'?" width=3D"158" height=3D"60" marginwidth=3D"0" marginheight=3D"0" =
frameborder=3D"0" scrolling=3D"no">');
document.write ('<a =
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Daf;artid=
=3Dnature04186;pos=3Dtop;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D=
;subco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D158x60;ord=3D' + =
ordval + '?">');
document.write ('<img =
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Daf;artid=3D=
nature04186;pos=3Dtop;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;=
subco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D158x60;ord=3D' + =
ordval + '?" style=3D"max-width:158px; height:60px; border:0;" =
/></a></iframe>');
document.write ('</nolayer>');
//--><!]]>
</SCRIPT>
<NOSCRIPT>
<DIV><A=20
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Daf;artid=
=3Dnature04186;pos=3Dtop;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D=
;subco=3D;chaco=3D;keywd=3D;abr=3D!NN2;sz=3D158x60;tile=3D1;ord=3D0789319=
5?"><IMG=20
style=3D"BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 60px; BORDER-RIGHT-WIDTH: 0px; =
max-width: 158px"=20
alt=3DAdvertisement=20
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Daf;artid=3D=
nature04186;pos=3Dtop;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;=
subco=3D;chaco=3D;keywd=3D;abr=3D!NN2;sz=3D158x60;tile=3D1;ord=3D07893195=
?"></A></DIV></NOSCRIPT></DIV>
<DIV id=3Darticlenav>
<H2><SPAN class=3Dhidden>ARTICLE NAVIGATION - </SPAN>FULL TEXT</H2>
<DIV class=3Dprevnext><A class=3Dprev title=3D"previous article in this =
issue"=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04338.=
html">Previous</A><SPAN=20
class=3Ddivider> | </SPAN><A class=3Dnext title=3D"next article in this =
issue"=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04353.=
html">Next</A></DIV>
<UL>
  <LI class=3Dtoc><A class=3Dtoc=20
  href=3D"http://www.nature.com/nature/journal/v438/n7069">Table of =
contents</A>=20
  <LI class=3Ddownload-pdf><A class=3Ddownload-pdf=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/pdf/nature04186.p=
df">Download=20
  PDF</A>=20
  <LI class=3Dsendtofriend><A class=3Dsendtofriend=20
  =
href=3D"http://www.nature.com/foxtrot/svc/mailform?file=3D/nature/journal=
/v438/n7069/full/nature04186.html">Send=20
  to a friend</A>=20
  <LI class=3Dexport><A class=3Dexport=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/ris/nature04186.r=
is">Export=20
  citation</A>
  <LI class=3Dexport><A class=3Dexport=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/ris/nature04186re=
fs.ris">Export=20
  references</A>=20
  <LI class=3Dpermissions><A class=3Dpermissions=20
  =
href=3D"https://s100.copyright.com/AppDispatchServlet?publisherName=3DNPG=
&amp;publication=3DNature&amp;title=3DVEGFR1-positive haematopoietic =
bone marrow progenitors initiate the pre-metastatic =
niche&amp;author=3DRosandra N. Kaplan, Rebecca D. Riba, Stergios =
Zacharoulis, Anna H. Bramley, Lo|[iuml]|c Vincent<i> et =
al.</i>&amp;contentID=3D10.1038/nature04186&amp;publicationDate=3D12/08/2=
005&amp;Vol=3D438&amp;Issue=3D7069">Rights=20
  and permissions</A>=20
  <LI class=3Dsave><A class=3Dsave=20
  =
href=3D"http://www.connotea.org/add?uri=3Dhttp://www.nature.com/nature/jo=
urnal/v438/n7069/full/nature04186.html">Bookmark=20
  in Connotea</A><!--<li class=3D"purchase-article"><a href=3D"" =
class=3D"purchase-article">Buy this article</a></li><li =
class=3D"purchase-issue"><a href=3D"" class=3D"purchase-issue">Buy this =
issue</a></li><li class=3D"purchase-issue last"><a href=3D"" =
class=3D"purchase-issue">Buy this supplement</a></li>-->=20

  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#abs">Abstract</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#BMDCs colonize pre-metastatic sites before tumour cells">BMDCs=20
  colonize pre-metastatic sites before tumour cells</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#Sites of BMDC clusters are tumour-type specific">Sites=20
  of BMDC clusters are tumour-type specific</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#Recruited BMDCs consist of haematopoietic progenitors">Recruited=20
  BMDCs consist of haematopoietic progenitors</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#BMDC clusters occur in a spontaneous tumour model">BMDC=20
  clusters occur in a spontaneous tumour model</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#BMDC clusters are recruited to pre-metastasic human tissue">BMDC=20
  clusters are recruited to pre-metastasic human tissue</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#Functional role for VEGFR1|[plus]| BMDCs in directing =
metastasis">Functional=20
  role for VEGFR1+ BMDCs in directing metastasis</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#VLA-4, MMP9 and Id3 mediate the pre-metastatic niche">VLA-4,=20
  MMP9 and Id3 mediate the pre-metastatic niche</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#Fibronectin upregulation supports adhesion of VLA-4|[plus]| =
BMDCs">Fibronectin=20
  upregulation supports adhesion of VLA-4+ BMDCs</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#VEGFR1|[plus]| cells promote tumour adherence and growth">VEGFR1+=20
  cells promote tumour adherence and growth</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#Tumour-derived conditioned media dictate metastatic =
patterns">Tumour-derived=20
  conditioned media dictate metastatic patterns</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#Methods">Methods</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#References">References</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#acknowledgements">Acknowledgements</A>
  <LI><A class=3Dfigures=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/fig_tab/nature041=
86_ft.html">Figures=20
  and tables</A>
  <LI><A=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/suppinfo/nature04=
186.html">Supplementary=20
  info</A></LI></UL></DIV>
<DIV class=3D"extra pink">
<H2>SEE ALSO</H2>
<UL>
  <LI><A=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/438750b.html=
">News=20
  and Views by Steeg</A>
  <LI><A=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/edsumm/e051208-07=
.html">Editor's=20
  Summary</A></LI></UL></DIV>
<DIV class=3D"extra grey">
<H2>SEARCH PUBMED FOR</H2>
<UL>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DKaplan+R">Rosandra=20
  N. Kaplan</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DRiba+R">Rebecca=20
  D. Riba</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DZacharoulis+S">Stergios=20
  Zacharoulis</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DBramley+A">Anna=20
  H. Bramley</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DVincent+L">Lo=EFc=20
  Vincent</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DCosta+C">Carla=20
  Costa</A>
  <LI class=3Dmore><A=20
  =
href=3D"http://www.nature.com/nature/journal/v438/n7069/pubmed/nature0418=
6.html">more=20
  authors of this article</A></LI></UL></DIV><!-- old nature.vm template =
being used, should use new njobs.vm instead -->
<DIV class=3Dbox id=3Dnatjob>
<H2 class=3Dnatjob><A href=3D"http://www.nature.com/naturejobs/"><SPAN=20
class=3Dfirst>nature</SPAN><SPAN class=3Dhidden> </SPAN><SPAN=20
class=3Dsecond>jobs</SPAN></A></H2>
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--

var jobs  =3D [=20
["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D4460b0b9=
4a0b0&lookid=3Dnature", "Laboratory Head", "Sanofi Aventis", "Frankfurt =
am Main, Germany D-65926", "Analytical =
Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D4460c59c4a0360&lookid=3Dnature", "Research Scientist", "VASTox plc", =
"Abingdon, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D4446449c4a0d190&lookid=3Dnature", "Director", "National Institutes of =
Health", "Bethesda, MD United States", =
"Immunology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D445f18844a0260&lookid=3Dnature", "Senior Staff Scientist", =
"National Institutes of Health", "Bethesda, MD United States", =
"Neuroscience"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D4458ac8f4a02d0&lookid=3Dnature", "Non-Clinical Lecturer", =
"University of Sheffield", "Sheffield, United Kingdom", =
"Dentistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D4458ac8f4a060&lookid=3Dnature", "Postdoctoral Researcher", "King's =
College London", "London, United Kingdom", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D4458ac8c4a0300&lookid=3Dnature", "Post-Doc Physiological =
Chemistry", "UMC", "Utrecht, Netherlands", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D4458ac904a06c0&lookid=3Dnature", "Research Associate", "University =
of Leicester", "Leicester, United Kingdom", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D4460b0b64a0a0&lookid=3Dnature", "Post-Doctoral Fellows", "Leland =
Stanford Junior University", "Stanford, CA United States", =
"Bioinformatics"],["http://naturejobs.nature.com/texis/jobsearch/details.=
html?id=3D4460b0b84a0420&lookid=3Dnature", "Senior Research Officer", =
"The University of Queensland", "Brisbane, Australia", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
4460b0b94a020&lookid=3Dnature", "Director", "The University of =
Queensland", "Brisbane, Australia", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
4458ac8b4a07200&lookid=3Dnature", "Preliminary Scientific Program", =
"Nerviano Medical Sciences", "Milan, Italy", "Cancer Research / =
Oncology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D445f7bce4a0410&lookid=3Dnature", "Staff Investigator", "Vertex =
Pharmaceuticals Incorporated", "Cambridge, MA United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d364a03e0&lookid=3Dnature", "Surgical / Cytopathologist", =
"Emory University Hospital", "Atlanta, GA United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d364a01f0&lookid=3Dnature", "Chair", "Stony Brook University", =
"Stony Brook, NY United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d354a0e2b0&lookid=3Dnature", "Director of Surgical Pathology", =
"University of Kansas", "Kansas, KS United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d354a0e200&lookid=3Dnature", "Head of New Cancer Genomics =
Lab", "Instituto Tecnologico de Monterrey", "Monterrey, Mexico", =
"Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D445f18844a0e0&lookid=3Dnature", "Scientific Project Manager", =
"National Institutes of Health", "Bethesda, MD United States", =
"Immunology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D445ba2fe4a0160&lookid=3Dnature", "PhD student position in =
Cardiovascular Physiology", "University of Heidelberg, Inst. Physiology =
Pathophysiology", "Heidelberg, Germany", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D4450d1654a0b0&lookid=3Dnature", "Research Leader", "USDA", =
"Parlier, CA United States", =
"Agriculture"],["http://naturejobs.nature.com/texis/jobsearch/details.htm=
l?id=3D444fc5464a0a00&lookid=3Dnature", "President", "Institute of =
Ecosystem Studies", "New York, NY United States", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D44509ab74a0220&lookid=3Dnature", "Manager", "University of South =
Alabama", "Mobile, AL United States", =
"Zoology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D44509ab74a0190&lookid=3Dnature", "Academic Pathologist and Anatomical =
Pathologist", "University Health Network", "Toronto, Canada", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44509ab74a0100&lookid=3Dnature", "Postdoctoral Position", =
"Karolinska Institute", "Sweden", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444ff6bd4a0e0&lookid=3Dnature", "Drug Discovery Team Leader - Renal =
Fibrosis", "ICOS Corporation", "Bothell, WA 98021 United States", =
"Biotechnology"],["http://naturejobs.nature.com/texis/jobsearch/details.h=
tml?id=3D444fc97b4a0570&lookid=3Dnature", "Postdoctoral Research =
Associate", "Loyola University", "Chicago, IL United States", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc97b4a0280&lookid=3Dnature", "Postdoctoral Fellow", "University of =
Arkansas for Medical Sciences College of Medicine", "Little Rock, AR =
United States", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9794a03f0&lookid=3Dnature", "Professor of Structural =
Bioinformatics", "University of Zurich", "Zurich, Switzerland", =
"Bioinformatics"],["http://naturejobs.nature.com/texis/jobsearch/details.=
html?id=3D444fc9794a0320&lookid=3Dnature", "Chair in Molecular =
Endocrinology", "University of Birmingham", "Birmingham, United =
Kingdom", =
"Endocrinology"],["http://naturejobs.nature.com/texis/jobsearch/details.h=
tml?id=3D444fc9794a0230&lookid=3Dnature", "Postdoctoral Scientist", "The =
Hospital for Sick Children Research Institute", "Toronto, Canada", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9784a0680&lookid=3Dnature", "Postdoctoral Fellow", "The Children's =
Hospital of Philadelphia", "Philadelphia, PA United States", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9774a04f0&lookid=3Dnature", "Research Program Managers", =
"U.S. Department of Energy", "Germantown, WA United States", "Env. Earth =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9774a0220&lookid=3Dnature", "Research Laboratory Manager", =
"Channing Laboratory", "Boston, MA United States", "Clinical =
Medicine"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9774a0190&lookid=3Dnature", "Tenure Track Positions", "Montana =
State University", "Bozeman, MT United States", =
"Microbiology"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9774a0120&lookid=3Dnature", "Director", "University of =
Hawaii-Manoa", "Honolulu, HI United States", "Earth =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9774a0b0&lookid=3Dnature", "Director of Stem Cell Biology", =
"University of Medicine and Dentistry of New Jersey", "Newark, NJ United =
States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc9774a040&lookid=3Dnature", "Scientific Investigator =
Positions", "Van Andel Research Institute", "Grand Rapids, MI United =
States", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9764a01d0&lookid=3Dnature", "Lecturer / Senior Lecturer", =
"University of Newcastle upon Tyne", "Newcastle upon Tyne, United =
Kingdom", "Medical =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9764a0160&lookid=3Dnature", "Member", "Natural Environment =
Research Council", "Swindon, United Kingdom", =
"Ecology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9764a0f0&lookid=3Dnature", "Postdoctoral Research Scientist", =
"University of Oxford", "Oxford, United Kingdom", "Structural =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9754a0260&lookid=3Dnature", "Experimental Officer / Senior =
Experimental Officer", "University of Manchester", "Manchester, United =
Kingdom", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9754a0160&lookid=3Dnature", "Experimental Officer", =
"University of Manchester", "Manchester, United Kingdom", =
"Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc9744a0540&lookid=3Dnature", "Postdoctoral Research Associate", =
"University of Manchester", "Manchester, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9744a0330&lookid=3Dnature", "Research Fellow", "University of St =
Andrews", "St Andrews, United Kingdom", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9744a01a0&lookid=3Dnature", "Research Scientists & Engineers", =
"Lucent Technologies", "Dublin, Ireland", "Materials =
Science"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9734a0420&lookid=3Dnature", "Professor", =
"Martin-Luther-University", "Halle / Saale, Germany 06120", "Life =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9734a0280&lookid=3Dnature", "Grant and Manuscript Writer", =
"Oncimmune", "Nottingham, United Kingdom", "Cancer Research / =
Oncology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9734a01c0&lookid=3Dnature", "Medical Statistician", "Oncimmune", =
"Nottingham, United Kingdom", =
"Statistics"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9734a0150&lookid=3Dnature", "Research Fellow", "University of =
Birmingham", "Birmingham, United Kingdom", =
"Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc9734a0a0&lookid=3Dnature", "Lecturer A / B in Gene Expression", =
"University of Leicester", "Leicester, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9724a04a0&lookid=3Dnature", "Senior Research Fellowships", =
"Wellcome Trust", "London, United Kingdom", "Medical =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9714a0330&lookid=3Dnature", "Professor", =
"Georg-August-Universitat Gottingen", "Gottingen, Germany 37073", =
"Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9714a0100&lookid=3Dnature", "Academic Fellowship", "University of =
Edinburgh", "Edinburgh, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9704a0b30&lookid=3Dnature", "Postdoctoral Research Fellow", =
"University of Dundee", "Dundee, United Kingdom", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9704a0350&lookid=3Dnature", "Director", "University of Leeds", =
"Leeds, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9704a0250&lookid=3Dnature", "Laser Spectroscopy Facilities =
Manager", "University of Leeds", "Leeds, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9704a01c0&lookid=3Dnature", "Lecturers in Biological Sciences", =
"University of Stirling", "Stirling, United Kingdom", =
"Conservation"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9704a0150&lookid=3Dnature", "Postdoctoral Position", =
"Friedrich Miescher Institute", "Basel, Switzerland", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9704a0e0&lookid=3Dnature", "Professor of Cardiovascular Medicine", =
"University of Glasgow", "Glasgow, United Kingdom", "Cardiovascular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9704a050&lookid=3Dnature", "Career Development Fellowship", =
"Medical Research Council", "Cambridge, United Kingdom", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96f4a0490&lookid=3Dnature", "Research Scientist", "DKFZ", =
"Heidelberg, Germany D-69120", =
"Biophysics"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc96f4a0210&lookid=3Dnature", "Postdoctoral Position", =
"University of Cambridge", "Cambridge, United Kingdom", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96f4a00f0&lookid=3Dnature", "Dual Masters Degree in Brain and Mind =
Sciences", "University College London", "London, United Kingdom", =
"Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96e4a0400&lookid=3Dnature", "Director", "DKFZ", "Heidelberg, =
Germany D-69120", "Optics / =
Lasers"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96e4a0370&lookid=3Dnature", "Postdoctoral Position", "Friedrich =
Miescher Institute", "Basel, Switzerland", =
"Genomics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc96e4a0240&lookid=3Dnature", "Postdoctoral Researcher", =
"University of Liverpool", "Liverpool, United Kingdom", =
"Geophysics"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc96e4a01d0&lookid=3Dnature", "W3-Professor for Experimental =
Physics / Non-Linear Optics", "Friedrich-Schiller-Universitat Jena", =
"Jena, Germany D-07743", =
"Physics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96e4a0160&lookid=3Dnature", "W3-Professor for Experimental =
Physics / Quantum Electronics", "Friedrich-Schiller-Universitat Jena", =
"Jena, Germany D-07743", =
"Physics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96d4a0820&lookid=3Dnature", "ILL Fellow", "Institut =
Laue-Langevin", "Grenoble, France", "Computer =
Science"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0780&lookid=3Dnature", "Research Group Leaders", "Friedrich =
Miescher Institute", "Basel, Switzerland", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0560&lookid=3Dnature", "Chair in Biostatistics", "University =
of Bristol", "Bristol, United Kingdom", =
"Mathematics"],["http://naturejobs.nature.com/texis/jobsearch/details.htm=
l?id=3D444fc96d4a02f0&lookid=3Dnature", "Post-Doctoral Position", =
"University of Rennes", "Rennes, France", "Gene =
Therapy"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0280&lookid=3Dnature", "PhD Studentship", "King's College =
London", "London, United Kingdom", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0210&lookid=3Dnature", "Research Studentships", "University of =
Warwick", "Warwick, United Kingdom", =
"Ecology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96d4a0c0&lookid=3Dnature", "Senior Research Fellowships", =
"Wellcome Trust", "London, United Kingdom", "Biomedical =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96d4a050&lookid=3Dnature", "Research Technician", "University of =
Oxford", "Oxford, United Kingdom", =
"Neuroscience"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc96c4a0830&lookid=3Dnature", "Neurophysiologist / =
Neurocytologist", "University of Oxford", "Oxford, United Kingdom", =
"Neuroscience"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc96c4a07b0&lookid=3Dnature", "Postdoctoral Research Fellow", =
"Royal Veterinary College", "London, United Kingdom", =
"Immunology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9604a0650&lookid=3Dnature", "Researchers", "Tokyo Women's =
Medical University", "Tokyo, Japan", "Molecular =
Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9604a05e0&lookid=3Dnature", "Assistant / Associate / Professor", =
"University of Kuwait", "Safat, Kuwait", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9604a0550&lookid=3Dnature", "Assistant / Associate / =
Professor", "University of Kuwait", "Safat, Kuwait", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc95f4a020&lookid=3Dnature", "Faculty Positions", "Christian =
Medical College", "Vellore, India", =
"Biotechnology"],["http://naturejobs.nature.com/texis/jobsearch/details.h=
tml?id=3D444fc95e4a0190&lookid=3Dnature", "Team Leader", "AstraZeneca", =
"Molndal, Sweden", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc95d4a090&lookid=3Dnature", "Neuroscientist", "AstraZeneca", =
"Molndal, Sweden", =
"Neurology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc95d4a040&lookid=3Dnature", "Post Doctoral Fellows", "Marie =
Curie Research Training Network", "Vienna, Austria", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc95a4a0f0&lookid=3Dnature", "Chemical Toxicologist / =
Biotransformation", "AstraZeneca", "Molndal, Sweden", =
"Toxicology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9594a0a00&lookid=3Dnature", "New Academic Posts", "University =
of Wales", "Bangor, United Kingdom", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9594a08e0&lookid=3Dnature", "Postdoc Position", "Charite", =
"Berlin, Germany", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9594a0600&lookid=3Dnature", "Full Professor", "Wageningen =
University", "Wageningen, Netherlands", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59c4a0330&lookid=3Dnature", "Lecturer in Chemistry - Centre =
for Magnetic Resonance", "University of York", "York, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59c4a02a0&lookid=3Dnature", "Professor of Medicinal =
Chemistry", "University of Strathclyde", "Strathclyde, Scotland", =
"Medicinal and pharmaceutical =
chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc59c4a0210&lookid=3Dnature", "Master of Science in Micro and =
Nanotechnology", "University of Neuchatel", "Neuchatel, Switzerland", =
"Microtechnology"],["http://naturejobs.nature.com/texis/jobsearch/details=
.html?id=3D444fc59c4a0170&lookid=3Dnature", "Postdoctoral Researcher", =
"University of Liverpool", "Liverpool, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59c4a0e0&lookid=3Dnature", "Formulation Development =
Scientists", "SSL", "Peterlee, United Kingdom", "Life =
sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc59c4a050&lookid=3Dnature", "Thermal Analysis Technology Leader", =
"SRG", "Teesside, United Kingdom", =
"Catalysis"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a0ac0&lookid=3Dnature", "C1, Head of Chemistry", "Scottish =
Agricultural Science Agency", "Edinburgh, Scotland, UK", "Analytical =
Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc59b4a0840&lookid=3Dnature", "Senior Chemist", "Nalco", "Fawley, =
United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a0750&lookid=3Dnature", "Various", "Matchtech", =
"Nationwide, United Kingdom", "Analytical =
Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc59b4a03b0&lookid=3Dnature", "Polymer Scientist", "Huntsman", =
"Wilton, Teesside, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a01f0&lookid=3Dnature", "Materials Formulation Chemist", =
"Gurit", "Newport, Isle of Wight, United Kingdom", "Chemistry"]];			 =20

if(jobs.length > 0) {
	var first =3D Math.round((jobs.length - 1) * Math.random());
	var second =3D Math.round((jobs.length - 1) * Math.random());

	if(jobs.length =3D=3D 1) {
		first =3D 0;
	} else if (jobs.length =3D=3D 2) {
		first =3D 0;
		second =3D 1;
	} else {
		while(first =3D=3D second) {
			second =3D Math.round((jobs.length - 1) * Math.random());
		}
	}
  =20
	document.write('<ul class=3D"natjob">');
=09
	document.write('<li><h3 class=3D"first"><a href=3D"');
	document.write(jobs[first][0]);
	document.write('">');
	document.write(jobs[first][1]);
	document.write('</a></h3>');
	document.write('<ul>');
	if (jobs[first][4]) {
		document.write('<li>' + jobs[first][4] + '</li>');
	}
	document.write('<li>' + jobs[first][2] + '</li>');
	document.write('<li>' + jobs[first][3] + '</li>');
	document.write('</ul>');
	document.write('</li>');

	if(jobs.length !=3D 1){	  =20
		document.write('<li><h3><a href=3D"');
		document.write(jobs[second][0]);
		document.write('">');
		document.write(jobs[second][1]);
		document.write('</a></h3>');
		document.write('<ul>');
		if (jobs[second][4]) {
			document.write('<li>' + jobs[second][4] + '</li>');
		}
		document.write('<li>' + jobs[second][2] + '</li>');
		document.write('<li>' + jobs[second][3] + '</li>');
		document.write('</ul>');
		document.write('</li>');
	}
   document.write('</ul>');
}

//--><!]]>
</SCRIPT>

<DIV class=3Dnatjobmore><A href=3D"http://naturejobs.nature.com/">More =
science=20
jobs</A></DIV></DIV>
<DIV class=3Dbox id=3Dnatprod>
<FORM action=3Dhttp://www.biocompare.com/nature/search.asp =
method=3Dpost>
<H2 class=3Dnatprod><A href=3D"http://www.biocompare.com/nature/"><SPAN=20
class=3Dfirst>nature</SPAN><SPAN class=3Dhidden> </SPAN><SPAN=20
class=3Dsecond>products</SPAN></A></H2>
<DIV class=3Dnatprodmore><LABEL class=3Dhidden for=3Dbuyerguide>enter =
buyers guide=20
search text here</LABEL><INPUT id=3Dbuyerguide name=3Dsearch><BR><INPUT =
class=3Dbutton type=3Dsubmit value=3D"search buyers =
guide"></DIV></FORM></DIV>
<DIV class=3Dad-vert>ADVERTISEMENT<BR>
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.write ('<ilayer id=3D"layer2" visibility=3D"hidden" =
width=3D"160" height=3D"600"></ilayer>');
document.write ('<nolayer>');
document.write ('<iframe =
src=3D"http://ad.doubleclick.net/adi/nature.com/article;type=3Daf;artid=3D=
nature04186;pos=3Dright;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D=
;subco=3D;chaco=3D;keywd=3D;;sz=3D160x600;ord=3D' + ordval + '?" =
width=3D"160" height=3D"600" marginwidth=3D"0" marginheight=3D"0" =
frameborder=3D"0" scrolling=3D"no">');
document.write ('<a =
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Daf;artid=
=3Dnature04186;pos=3Dright;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natc=
l=3D;subco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D160x600;ord=3D=
' + ordval + '?">');
document.write ('<img =
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Daf;artid=3D=
nature04186;pos=3Dright;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D=
;subco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D160x600;ord=3D' + =
ordval + '?" style=3D"max-width:160px; height:600px; border:0;" =
/></a></iframe>');
document.write ('</nolayer>');
//--><!]]>
</SCRIPT>
<NOSCRIPT>
<DIV><A=20
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Daf;artid=
=3Dnature04186;pos=3Dright;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natc=
l=3D;subco=3D;chaco=3D;keywd=3D;abr=3D!NN2;sz=3D160x600;ord=3D07893195?">=
<IMG=20
style=3D"BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 600px; BORDER-RIGHT-WIDTH: 0px; =
max-width: 160px"=20
alt=3DAdvertisement=20
src=3D"http://ad.doubleclick.net/ad/nature.com/article;pos=3Dright;abr=3D=
!NN2;sz=3D160x600;ord=3D07893195?"></A></DIV></NOSCRIPT></DIV></DIV></DIV=
></DIV>
<DIV class=3Dcleardiv><!--  --></DIV>
<P class=3D"back-to-top hidden"><A title=3D"Return to the top of this =
page"=20
href=3D"http://www.nature.com/nature/journal/v438/n7069/full/nature04186.=
html#top">Top</A></P>
<DIV class=3Dfooter id=3Dfoot-er>
<DIV id=3Dfooter-journal>
<DIV class=3D"footer-constrain clearfix">
<P class=3Djournal-name>Nature</P>
<P class=3Dissn style=3D"BORDER-RIGHT: #000 1px solid"><ABBR=20
title=3D"International Standard Serial Number">ISSN</ABBR><SPAN=20
class=3Dhidden>:</SPAN> 0028-0836</P>
<P class=3Deissn><ABBR=20
title=3D"Electronic International Standard Serial =
Number">EISSN</ABBR><SPAN=20
class=3Dhidden>:</SPAN> 1476-4687</P>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV id=3Dfooter-links>
<DIV class=3Dfooter-constrain>
<UL>
  <LI><A class=3Dabout-npg=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/02_intro.xml=
&amp;style=3Dxml/02_intro.xsl">About=20
  <ABBR title=3D"Nature Publishing Group">NPG</ABBR></A>
  <LI><A=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/01_home.xml&=
amp;style=3Dxml/01_home.xsl">Contact=20
  <ABBR title=3D"Nature Publishing Group">NPG</ABBR></A>
  <LI><A href=3D"http://www.nature.com/naturejobs/">Nature<SPAN =
class=3Dhidden>=20
  </SPAN>jobs.com</A>
  <LI><A=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/08_privacy.x=
ml&amp;style=3Dxml/08_privacy.xsl">Privacy=20
  policy</A>
  <LI><A href=3D"http://www.nature.com/common/legal_notice.html">Legal =
notice</A>
  <LI><A=20
  =
href=3D"http://www.nature.com/common/accessibility_statement.html">Access=
ibility=20
  statement</A>
  <LI><A class=3Drss=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/02_newsfeed.=
xml&amp;style=3Dxml/02_newsfeed.xsl"><ABBR=20
  title=3D"RDF Site Summary">RSS</ABBR> feeds</A>
  <LI><A=20
  =
href=3D"http://nature.custhelp.com/cgi-bin/nature.cfg/php/enduser/std_alp=
.php">Help</A>=20
  </LI></UL>
<DIV class=3Dcleardiv><!--  --></DIV></DIV></DIV>
<DIV id=3Dfooter-copyright>
<DIV class=3Dfooter-constrain>
<P class=3Dlogo><A class=3Dfooter-copyright title=3D""=20
href=3D"http://www.nature.com/common/copyright_statement.html">=A9 2006 =
Nature=20
Publishing Group</A> =96 partner of <A=20
href=3D"http://www.nature.com/common/partners.html">AGORA, HINARI, =
Cross<SPAN=20
class=3Dhidden> </SPAN>Ref and COUNTER =
</A></P></DIV></DIV></DIV><!--extra code for 160 x 600 ad-->
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.writeln ('<layer =
src=3D"http://ad.doubleclick.net/adl/nature.com/article;pos=3Dright;type=3D=
af;artid=3Dnature04186;pos=3Dright;issue=3D7069;webfo=3D;prod=3Dyes;natco=
=3D;natcl=3D;subco=3D;chaco=3D;keywd=3D;sz=3D160x600;ord=3D' + ordval + =
'?" visibility=3D"hidden" style=3D"max-width:160px; height:600px;" =
onload=3D"moveToAbsolute(layer2.pageX,layer2.pageY);clip.height=3D600;cli=
p.width=3D160;visibility=3D\'show\';"></layer>');
//--><!]]>
</SCRIPT>
<!--end of extra code--><!--extra code for 158 x 60 ad-->
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.writeln ('<layer =
src=3D"http://ad.doubleclick.net/adl/nature.com/article;type=3Daf;artid=3D=
nature04186;pos=3Dtop;issue=3D7069;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;=
subco=3D;chaco=3D;keywd=3D;sz=3D158x60;ord=3D' + ordval + '?" =
visibility=3D"hidden" style=3D"max-width:158px; height:60px;" =
onload=3D"moveToAbsolute(layer1.pageX,layer1.pageY);clip.height=3D60;clip=
.width=3D158;visibility=3D\'show\';"></layer>');
//--><!]]>
</SCRIPT>
<!--end of extra code--></BODY></HTML>

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/images/journal_header.gif

R0lGODlhowFKAMQAANsaIf///+yFifbGx+VXXO2NkPXCxORTWd0pMP3x8eA5P90oL/Oztfri4/rg
4el2evjU1fGjpulwdf3w8OJFS/Gpq+A3PfjR0+6Ul+dma+ZiZ++anfS3uet/gwAAAAAAACH5BAEA
AAAALAAAAACjAUoAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRK
rVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGS
k5SVlpdYGgESmJ2eVAsJAR2fpaZKCxABAQenrq9AqaussLW2IhQHBxYwsrOtbRa6t8QmGgkcJgsS
FQPOHB28vRIcDbOzDRXAKRSq19tPFAkQJQccEA0DnCjLFdbXyOvFtR2rAyQLFdf7A9IrCwVEBUjg
zNu1CimO7QvAoYDDAs4iDng3q8CJDg8LbJDoTF5CgSMWDFiIsARAgQHS/0Gk2MDjvE8LOMy6J0Lh
QngUVthMQGqEuH0l8W24SbRoAJolUBJFemLB0Fm4lF7z2AFlBX8iJKDksODlpwMUj4p4anRVgpwo
Csw6a+LAQrS4whKFILEo03ISRi68SwLsPgAWpF5LBiDfWg0ofq6C0NWrJQt6r93TFwDCww1ysaEg
GwDxCbkWR1AmCteEWn4sDM48YUHmQl9LC6sGZ3qwY0p5iSKrTBuA1psuAWhajSLyqtAmVK9asZfF
acklKIxeaC2d4AAIjSNHYWGf59uPupdlnPhmUBGhrn03YTzAdhLPoapoviL+qg1Jy5YUufAA5wSN
cbNPA+BJYsFvCwGoAv9ni5UQH4EptPfeCPYFwBxqOi004QI2DVgCZxK4dQ1+K7h2TWkFOiLBTRNG
d1MJYZFY3D4tAmAfOfNhqIKI19Q43D49kUBBBxLwIqEKGrR3XIqRiLcPiie8SMKTKhx5AoN8lbAQ
YTtqmMJNvfWVYAUZObTRdUsyCYmUK2RWgl4NrHeClezpiIKXK/BYUQqZBXjCdGWVVaOaiFDXgpJt
hZkcjTNCl4KTe+aJ55wLrSBYQ2UWwAFHzpg1AJSEJkLfCojOsMCkb9rZFqoo6LlKkHX+lYKrlYVq
y6hVVjpDPYxS6mirrJ5Aq6IAlJrWQjLa6gquEeoaQ4WbNEocsL12uQ//scZeGayynzArrXwvSJDZ
Koq2l+UItA6Kbn/NXoPjt2lye4q3vl7jwjLvVGDiL/CeK0K6LAzb7rT1Eixvt6rCayEL4q5SQVcC
FyzWrNuWw26/uSZ8MCb0xmqvCg2ntE3EHttjbY8BXyyxvwDsC+7GnnScqqysRUbeutdiTHG1O38z
sMkpQAsqzJTITEK2JHR4M84+n6AcywCvsGLOOqMw9T7J9qCAAAYYwAABTlwwgQI2KMCAAQ/swLUB
JazNQgYBYFAEAhgYIDcLXDvAdgsYBJCBEEaPgHRW1zTg57+v3akx05GqUCG2i4sAqWaAByDAChmA
7cPdEwQw9AsGWL4D/wHLkUD6wioIEAADRqi+d+qWh/45CQyIHkTgIgyu2CrB+easCUZH7bjKJU/M
J3CVX87NBJrz8MDCCszuQujK53B6CdezQAACrQfwegrUIyD9CAg0DwTuxf6eOzybqT9l5ADQep7C
kP96bIKH6zT+CKtcTgEB2yOAAMj2EwHkBAECEAD3/re9rTFQAVtr3tYEoLnnBYAADOQeADIggAdw
TwEAhCAFfZJAsgGAej4BIAFACEAEgJBsApRgB0VwvfKt8HQsXKENNWhDtCDgAQL4GwAySMQWbq2H
CEybCCaoOdeV4IdBxMUFAhABE4oAiNGjYQddGEItgg2JMxQBAg04Av8sKs5+PyvdCCZ3LuWgblGF
OxnlHgWmNL6xKddZmtSi5YL+AQABq7BbACYAANVR0YMOEEAEJoAAQFqucwKY4gUw0LmcPOACAKid
ByPQP7hdEAARcAACGHAB7kmSkp4DJQYQ4AC2oBAXq/Bg6PYmSgGcRXQEYJ7eAJA9DESAl6tgpfdE
kEAS9I1tCLgAA1j5S0dubxXPfKTl+uaACEzxcpfMZADS5kTyKZOZAHiAA7zXPAysMgLYDAAr2XbN
Qt7yctS0puiSiYHnge1s9jTB5IyXsY8xjp//JJfC8heSm8DKJG7k42fcV5ub6LEp+nhXC/wIgFhW
9JPQBOUFVXe5VSz/kwEUCN0vUbiKrQ0ze9B8ntxIN1IqntBypHPASy/3ShHU7peqI6QCHqCAYS5n
nC8F4HLoRsPlWJB7qySBEzn5N9WlLaNQXd0oKaA6mTqxpE7spgiYWshtznRKE6AAAnvKNgYQknpk
vWhXrTpMTmLQcs+j4DAt5iEWKAkr9lEQPhK6HU2JwGWjUEFmEiCnfyXUPV9iKEJ1UwCC+sYaCcAK
CygaVbBltHMRmOVFhfhVFGLgoyctHTRrdznSnVV04WPAAMdJU9tdMZh985sCq2rI2rL2dMkUYvYg
Wci2DbNzYFMd6yq72RFkdZifHeUwtQoA4HaVdTUFwDhF50QXzpS2/9A8Ltucm5PaGYCTd4wfm3JE
tZqQBB/6UFICJMChkZSkQoTtywbWa6O5FEAXByiANzS1EIni4yaSPcHuEtQQDeiiABUQCFtgQFmM
Otiyn+RfhDtru0h6F5gLgyYKr4dCFNLNAO2MbnMPWTvVdvV12Suq9wIgUwwTk8UZQNFVPzljCNvY
uMudq4Vz/L2MOjG6isGA6jA5AuoxV7vFFYGIScCgV0kKVfs8ioEblgwlwUMaFNDNAAyyHzQhD1rp
cAZyeAWUFgw4UItxbI6UR9zLuvaizeuw6NzqRJRekJOlZTGFFSg2BMi5elsd5AZXkRND+iSjKu4p
LkvnyO+9mG3jDP+uS9s8YSTTmcckiHRXWwroRtbOcsEssuUMjWO2ObFzd9OmoyUHreM4FkH7WG+A
ALWlrmRZN+uxMs9+ZJQGoKXVlalATiwA7AZEYwUWOCxRsvaCBt8YmhTgpCjDCWdRt9aAweQk23Cr
aKHKLa57HrJ0UfvmIbq0uURW9OUyIEzWsXA5hgShGjmpRKXm+G9uHfFbH1zqE98aAdo+sb3x/cno
si6TDlAAb8WKVj+yG8l9YyQvLWhJEbgDzZ8aQQcG4OVZQIAUsEEVrLGBosDYBUoduskGAtSeBmxA
A425OJoJ0jsKddwe+zOBSQNwAaHC1I+cvIACksniZZ5OeQoYJ0j/lU4BzKruLET/mh8FMIEMKBMA
SV8dBZTuSUXyfOtSLYEDhBiBelsQbUPs3CS7ekFFX8CQmlO4Bu29N1JmYALKo2Ztjy7G2vm6dgl3
+kAoAHgrZvICd/ef0q3ogK9dIG1nz0DWl3l2D/qd8Cwe+hSryT1OTsAAaNnUADaQKTNFZBvNEHPp
EeyMnhgGHlfR50Yqw4GaQybW2kgBQOTicsnq5eMBTj2ZVu+QiNQ8JNS4ictzfoPtjQCDMcjiEE1Y
vhOUz/ACNqHzU2DFoZMAhHO/fgxSTfcRgF9I2HeB9CmQ/u9vHwWNfH/55u5++iemNP9rgjA6MIwc
LAC/zJcLujA0bPkVYEUggLpggC8xVTFWAkD0PAdHNBLYB1kWAeRnU4jnNxO4gXzAQfb3RwlkPhw4
giRYgiZ4giiYgiq4gizYgi74gjAYgzI4gzRYgzZ4gziYgzq4gzzYgz74g0AYhEI4hERYhEZ4hEiY
hKUQAgA7

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/nature.com/article;type=af;artid=nature04186;date=200512;issue=7069;prod=yes;subco=;chaco=;keywd=;njdis=;njreg=;crstg=;pos=top;sz=728x90;fidid=7;posid=10;plaid=157;maact=${dcFieldValue};prisp=75;secsp=${dcFieldValue};proqu=${dcFieldValue};abr=!NN2;tile=1;ord=123456789?
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/common/images/clear.gif

R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/alpha/black/med/base/glyph.gif

R0lGODlhBwAIAIAAAAAAAP///yH5BAEAAAEALAAAAAAHAAgAAAINjG8AGdvvFJtRtopOAQA7

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/beta/black/med/base/glyph.gif

R0lGODlhCgALAJEAAAAAAP///////wAAACH5BAEAAAIALAAAAAAKAAsAAAIWlIGmAtr72JJnNhSr
g9zFDASYNXVTAQA7

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/plus/special/plusmn/black/med/base/glyph.gif

R0lGODlhDQAMAJH/AP///wAAAMDAwAAAACH5BAEAAAIALAAAAAANAAwAQAISlI+pG+2+RIho0otZ
tpm91xkFADs=

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/math/special/times/black/med/base/glyph.gif

R0lGODlhCAAJAIABAAAAAP///yH5BAEAAAEALAAAAAAIAAkAAAIPRI6gGLttjnopVvqchVsWADs=

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/v438/n7069/images/nature04186-f1.0.jpg
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=

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/micro/black/med/base/glyph.gif

R0lGODlhCgAMAIAAAAAAAP///yH5BAEAAAEALAAAAAAKAAwAAAITjI+pi2CeIGxPyTAxcBkz/4VL
AQA7

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/v438/n7069/images/nature04186-f2.0.jpg

/9j/4AAQSkZJRgABAgAAZABkAAD/7AARRHVja3kAAQAEAAAAPAAA/+4AJkFkb2JlAGTAAAAAAQMA
FQQDBgoNAAAFBwAACGYAAA1kAAAUpv/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoKDBAM
DAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8fHx8f
Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8IAEQgAOwCWAwERAAIR
AQMRAf/EANEAAAEFAQEAAAAAAAAAAAAAAAMBBAUGBwIAAQADAQEBAAAAAAAAAAAAAAAAAQIDBAUQ
AAEDAgUDAgUFAQAAAAAAAAECAwQAERAgEhMFMCEGMTNAMhQ0FUEiQiMkFhEAAQMCAgYFCgYCAwAA
AAAAAQARAiEDMRJBUWFxIjKBkXITBBChscHRQlKS0jMg8OFigiOiFENTgxIAAwEAAAAAAAAAAAAA
AAAAQGBwERMBAAICAQQBBAMBAQAAAAAAAQARITFBEFFhcYEg8JGhscHR4fH/2gAMAwEAAhEDEQAA
AbjYGiQgaUeQ4VeqBjE1RUqjoOLTbnriRKAjdwmo+R7vouhKDNs0nTZ0ec9TeU6Z1rSZnFyPHdO6
EJsI5WEXRxo97qChSWZy5ucVoxfIOHIQzilT6TpQudisY5UFijI2sPcahnRHy6PUW+HeG4515z5V
AkVmkjCM6R3lTZgWJIQdfB7FSecsNHY7LTvmxqfJ2jGpOHnBZtoUHCL3kU/ZNaCJdBkuFz+Vjkgt
87LSt28ipDQaKlcdYVqKoYPq5eOjLCNoNKI2oskzqQxfNFepXy1cbULpKA8yqezuqlRN3X67Evm0
uOUDboRM9R2snjNQWgbV2yrVkZ30Q2als6tGdU7Rwd6VdbuCtPXnhbWX0HLX/9oACAEBAAEFAmTc
OOlAW04KWlyk6dOuRSypNPHaU1uV5JIdblCVKpMqTd6VJFNTJW87Klb31cu6fyKg5ImpoS5dbhQ2
sXU67uUhSE02e6y7cABsLZ2mVh5jyL7oVx7aTXLiMqMySH3vf70iapKHJSnkj5tVNvNFvyNX+EkC
vGEpVJjpuhJWijocQj+uvKFpcmi10OWqQ646plv+x/3sCew+RPLcUKTyXHBnmvx0uKePbTXjUVLc
laVpK1BdIDy6EN5LvLcHNmvK8dloocDIv+DkUng5W454lyalr8Vnoo+Nyb/85KoeNyrSr7kH6ezL
kfS+6HK8W2NUmS6+rVWqo/INqbbWkJS88uVeik0knUXUoakOrdW2CKNClpK5HHcdrM6RsKVLdcHj
hNKWThfv2pSkpgJe11yMt6OByMvQjlny5KdGrVrKEI2tgl5LKKUr6eU5P3C5JaWgoKVeMx912bAU
wL4RAlcnkWEphtoFcuFCibmO1pdeN3mrCmdaaIK3Rq2HtvdGijosrRbxH33L6JHu1xP3kn7b+fLe
kj1jWp33EXt3v+76oX0//9oACAECAAEFAqt0Biclx074mk3viU0hOe+QY2rTkON6vV816vher5yq
v1R2wAxt1FGhY4DMMgwJxIrTQTiDiclqtltnGBxFKoZDh//aAAgBAwABBQL4C/ROBFsb0T1CLUcp
HStkBwJ6gwKr/A2q+cHENVpHwKPUqq2S/a4v000qh6Zf/9oACAECAgY/Ajsev//aAAgBAwIGPwKM
f//aAAgBAQEGPwI5nL8T6tgU5UyuwD8W9ZXpiJ/nBFvdw044daJBJq1cUGjExZzcJZtjKtM1Y7kY
wBuBh3tcFV+DiMH0a3UYxJhmhokaV2L7s/nK+9c+Yr70/mkoPeucw94qf982zGmYql+4f5FE95c+
cqt643aKl/fPD4jrUSzk0lHYAs8LYlBhmjLXsOxcds2y2sNX1o5ZsRGlQxQY6pPvWSMsglHinjuo
hbnM5Y0lM4mW7QsCzEPrQvWSJXo0O1tBVt6cJpq4sE6ndnlaDcyhMREZH7bBuHarfaHpVztH0+TL
lfpWSEAIRHnUt2KBniIhjq361lm4+Et7FB/+wOddCm61e7IfrXeW5d5aJzPc247VK5dOczoC2D6B
1oRuRAhb5ujCmKjdzg6CAcdihIfD6/Jl0IOXUO2PSrnaPp/BL86V/b4uFKUfEdCjCHjId6TxSL1G
ymKEPC+KticZuc5LYbiml4zw+bfL6VenG9bvcI4bRL+cBSIi0ZczlRe5yu8QQx1JhLvZa3Dp4wA0
5dZ1lQuWhC2IxymBJ17imN6yCNp9i+/Y+aX0r79h+0fYoHv7DAjAnR0KRE7bEk+99K47loPhWX0p
v9iy++X0pv8AYs9cvpUh39nDXLX2VKtIkiPW6z3J8UXa01Sd6FyzaOf33Dh9alK9a4o1MmZeJJ5c
ozg9OpOcNEdXkDU9KhG5Jp+8dHWpF9qy1ZyTLVpqv3KT8wY7SoxPLR1mUp6dARr0pnopV/OYKUMe
IsBvVu7bnllAtdEw4CuQjDu7xIE/hGX4d6uZq56noXiP4P51X8Eb/wDzvkjPYi7k4kq33Lcb02IE
iDAUbEIZcpzSiCCKo248ox9i1DSAu8cgPVm6EYykCA2aalCraDTlcBG5A8bnLqxXG5+IClUY937u
Xi6/JdhakY1iZS05arPGtrSTo8tqEuISLSGxlktxaMZ4fqjlFMJF20rw5A0nqZSiTlDKL/EGPSph
jzGgQDUBTYPSOnzqRZpEV1OMJMjx8Y2aXGhS5eaXx69C0f5Oh686OH+Su5f28nTjmUt3vM3Spcn/
AJ8vR5BhgcfUrvrXtVnHTh5IdoelT7aH6LY+lm6NKlulg2pHn+30Yhf/2gAIAQEDAT8hsYdWVgKN
f8so6AFrBdjt6hWAIurNGm05S8VV7q/IYYo0BlxvJrZFK+XNGp245gKVV8j8Ex3/ADKAiS2qbFvd
lw1E8zytdaLIfaFDu6ywN8x7X3vuUdYvTX5ixhXt/tEs67Dz+4LWgr33zDFQvkx/eIzJBiuTxmJ+
if8AvMV73jeZbIoYI1LKdf8AYIb0RVM8mkrNVAKlV/iKAlarqbO5RUBSjAatlv8AiUeWVQBa+RzM
EhUFTin5VLkTTanzrW9QMKrfF80KCMC+Z+kxjKRlGrbmq8amUSosvg7xgPDFyCdr+YE0TdjxxKyA
AOvJXmPJf+lkKohtI0rNOG8RKyBtbdtbfMW4WPcU7vISjOUr5c94YWgvRSkfJbFa3GgXozdh7w6z
ZZAhRU38oCIzR2uVF3ZqJIoMIXhcOQ/EvnpZT4Qx7HHiF7F3q5q2Yz44nBmE9lIvu+U9mGaaHDzE
WrnF+43Q6tfhKm+6BhgvyJvb3GWOeBXKXCDhrGjJb2mhGU3ri5Ti1bK/+mIFzGed345nBzBzBleX
CcSspm1brFxsU8fYfZNaqQDlioIO3g3zRJxJWh/tCxCpvhlFW9k1s0HPM8mKO31Py4jsRXU2r0Yt
8H8FF6frwr+SyllSVygY5BfqFFHVarndVIKIMKtzgAO8OxL1hWMISFDdWh/vmWOZbJ2OSy3uJvpp
DJ4aaua9Bac16mC+ysGVbW9XCwCtzXw64pl7CFkKwZ3vvcpgO4cVgNeKZfDdDQcpuIU034u6rj5i
trCt6Wm/fuZY56sbG/EJYwsq8ZTQdswEW3my9kpVdZs7VVa7y78EmLOwKJvCyqqqZvlCY6/RnNwv
tG5gLlgrjUY4UXIybHvg55zCvyHZZ9YmfRQUOnFQjRpKA2pvzGS0xPLe/M0sZuGFXhzbuVJACzAd
cw3sjAumhvmVC8gorh2VtxMubPCyma3fEvqSyS7Kv4qIF7m8418bLI5MmtGm8hvD5lMfyTsPqdGv
GdS/qXAuzp/3pX8zLEmbycxP3TEoTPdtlazjhKGndjCThPg+ZUboXA5JH4EuqgbwX8ThyoKJfbW/
UAKMhrolNWypyQ81Azr5B72kvPQ3XbNxrzP5oYf6TX5v5+PM7dr7vE+AzT1r53V/E/c/LPstT+09
f2xGX/0T/r+pbJqy8a2brP4jtq7+3a/6nqPg1+ZXt47ziV8v4XzL8VWv9/Nzte8Xhvj+rmvXP6ny
d5wr+zZ/fmeZ7a/pV/U//9oACAECAwE/IahGIdOZUMx6CIQ1Lhua6TVyoEJUejDpT4h0bptmQXg/
mDDpbKb5e8vPRJqXUYWh03DDp46h9DScdKL00iy4jLqCQ6C9K2XLiSmVEiGi5S5cwacdKOlR6Lg9
agV9B5mHzDQ/fz02h9CZ6HEuXB0ol46H76Xu+3TB9SJTcQu5iQ10wxKZaq56ffmcR+pOm/TpDXXT
p//aAAgBAwMBPyH6aK8/Q/WwfWVFb26LtHoUZZ9VfSRFTEOiulVHpk6X9B1qXldQOIxHfSpUqV1u
XLjBccNnQNfXX0vXcKZjh5+tariMC5gtjwfUMuX1rqQ6KoTJD6BanabFY7fW9D6TZ9B0/9oADAMB
AAIRAxEAABBRDW50DXiPRvYmmeV8OvlRZxTGA25pevtJ+ZjBp2xD8vWvYaevFhSGMH1P+KZBI8to
AH7yLW6aWGX/2gAIAQEDAT8Qyuk+hVGffXmPCzajMPnwyiMJEAgdIypp78TGxoHVqmSehrN+ILsa
sp4BFSaLZUEc2FjRW2lt/tSrAl1ilFjZ7kPd5iF1ggNgRt+My/kaE+dB+MwDsKChpFBasMyBvCU/
ueEgtDLy7modUjZqq7Eg/GWjGyHZ8SwqvDqcBwKlcQ0EYXmzFeGhlqztmROCbT0uLq+RHCYRWDE0
FoyZAFabxeYIgs3ogKGFQji4ePVR/b3woYvcs0KENkwXqTtkgMCo6uJVmkwpz2IwopgC1L5ATm1i
MAhVYoFdAf4MxJ7oEcgqkuTW7ue7oopaMHT3jSUsjIKUN64nYUl1d1VZvioVeK7q6Wd2ny3LUuEK
opIt2zdMQFEuewTC8Jec7QBsz5d5haAjVrkux4hJDElgqZhyazCy+CfF9tX4i4IYlwMt5AM+c4S4
JO+ykTbC4XMsdQWgRDYcyLgf0hgWjmUGBqDBAA1AMnTJoWqESIcMb0LFindoO5WKUADVlbMjYxeI
MAimKiuKyvKCRRFOKw0ubJiFqiFnTTfuEgqqdnZVJL8yDNQAA7Cg4iKtN0N+Qx2nuIAqXwVmCzzC
sMClNmeWNkSpDixho5qVoB3LTpx4zK12vgzarS64mJEGgimoF1+ZX0CGSssOD7RxMoGL2Bq1zCTt
gWCK1jDAHPB12Dw8oGazK9o0QoX+0rCrL5DRUCtc1GLtKkAHsOQV3iMK7TmjU3e4/wD/AFcniQrg
AaLkGzI4MYSkKa7ZHUIYLEC1RM+MbxO+Nk12eYSFRql0ZA4RQFIJA1W5TEC1pueZqhVZ4gH92pSt
gOqoFVd0ZbiXoNyEriHzpXEpCgDu6Ijzdaj3sjJR2xbOf9lVVQ9Rp9ikO+4xoVzLV+a7/DEcUXZe
P3G5esjA7gduIqzFsKwmFbZxH4KBiINY9sQEisy7JCcRa/tAE1pyM4A4I3rsEzgUTVlgbTD/AAQi
hNEl9g4NeZD5zaBgtL0VWblWdERgADcq04PuM4UWBYKvSpW1RWLj55YuXbAcahUhUl3iDg2y/Eqf
BA2HgVuNr/MoRVIW3bDEyDlGVEBs75iDP2IrK9gWPhUwWukLDXqb1BpeuMe6iBWb0nfEO2BvOf1C
9qsuNZ3r3MD+hTTAx4j5Iss7ZXIljoWKKbjFjtNSaE2jYxUsyzBkLVmUMvdAAQAo+6Xt3Q7wvMu2
q36hs2MDyXjBW6al+BVQEYkLZ2qtXDeCBF9sowfiEpzVvApm2Gh/EALNQhgR3Z+YdCniT1zLAqxq
XnyA0ALMClU3z2hTjS6Gi94ncUPq7QNht+UYH/WYQpSz0iCqaAMGT3cBFwgx8wBsMIyRaVznDZUJ
IAAIlklF9zMKOFYSBVossvdZsgbRYTAgzd2ByrncYU1K0sNBnmO9QQZpsspzCEroLU5NjlfOcMQX
EM6GKNi15pKrwwebI/IFOyVOsY0GyF7Jo1hBZjoOoZDVBwAAnWZuf7rcPsz1OKp3d/uNcV9mb7Ct
f7rP54nmvzAOPzr0n3aqf+vicbl+G5fvulrPZ2v4mgyx49t548r7uZzGNLOB/wAsqr+1mWx7PZp3
0/Uyr405a8TN/s9P9nE1HaVXdU3+n5njFu0W9t+T4j7B7n9nPEOwcey7X3VXLHDM0Gx4Xl/RP//a
AAgBAgMBPxBrCaIRSJkiaBiAYOWID8wGZVaqcE14h0OYZWwG3aFLGa/cvcyqgzapZFwuYU0jB3jA
uoU8sRuCOIyWeYZydz7/AOagCLbM3+X9RBs3LDiIm4KseO0Cys22N/epy38/ZAxiLdkshGNZiBs7
QBZAmFifNyzAmwZW9/f/AGBTbEjR2/7n9zDxV/ki4g3vTLpo1GtncWqRaLOY2CY49wdK8QI1n7+7
l7cD2jnkIAZGAvzALhhiK1Q4mDqmaQohjXEFwR3QzFVS9VUoyOCH1kc9rafwZ91KgQi1m6x/171z
M/BGfT/niUNd4UVGFNTmDuJLlLmFpUh0WUvLBBKHDV1m+PthJ5oec59LuHoXvz0h0eh5ERcbpBb2
V+I2LN9pit6cpxGluY94fD2PiBHdI4N1/esSkWBL7eR1jtKzTKC+Zdh64wzcEEAbmUUAx5hcXdTR
0oKYVhzHYe05/Pr4hx7/AJceYfb74/uavojohNOYzWbdNG/iaz7f889+Jo9dOefifaz/AGf/2gAI
AQMDAT8Q+ktq+lfu/pXBYN9F6ARWSvqYy58QkQp27So1Rpq+orEuodKK/wAldaLlZxzOzqkBZdxH
IUkoNA73fmDUVtKV5nuBZGC89B0Ipb0tGCxgR9wRKK6e0ygpa6xnt2iS8YvCv0KdAgrcUBFkLgoJ
8xZcuDE5iEeizpcXSptRAoGFYr/x29zXzGL0Hps/dXnvBHdG59lvEqWosqooblX0obnhDixmWP0D
pizOGe87BvcIWBHMe8pFpPvNXPdfLj3GEd/WnTd+/wAznL/FDcYa6OZ//9k=

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/v438/n7069/images/nature04186-f3.0.jpg
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/v438/n7069/images/nature04186-f4.0.jpg
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/v438/n7069/images/nature04186-f5.0.jpg
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/v438/n7069/images/nature04186-f6.0.jpg
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/beta/black/bold/base/glyph.gif

R0lGODlhCQALAIAAAAAAAMDAwCH5BAEAAAEALAAAAAAJAAsAQAIUTIBglrmNnjqTSlaX3TviS02e
pxUAOw==

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/nature.com/article;type=af;artid=nature04186;pos=top;issue=7069;webfo=;prod=yes;natco=;natcl=;subco=;chaco=;keywd=;abr=!NN2;sz=158x60;tile=1;ord=07893195?
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/nature.com/article;pos=right;abr=!NN2;sz=160x600;ord=07893195?
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------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/layout.css

#header {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#breadcrumb {
	MARGIN-LEFT: 1%; MARGIN-RIGHT: 1%
}
#constrain {
	FLOAT: left
}
#constrain DIV.constrain {
	FLOAT: left
}
#constrain {
	FLOAT: none
}
#constrain DIV.constrain {
	FLOAT: none
}
#content-journalnav {
	BORDER-TOP: #fff 1px solid; DISPLAY: inline; FLOAT: left; MARGIN-LEFT: =
1%; WIDTH: 79%
}
#content-journalnav:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #content-journalnav {
	HEIGHT: 1%
}
#journalnav {
	FLOAT: left; WIDTH: 21%
}
#journalnav:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #journalnav {
	HEIGHT: 1%
}
#content {
	FLOAT: right; PADDING-BOTTOM: 1em; MARGIN-LEFT: 2%; WIDTH: 76%
}
#content:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #content {
	HEIGHT: 1%
}
#extranav {
	BORDER-TOP: #fff 1px solid; DISPLAY: inline; FLOAT: right; WIDTH: 17%; =
MARGIN-RIGHT: 1%
}
#extranav:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #extranav {
	HEIGHT: 1%
}
#footer {
	CLEAR: both; PADDING-RIGHT: 1%; BORDER-TOP: black 4px solid; =
PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#footer-copyright {
	CLEAR: both; PADDING-RIGHT: 1%; BORDER-TOP: black 1px solid; =
PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#footer-sponsor {
	CLEAR: both; PADDING-RIGHT: 1%; BORDER-TOP: black 1px solid; =
PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; TEXT-ALIGN: =
center
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: 7bit
Content-Location: http://www.nature.com/common/style/layout_wide_banner.css

 HTML #content-journalnav {
	WIDTH: 74%
}
#content-journalnav {
	WIDTH: 75%
}
#extranav {
	WIDTH: 22%
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/main.css

 HTML BODY {
	FONT-SIZE: 90%
}
 HTML BODY {
	FONT-SIZE: 89%
}
BODY {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; BACKGROUND: =
#fff; PADDING-BOTTOM: 20px; MARGIN: 0px; COLOR: #000; PADDING-TOP: 0px; =
FONT-FAMILY: Verdana, arial, Helvetica, sans-serif
}
A:link {
	COLOR: #36c
}
A:visited {
	COLOR: #639
}
A:hover {
	COLOR: #c03
}
.print-header {
	DISPLAY: none
}
.hidden {
	LEFT: 0px; OVERFLOW: hidden; WIDTH: 1px; POSITION: absolute; TOP: =
-500px; HEIGHT: 1px
}
.clearfix:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML .clearfix {
	HEIGHT: 1%
}
DIV.cleardiv {
	CLEAR: both; PADDING-RIGHT: 0px! important; PADDING-LEFT: 0px! =
important; PADDING-BOTTOM: 0px! important; PADDING-TOP: 0px! important
}
SPAN.cleardiv {
	CLEAR: both! important; PADDING-RIGHT: 0px! important; DISPLAY: block! =
important; PADDING-LEFT: 0px! important; PADDING-BOTTOM: 0px! important; =
MARGIN: 0px; PADDING-TOP: 0px! important
}
.no-css {
	DISPLAY: none; HEIGHT: 0px
}
#npglogo {
	MARGIN-LEFT: -34px; POSITION: relative; TOP: -10px
}
#npglogo {
	DISPLAY: block
}
UNKNOWN {
	DISPLAY: none
}
UNKNOWN {
	DISPLAY: block
}
#npglogo IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; Z-INDEX: 1; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 26px; POSITION: absolute; TOP: 1em; =
HEIGHT: 26px; BORDER-RIGHT-WIDTH: 0px
}
#accessibility-bar #npglogo A {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; =
BACKGROUND-IMAGE: none; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
.button {
	FONT-WEIGHT: bold; FONT-SIZE: 80%; COLOR: #fff; BACKGROUND-COLOR: #000
}
.clear {
	CLEAR: both
}
.clearleft {
	CLEAR: left
}
OL.decimal {
	LIST-STYLE-TYPE: decimal
}
OL.decimal-leading-zero {
=09
}
OL.lower-alpha {
	LIST-STYLE-TYPE: lower-alpha
}
OL.upper-alpha {
	LIST-STYLE-TYPE: upper-alpha
}
OL.lower-roman {
	LIST-STYLE-TYPE: lower-roman
}
OL.upper-roman {
	LIST-STYLE-TYPE: upper-roman
}
OL.lower-greek {
=09
}
.align-left {
	TEXT-ALIGN: left
}
.align-center {
	TEXT-ALIGN: center
}
.align-right {
	TEXT-ALIGN: right
}
.align-baseline {
	VERTICAL-ALIGN: baseline
}
.align-sub {
	VERTICAL-ALIGN: sub
}
.align-super {
	VERTICAL-ALIGN: super
}
.align-text-top {
	VERTICAL-ALIGN: text-top
}
.align-middle {
	VERTICAL-ALIGN: middle
}
.align-bottom {
	VERTICAL-ALIGN: bottom
}
.align-text-bottom {
	VERTICAL-ALIGN: text-bottom
}
A.seealso {
	MARGIN-TOP: 1em; DISPLAY: block; FONT-SIZE: 70%; TEXT-DECORATION: none
}
A.seealso SPAN.see {
	FONT-WEIGHT: bold; COLOR: #c03
}
A.seealso SPAN.link {
	TEXT-DECORATION: underline
}
A.rss {
	PADDING-LEFT: 34px; BACKGROUND: url(/common/images/icons/rss.gif) =
no-repeat left center
}
A.rss:hover {
	BACKGROUND: url(/common/images/icons/rss_on.gif) no-repeat left center
}
#extranav A.rss {
	PADDING-LEFT: 22px; BACKGROUND: url(/common/images/icons/newsfeeds.gif) =
no-repeat left center; PADDING-BOTTOM: 2px; PADDING-TOP: 1px
}
#extranav A.receive {
	PADDING-LEFT: 22px; BACKGROUND: url(/common/images/icons/newsfeeds.gif) =
no-repeat left center; PADDING-BOTTOM: 2px; PADDING-TOP: 1px
}
#content SPAN.free {
	COLOR: #c03; TEXT-DECORATION: none
}
.dev-error {
	FONT-WEIGHT: bold; FONT-SIZE: 80%; BACKGROUND: #f00; COLOR: #fff
}
.b {
	FONT-WEIGHT: bold
}
.i {
	FONT-STYLE: italic
}
.latin {
	FONT-STYLE: italic
}
H1.page-header {
	FONT-WEIGHT: bold; FONT-SIZE: 140%; PADDING-BOTTOM: 4px; MARGIN: 15px =
0px 10px; BORDER-BOTTOM: #eaeaea 1px solid
}
SPAN.page-header-spacer {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 140%; VISIBILITY: hidden; =
PADDING-BOTTOM: 4px; MARGIN: 15px 0px 0px
}
SPAN.journalname {
	FONT-STYLE: italic
}
SPAN.journalnumber {
	FONT-WEIGHT: bold
}
SPAN.tm {
	VERTICAL-ALIGN: super
}
 HTML #breadcrumb DIV {
	PADDING-LEFT: 19.4%; PADDING-TOP: 1px
}
#breadcrumb DIV {
	CLEAR: left; PADDING-LEFT: 19.6%; BACKGROUND: #eaeaea; PADDING-BOTTOM: =
0.2em
}
#breadcrumb DIV A:link {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#breadcrumb DIV A:visited {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#breadcrumb DIV A:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#breadcrumb SPAN.divider {
	FONT-SIZE: 70%; COLOR: #000
}
#breadcrumb SPAN.thisitem {
	FONT-SIZE: 70%; COLOR: #000
}
#login-inpage {
	MARGIN: 0px; COLOR: #000; BACKGROUND-COLOR: #eaeaea
}
#login-inpage A {
	FONT-SIZE: 70%
}
#login-inpage DIV.userpassbox {
	FLOAT: left; WIDTH: 8em
}
#login-inpage .passdetails {
	CLEAR: left
}
#login-inpage INPUT.text {
	FONT-SIZE: 80%; MARGIN: 0px; WIDTH: 9em; COLOR: #000
}
#login-inpage LABEL {
	FONT-SIZE: 70%
}
#login-inpage INPUT.button {
	MARGIN-TOP: 5px
}
#login-inpage #savepass-inpage {
	MARGIN-BOTTOM: -2px
}
#login-inpage DIV.error {
	PADDING-LEFT: 20px; FONT-SIZE: 80%; BACKGROUND: =
url(/common/images/login_error.gif) no-repeat 0px 4px; MARGIN-BOTTOM: =
5px; COLOR: #c30
}
#login-inpage DIV.error SPAN {
	FONT-WEIGHT: bold
}
#head-er HR {
	DISPLAY: none
}
#head-er .header-nonad-wrapper {
	PADDING-BOTTOM: 15px; BORDER-BOTTOM: #fff 1px solid
}
#head-er .accessibility-login-wrap {
	FLOAT: left; WIDTH: 100%; BORDER-BOTTOM: #000 1px solid; =
BACKGROUND-COLOR: #eaeaea
}
#head-er .accessibility-login {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 4px; TEXT-ALIGN: right
}
#head-er .accessibility-login A.nature-link {
	FLOAT: left; FONT: bold 160%/80% Garamond, serif; WIDTH: 4.9em; COLOR: =
#b1062e; MARGIN-RIGHT: 20px; TEXT-ALIGN: left; TEXT-DECORATION: none
}
 HTML #head-er .accessibility-login A.nature-link:hover {
	BACKGROUND: none transparent scroll repeat 0% 0%
}
#head-er .accessibility-login A.nature-link:hover {
	BACKGROUND: =
url(/common/includes/header/images/nature.com.underline.gif) no-repeat =
left bottom
}
#head-er .accessibility-login IMG.nature-logo {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 1px 20px 0px 0px; WIDTH: 82px! =
important; HEIGHT: 11px; BORDER-RIGHT-WIDTH: 0px
}
#head-er .accessibility-login .jumplinks {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: =
0px; MARGIN: 0px; WIDTH: 45%; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; =
TEXT-ALIGN: left
}
#head-er .accessibility-login .jumplinks LI {
	DISPLAY: inline; PADDING-LEFT: 15px
}
#head-er .accessibility-login .jumplinks LI.first {
	PADDING-LEFT: 0px
}
#head-er .accessibility-login .jumplinks A {
	PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/icons/b1062e/arrow_down.gif) no-repeat left center; =
COLOR: #000; TEXT-DECORATION: none
}
#head-er .accessibility-login .jumplinks A:hover {
	TEXT-DECORATION: underline
}
#head-er DIV.logon {
=09
}
#head-er .logon .onlyformacie {
	FONT-SIZE: 3px
}
#head-er .logon .onlyformacie {
	DISPLAY: none
}
#head-er .logon A.login {
	PADDING-RIGHT: 15px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/includes/header/images/logon.gif) no-repeat right center; =
PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; COLOR: #b1062e; =
PADDING-TOP: 0px; LETTER-SPACING: -0.1em; TEXT-DECORATION: none
}
#head-er .logon A.login:hover {
	BACKGROUND: url(/common/includes/header/images/logon_over.gif) =
no-repeat right center; TEXT-DECORATION: underline
}
#head-er .logon A.login:active {
	BACKGROUND: url(/common/includes/header/images/logon.gif) no-repeat =
right center
}
#head-er .logon A.logoff {
	PADDING-RIGHT: 15px; PADDING-LEFT: 15px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/includes/header/images/logoff.gif) no-repeat right center; =
PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; COLOR: #b1062e; =
PADDING-TOP: 0px; LETTER-SPACING: -0.1em; TEXT-DECORATION: none
}
#head-er .logon P {
	MARGIN: 0px
}
#head-er .logon .user {
	FONT-WEIGHT: bold
}
#head-er .logon .inst {
	FONT-WEIGHT: bold
}
#head-er .image-user-services-wrap {
	FLOAT: left; WIDTH: 100%; BACKGROUND-COLOR: #d6335c
}
#head-er .image-user-services {
	BORDER-BOTTOM: transparent 1px solid
}
 HTML #head-er .image-user-services {
	BORDER-BOTTOM-WIDTH: 0px
}
#head-er .image-user-services IMG.journal-header {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 0px; WIDTH: 344px; HEIGHT: 74px; =
BORDER-RIGHT-WIDTH: 0px
}
#head-er .user-services {
	FLOAT: right
}
#head-er .div1 {
	WIDTH: 12.35em! important
}
#head-er .div2 {
	WIDTH: 8.7em! important
}
#head-er .user-services UL {
	BORDER-RIGHT: #fff 0px solid; PADDING-RIGHT: 0px; BORDER-TOP: #fff 1px =
solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 22px 0px 21px; =
BORDER-LEFT: #fff 1px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #fff 0px =
solid; LIST-STYLE-TYPE: none; TEXT-ALIGN: right
}
#head-er .user-services UL.list1 {
	BORDER-RIGHT: #fff 1px solid
}
#head-er .user-services LI {
	BORDER-BOTTOM: #fff 1px solid
}
#head-er .user-services A {
	PADDING-RIGHT: 13px; DISPLAY: block; PADDING-LEFT: 0px; BACKGROUND: =
url(/common/images/icons/fff/arrow_s.gif) #767474 no-repeat right =
center; PADDING-BOTTOM: 1px; TEXT-TRANSFORM: uppercase; COLOR: #fff; =
PADDING-TOP: 1px; TEXT-DECORATION: none
}
#head-er .user-services A:hover {
	BACKGROUND: url(/common/images/icons/fff/arrow_s.gif) #000 no-repeat =
right center
}
#head-er .publications-search-wrap {
	BACKGROUND: #000
}
 HTML #head-er .publications-search {
	PADDING-BOTTOM: 3px; PADDING-TOP: 3px
}
#head-er .publications-search {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 4px; =
PADDING-TOP: 4px
}
 HTML #head-er .publications {
	MARGIN: 6px 0px 0px
}
#head-er .publications {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: =
0px; MARGIN: 4px 0px 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#head-er .publications LI {
	DISPLAY: inline; MARGIN-LEFT: 10px
}
#head-er .publications LI.first {
	MARGIN-LEFT: 0px
}
#head-er .publications A {
	PADDING-RIGHT: 15px; BACKGROUND: =
url(/common/images/icons/fff/arrow_s.gif) no-repeat right center; =
TEXT-TRANSFORM: uppercase; COLOR: #fff; TEXT-DECORATION: none
}
#head-er .publications A:hover {
	TEXT-DECORATION: underline
}
#head-er .search {
	TEXT-ALIGN: right
}
#head-er .search FORM {
	DISPLAY: inline; MARGIN: 0px
}
#head-er .search FORM A {
	PADDING-RIGHT: 14px; BACKGROUND: =
url(/common/images/icons/fff/arrow_s.gif) no-repeat right center; =
TEXT-TRANSFORM: uppercase; COLOR: #fff; TEXT-DECORATION: none
}
#head-er .search FORM A:hover {
	TEXT-DECORATION: underline
}
#head-er #searchtext {
	WIDTH: 10em
}
#head-er .publications-search LABEL {
	TEXT-TRANSFORM: uppercase; COLOR: #fff
}
#head-er INPUT {
	FONT-SIZE: 100%
}
#head-er SELECT {
	FONT-SIZE: 100%
}
#head-er .publications-search INPUT.button {
	PADDING-RIGHT: 3px; PADDING-LEFT: 3px; FONT-WEIGHT: bold; BACKGROUND: =
#eaeaea; PADDING-BOTTOM: 0px; COLOR: #000; PADDING-TOP: 0px
}
#head-er .accessibility-login {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%
}
#head-er .image-user-services {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%
}
#head-er .publications-search {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%
}
.header-leaderboard-wrap {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%; BACKGROUND: =
url(/common/includes/header/images/bg_leaderboard.gif) no-repeat 50% 0px
}
.header-leaderboard {
	TEXT-ALIGN: center; max-height: 105px
}
 HTML .header-leaderboard IMG {
	BORDER-BOTTOM-WIDTH: 1px
}
 HTML .header-leaderboard ilayer {
	BORDER-BOTTOM-WIDTH: 1px
}
 HTML .header-leaderboard IFRAME {
	BORDER-BOTTOM-WIDTH: 1px
}
 HTML .header-leaderboard EMBED {
	BORDER-BOTTOM-WIDTH: 1px
}
.header-leaderboard IMG {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard ilayer {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard IFRAME {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard EMBED {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard TABLE {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN-LEFT: auto; WIDTH: =
100%; MARGIN-RIGHT: auto; PADDING-TOP: 0px; BORDER-BOTTOM: #fff 1px =
solid; BORDER-RIGHT-WIDTH: 0px; max-width: 728px
}
 HTML .header-leaderboard TABLE IMG {
	HEIGHT: auto
}
#global-subject-areas {
	BORDER-RIGHT: #ebebeb 1px solid; BORDER-TOP: #ebebeb 1px solid; =
BACKGROUND: #ebebeb; MARGIN: 0px 0px 20px; BORDER-LEFT: #ebebeb 1px =
solid; BORDER-BOTTOM: #ebebeb 1px solid
}
#global-subject-areas abbr {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; BORDER-RIGHT-WIDTH: 0px; TEXT-DECORATION: none
}
#global-subject-areas A:link {
	FONT-WEIGHT: bold; COLOR: #9d0006; TEXT-DECORATION: none
}
#global-subject-areas A:visited {
	FONT-WEIGHT: bold; COLOR: #9d0006; TEXT-DECORATION: none
}
#global-subject-areas A:hover {
	TEXT-DECORATION: underline
}
#global-subject-areas H2 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H3 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H4 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H5 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H3.view {
	PADDING-RIGHT: 17px; PADDING-LEFT: 17px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/bg.7x1.b1062e.gif) #fff repeat-y left top; =
PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #9d0006; PADDING-TOP: 5px; =
BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H4.view {
	PADDING-RIGHT: 17px; PADDING-LEFT: 17px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/bg.7x1.b1062e.gif) #fff repeat-y left top; =
PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #9d0006; PADDING-TOP: 5px; =
BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H5.view {
	PADDING-RIGHT: 17px; PADDING-LEFT: 17px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/bg.7x1.b1062e.gif) #fff repeat-y left top; =
PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #9d0006; PADDING-TOP: 5px; =
BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: =
0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#global-subject-areas UL UL {
	FONT-SIZE: 100%
}
#global-subject-areas UL LI {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; =
LINE-HEIGHT: 150%; PADDING-TOP: 5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas UL LI LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 5px; BORDER-BOTTOM-WIDTH: 0px; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#global-subject-areas UL LI H4 {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
FONT-WEIGHT: normal; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 100%; =
BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #666; PADDING-TOP: 0px; =
FONT-STYLE: italic; BORDER-RIGHT-WIDTH: 0px
}
#global-subject-areas UL LI H5 {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
FONT-WEIGHT: normal; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 100%; =
BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #666; PADDING-TOP: 0px; =
FONT-STYLE: italic; BORDER-RIGHT-WIDTH: 0px
}
#global-subject-areas UL LI H6 {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
FONT-WEIGHT: normal; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 100%; =
BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #666; PADDING-TOP: 0px; =
FONT-STYLE: italic; BORDER-RIGHT-WIDTH: 0px
}
MAP.journal-nav {
	DISPLAY: block; MARGIN-BOTTOM: 20px
}
MAP.journal-nav UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
MAP.journal-nav UL LI {
	MARGIN: 0px; BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #eaeaea
}
MAP.journal-nav UL LI.grouped {
	BORDER-BOTTOM: #eaeaea 1px solid
}
 HTML MAP.journal-nav UL LI A {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 2px
}
 HTML MAP.journal-nav UL LI A:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 2px
}
MAP.journal-nav UL LI A {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 5px; FONT-WEIGHT: =
bold; FONT-SIZE: 80%; PADDING-BOTTOM: 4px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 4px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI A:visited {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 5px; FONT-WEIGHT: =
bold; FONT-SIZE: 80%; PADDING-BOTTOM: 4px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 4px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #c00; TEXT-DECORATION: none
}
MAP.journal-nav UL LI A.on {
	COLOR: #fff; BACKGROUND-COLOR: #c00
}
MAP.journal-nav UL LI A.on:visited {
	COLOR: #fff; BACKGROUND-COLOR: #c00
}
MAP.journal-nav UL LI A.submission {
	PADDING-LEFT: 20px! important; BACKGROUND: =
url(/common/images/online_submissions.gif) no-repeat left center
}
MAP.journal-nav UL LI UL.subnav {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none; TEXT-ALIGN: left
}
MAP.journal-nav UL LI UL.subnav LI {
	BACKGROUND: url(/common/images/nav_dots2.gif) #fafafa no-repeat 11px =
5px; BORDER-BOTTOM-WIDTH: 0px; MARGIN: 0px
}
MAP.journal-nav UL LI UL.subnav LI.on {
	BACKGROUND: url(/common/images/nav_dots1.gif) #c00 no-repeat 11px 5px; =
BORDER-BOTTOM: #fafafa 1px solid
}
 HTML MAP.journal-nav UL LI UL.subnav A {
	PADDING-RIGHT: 10px; PADDING-LEFT: 20px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px
}
MAP.journal-nav UL LI UL.subnav A:link {
	PADDING-RIGHT: 10px; DISPLAY: block; PADDING-LEFT: 20px; FONT-WEIGHT: =
normal; FONT-SIZE: 70%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 2px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI UL.subnav A:visited {
	PADDING-RIGHT: 10px; DISPLAY: block; PADDING-LEFT: 20px; FONT-WEIGHT: =
normal; FONT-SIZE: 70%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 2px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI UL.subnav A:hover {
	BACKGROUND: url(/common/images/nav_dots1.gif) #fab934 no-repeat 11px =
5px; COLOR: #fff; TEXT-DECORATION: none
}
MAP.journal-nav UL LI UL.subnav A.on {
	COLOR: #fff
}
MAP.journal-nav UL LI UL.subnav A.on:visited {
	COLOR: #fff
}
#journalnav MAP.supplementary UL A {
	FONT-WEIGHT: normal; FONT-SIZE: 70%
}
#journalnav MAP.supplementary UL A:visited {
	FONT-WEIGHT: normal; FONT-SIZE: 70%
}
H2.society-resources {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
80%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: 2px; =
BACKGROUND-COLOR: #fab934
}
UL.society-resources {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 20px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
UL.society-resources LI {
	MARGIN: 0px; BACKGROUND-COLOR: #eaeaea
}
UL.society-resources A {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.society-resources A:visited {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.society-resources A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #fab934; TEXT-DECORATION: none
}
DIV.society-logo {
	MARGIN-BOTTOM: 20px; TEXT-ALIGN: center
}
DIV.society-logo IMG {
	WIDTH: 100%
}
H2.npg-resources {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
80%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: 2px; =
BACKGROUND-COLOR: #b1062e
}
UL.npg-resources {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 20px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
UL.npg-resources LI {
	MARGIN: 0px; BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #eaeaea
}
UL.npg-resources A {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-resources A:visited {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-resources A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #b1062e; TEXT-DECORATION: none
}
H2.npg-subjects {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
80%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: 2px; =
BACKGROUND-COLOR: #c03
}
UL.npg-subjects {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 20px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
UL.npg-subjects LI {
	MARGIN: 0px; BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #eaeaea
}
UL.npg-subjects A {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-subjects A:visited {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-subjects A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #c03; TEXT-DECORATION: none
}
UL.npg-subjects A.npgsubject-browseall:link {
	COLOR: #c03
}
UL.npg-subjects A.npgsubject-browseall:visited {
	COLOR: #c03
}
UL.npg-subjects A.npgsubject-browseall:hover {
	COLOR: #fff
}
A.backtotop:link {
	MARGIN-TOP: 5px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_white_up.gif) no-repeat 0px 0.6em; FLOAT: =
right; MARGIN-LEFT: 7px; COLOR: #fff; MARGIN-RIGHT: 10px
}
A.backtotop:visited {
	MARGIN-TOP: 5px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_white_up.gif) no-repeat 0px 0.6em; FLOAT: =
right; MARGIN-LEFT: 7px; COLOR: #fff; MARGIN-RIGHT: 10px
}
A.backtotop:hover {
	COLOR: #fff
}
H1.page {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #fab934; PADDING-BOTTOM: 3px; MARGIN: 0px 0px 10px; =
COLOR: #fff; PADDING-TOP: 3px
}
IMG.arrow {
	MARGIN-RIGHT: 5px
}
A.arrow-blue {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat 0px 0.5em
}
A.arrow-grey {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_grey.gif) =
no-repeat 0px 0.5em
}
A.arrow-red {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_red.gif) =
no-repeat 0px 0.5em
}
DIV.research-reviews {
	BORDER-RIGHT: #eaeaea 1px solid; BORDER-TOP: #eaeaea 1px solid; =
MARGIN-BOTTOM: 2em; BORDER-LEFT: #eaeaea 1px solid; BORDER-BOTTOM: =
#eaeaea 1px solid
}
DIV.research-reviews H1 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 90%; BACKGROUND: =
#eaeaea; PADDING-BOTTOM: 4px; MARGIN: 0px; COLOR: #900; PADDING-TOP: 3px
}
DIV.research-reviews P {
	FONT-SIZE: 70%; MARGIN: 1em 10px; COLOR: #900
}
DIV.research-reviews UL {
	PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 0px; MARGIN: 0px 10px 1em; PADDING-TOP: 1em; =
LIST-STYLE-TYPE: none
}
DIV.research-reviews LI {
	MARGIN: 0px 0px 0.5em
}
DIV.research-reviews LI A {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
DIV.research-reviews LI SPAN {
	FONT-SIZE: 70%
}
DIV.ad-horiz {
	CLEAR: both; BORDER-TOP: #eaeaea 1px solid; FONT-SIZE: 70%; =
MARGIN-BOTTOM: 20px; COLOR: #ccc; PADDING-TOP: 10px; TEXT-ALIGN: center
}
DIV.ad-horiz IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px; max-width: 468px
}
DIV.ad-horiz EMBED {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px; max-width: 468px
}
 HTML DIV.ad-horiz {
	MARGIN-LEFT: auto; OVERFLOW: hidden; WIDTH: 100%; MARGIN-RIGHT: auto; =
max-width: 468px
}
#extranav A.topten:link {
	PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; MARGIN-TOP: 0.6em; =
DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 1.2em; PADDING-BOTTOM: =
0px; PADDING-TOP: 0.8em
}
#extranav A.topten:visited {
	PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; MARGIN-TOP: 0.6em; =
DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 1.2em; PADDING-BOTTOM: =
0px; PADDING-TOP: 0.8em
}
#extranav A.topten:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 1.2em; =
TEXT-DECORATION: underline
}
DIV.ad-vert {
	FONT-SIZE: 70%; MARGIN-BOTTOM: 20px; COLOR: #ccc; TEXT-ALIGN: center
}
DIV.ad-vert IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 600px; =
BORDER-RIGHT-WIDTH: 0px; max-width: 120px
}
DIV.ad-vert EMBED {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 600px; =
BORDER-RIGHT-WIDTH: 0px; max-width: 120px
}
 HTML DIV.ad-vert {
	MARGIN-LEFT: auto; OVERFLOW: hidden; WIDTH: 100%; MARGIN-RIGHT: auto; =
max-width: 160px
}
.box#natjob {
	BORDER-RIGHT: #e7e7e7 1px solid; PADDING-RIGHT: 6px; BORDER-TOP: =
#e7e7e7 1px solid; PADDING-LEFT: 6px; BACKGROUND: #fff; PADDING-BOTTOM: =
6px; MARGIN: 10px 0px; BORDER-LEFT: #e7e7e7 1px solid; COLOR: #000; =
PADDING-TOP: 6px; BORDER-BOTTOM: #e7e7e7 1px solid
}
H2.natjob {
	PADDING-RIGHT: 7px; PADDING-LEFT: 7px; FONT-SIZE: 120%; BACKGROUND: =
#d8d8d8; PADDING-BOTTOM: 5px; MARGIN: 0px 0px 0.75em; TEXT-TRANSFORM: =
lowercase; PADDING-TOP: 5px; LETTER-SPACING: -0.04em
}
H2.natjob A {
	TEXT-DECORATION: none
}
H2.natjob SPAN.first {
	COLOR: #f00
}
H2.natjob SPAN.second {
	COLOR: #000
}
UL.natjob {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none
}
UL.natjob H3 {
	FONT-WEIGHT: bold; FONT-SIZE: 110%; MARGIN: 10px 0px 0px
}
UL.natjob H3.first {
	MARGIN: 0px
}
UL.natjob H3 A:link {
	COLOR: #000; TEXT-DECORATION: underline! important
}
UL.natjob H3 A:visited {
	COLOR: #000; TEXT-DECORATION: underline! important
}
UL.natjob LI H3 A:hover {
	COLOR: #c03
}
UL.natjob LI H3 A:unknown {
	COLOR: #c03
}
 HTML UL.natjob UL {
	LINE-HEIGHT: 120%
}
DIV.natjobmore {
	PADDING-RIGHT: 0px; BORDER-TOP: #cecece 1px solid; PADDING-LEFT: 0px; =
FONT-SIZE: 110%; PADDING-BOTTOM: 5px; MARGIN: 0px; PADDING-TOP: 5px
}
DIV.natjobmore A:link {
	DISPLAY: inline; PADDING-LEFT: 15px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/icons/next.gif) no-repeat 0px 0.3em; MARGIN: 0px; =
COLOR: #c03; TEXT-DECORATION: none
}
DIV.natjobmore A:visited {
	DISPLAY: inline; PADDING-LEFT: 15px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/icons/next.gif) no-repeat 0px 0.3em; MARGIN: 0px; =
COLOR: #c03; TEXT-DECORATION: none
}
.box#natjob DIV.natjobmore A:hover {
	BACKGROUND-IMAGE: url(/common/images/icons/next_hover.gif); =
TEXT-DECORATION: underline
}
.box#natjob DIV.natjobmore A:unknown {
	BACKGROUND-IMAGE: url(/common/images/icons/next_hover.gif); =
TEXT-DECORATION: underline
}
UL.natjob UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: =
0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
P.natjobmore {
	PADDING-BOTTOM: 5px; MARGIN: 0px
}
P.nateventmore {
	PADDING-BOTTOM: 5px; MARGIN: 0px; PADDING-TOP: 5px
}
.box#natprod {
	BORDER-RIGHT: #e7e7e7 1px solid; PADDING-RIGHT: 6px; BORDER-TOP: =
#e7e7e7 1px solid; PADDING-LEFT: 6px; BACKGROUND: #fff; PADDING-BOTTOM: =
6px; MARGIN: 10px 0px; BORDER-LEFT: #e7e7e7 1px solid; COLOR: #000; =
PADDING-TOP: 6px; BORDER-BOTTOM: #e7e7e7 1px solid
}
H2.natprod {
	PADDING-RIGHT: 7px; PADDING-LEFT: 7px; FONT-SIZE: 120%; BACKGROUND: =
#d8d8d8; PADDING-BOTTOM: 5px; MARGIN: 0px 0px 0.75em; TEXT-TRANSFORM: =
lowercase; PADDING-TOP: 5px; LETTER-SPACING: -0.04em
}
H2.natprod A {
	TEXT-DECORATION: none
}
H2.natprod SPAN.first {
	COLOR: #f00
}
H2.natprod SPAN.second {
	COLOR: #000
}
.box#natprod FORM {
	MARGIN: 0px
}
DIV.natprod {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 4px; PADDING-LEFT: 4px; =
BACKGROUND: #f3f2f2; PADDING-BOTTOM: 4px; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 4px; BORDER-BOTTOM: black 1px solid
}
DIV.natprodmore {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0.75em; =
PADDING-TOP: 0px
}
DIV.natprodmore A:link {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; COLOR: #c03; =
TEXT-DECORATION: none
}
DIV.natprodmore A:visited {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; COLOR: #c03; =
TEXT-DECORATION: none
}
DIV.natprodmore A:unknown {
	TEXT-DECORATION: underline
}
DIV.natprodmore A:hover {
	TEXT-DECORATION: underline
}
DIV.natprod SPAN {
	DISPLAY: block; FONT-SIZE: 70%; MARGIN-BOTTOM: 10px; LINE-HEIGHT: 110%
}
#natprod FORM {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
DIV.natprodmore FORM {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
DIV.natprodmore INPUT {
	MARGIN-TOP: 5px; FONT-SIZE: 110%; WIDTH: 98%! important
}
 HTML DIV.natprodmore INPUT {
	WIDTH: 96%! important
}
DIV.natprodmore INPUT {
=09
}
DIV.natprodmore INPUT {
=09
}
DIV.natprodmore INPUT.button {
	FONT-WEIGHT: bold; COLOR: #fff; BACKGROUND-COLOR: #000
}
#article-related #journal-header {
	DISPLAY: none
}
#article-related H2.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#article-related H2.figure-title {
	CLEAR: both; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#article-related P.from {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px; COLOR: #c03
}
#article-related P.aug {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related A.back-to-article:link {
	CLEAR: both; PADDING-RIGHT: 1em; PADDING-LEFT: 1em; FONT-WEIGHT: bold; =
FONT-SIZE: 70%; BACKGROUND: #000; FLOAT: right; PADDING-BOTTOM: 3px; =
MARGIN: 10px 0px; COLOR: #fff; PADDING-TOP: 3px; TEXT-DECORATION: none
}
#article-related A.back-to-article:visited {
	CLEAR: both; PADDING-RIGHT: 1em; PADDING-LEFT: 1em; FONT-WEIGHT: bold; =
FONT-SIZE: 70%; BACKGROUND: #000; FLOAT: right; PADDING-BOTTOM: 3px; =
MARGIN: 10px 0px; COLOR: #fff; PADDING-TOP: 3px; TEXT-DECORATION: none
}
#article-related A.back-to-article:hover {
	BACKGROUND: #fab934; COLOR: #fff; TEXT-DECORATION: none
}
#article-related DIV.container-image {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: #eaeaea; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; =
PADDING-TOP: 10px; TEXT-ALIGN: center
}
#article-related DIV.container-image-text {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: #eaeaea; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; =
PADDING-TOP: 10px
}
#article-related DIV.container-image-text P {
	FONT-SIZE: 90%
}
#article-related FORM {
	MARGIN: 0px
}
#article-related DIV.container-image-text UL {
	FONT-SIZE: 90%
}
#article-related DIV.container-image-text OL {
	FONT-SIZE: 90%
}
#article-related DIV.prevnext {
	CLEAR: both; BORDER-RIGHT: black 1px solid; BORDER-TOP: black 1px =
solid; BACKGROUND: #fff; BORDER-LEFT: black 1px solid; BORDER-BOTTOM: =
black 1px solid; TEXT-ALIGN: center
}
#article-related DIV.prevnext .hide {
	DISPLAY: none
}
#article-related DIV.prevnext A {
	FONT: 70% verdana, arial, helvetica, sans-serif; TEXT-DECORATION: none
}
#article-related A.previous:link {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_blue_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#article-related A.previous:visited {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_blue_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#article-related A.previous:hover {
	BACKGROUND: url(/common/images/arrow_red_left.gif) no-repeat left =
center
}
#article-related A.index:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; VERTICAL-ALIGN: middle; PADDING-TOP: 2px
}
#article-related A.index:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; VERTICAL-ALIGN: middle; PADDING-TOP: 2px
}
#article-related A.index:hover {
	BACKGROUND: url(/common/images/arrow_red_up.gif) no-repeat left center
}
#article-related A.next:link {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat right center; FLOAT: right; =
PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: 10px; =
PADDING-TOP: 2px
}
#article-related A.next:visited {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat right center; FLOAT: right; =
PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: 10px; =
PADDING-TOP: 2px
}
#article-related A.next:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat right center
}
#article-related DIV.container-figtab {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 0px solid
}
#article-related DIV.last {
	BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-figtab DIV.container-image IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; BORDER-RIGHT-WIDTH: 0px; max-width: 150px
}
#article-related DIV.container-figtab DIV.container-image {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: none transparent scroll repeat 0% =
0%; FLOAT: left; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: =
150px; PADDING-TOP: 0px; TEXT-ALIGN: right; BORDER-RIGHT-WIDTH: 0px
}
#article-related DIV.container-figtab DIV.container-image-text {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: none transparent scroll repeat 0% =
0%; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN-LEFT: 160px; =
PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: 0px
}
#article-related DIV.container-figtab DIV.container-image-text H3 {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-figtab DIV.container-image-text P {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-figtab A.full {
	MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: 25px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/full_figure.gif) no-repeat 0px 0px
}
#article-related DIV.container-figtab A.pp {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: =
25px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/fff/powerpoint.gif) no-repeat 0px 0px; =
PADDING-BOTTOM: 4px; PADDING-TOP: 0px
}
#article-related DIV.container-supplementary {
	CLEAR: both; BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 0px; =
PADDING-LEFT: 0px; BACKGROUND: #eaeaea; PADDING-BOTTOM: 0px; =
BORDER-LEFT: black 1px solid; PADDING-TOP: 0px
}
#article-related A.download-plugins:link {
	CLEAR: both; BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 0px; =
BORDER-TOP: black 1px solid; DISPLAY: block; PADDING-LEFT: 17px; =
FONT-SIZE: 70%; BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat =
10px 0.45em; PADDING-BOTTOM: 3px; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 0px; BORDER-BOTTOM: black 1px solid
}
#article-related A.download-plugins:visited {
	CLEAR: both; BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 0px; =
BORDER-TOP: black 1px solid; DISPLAY: block; PADDING-LEFT: 17px; =
FONT-SIZE: 70%; BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat =
10px 0.45em; PADDING-BOTTOM: 3px; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 0px; BORDER-BOTTOM: black 1px solid
}
#article-related A.download-plugins:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 10px 0.45em
}
#article-related DIV.container-supplementary H2 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 10px
}
#article-related DIV.container-supplementary P {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 90%; =
PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 0px; BORDER-BOTTOM: =
black 1px solid
}
#article-related DIV.container-supplementary P.last {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BORDER-BOTTOM-WIDTH: 0px; =
PADDING-BOTTOM: 10px; PADDING-TOP: 0px
}
#article-related DIV.container-sendfriend {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-plugins {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more2 {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more2 {
	BORDER-BOTTOM-WIDTH: 0px
}
#article-related DIV.wrapper {
	MARGIN-BOTTOM: 10px
}
#article-related P.explain {
	FONT-SIZE: 70%; MARGIN: 0px 0px 1em
}
#article-related DIV.container-plugins P {
	FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#article-related DIV.container-plugins P.last {
	MARGIN: 0px
}
#article-related P.results {
	FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#article-related A.article {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#article-related P.journal {
	FONT-SIZE: 70%; MARGIN: 0px; FONT-STYLE: italic
}
#article-related P.journal SPAN {
	FONT-STYLE: normal
}
#article-related DIV.container-more2 P.journal {
	MARGIN-BOTTOM: 1em
}
#article-related H3.area {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase
}
#article-related A.allmatches:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#article-related A.allmatches:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#article-related A.allmatches:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#article-related DIV.text {
	FLOAT: left; WIDTH: 210px; TEXT-ALIGN: right
}
#article-related DIV.text LABEL {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article-related DIV.text P {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.form {
	MARGIN-LEFT: 220px
}
#article-related DIV.form INPUT {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; WIDTH: auto; PADDING-TOP: 0px
}
#article-related DIV.form TEXTAREA {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; WIDTH: auto; PADDING-TOP: 0px
}
#article-related DIV.form INPUT {
	WIDTH: 100%
}
#article-related DIV.form TEXTAREA {
	WIDTH: 100%
}
#article-related INPUT.friend {
	CLEAR: both; FLOAT: right
}
 HTML #article-related TABLE.data {
	FONT-SIZE: 100%
}
#article-related TABLE.data {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #999 1px =
solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; BORDER-LEFT: =
#999 1px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #999 1px solid; =
BORDER-COLLAPSE: collapse; TEXT-ALIGN: left
}
#article-related TABLE.data THEAD {
	FONT-WEIGHT: bold
}
#article-related TABLE.data THEAD TH {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0.5em; PADDING-LEFT: =
0.5em; FONT-SIZE: 90%; BACKGROUND: #f6f6f6; PADDING-BOTTOM: 0.5em; =
BORDER-LEFT: #999 1px solid; PADDING-TOP: 0px
}
#article-related TABLE.data THEAD TH.colspan {
	BORDER-RIGHT: #999 1px solid; BORDER-TOP: #999 0px solid; BORDER-LEFT: =
#999 1px solid; BORDER-BOTTOM: #999 1px solid; TEXT-ALIGN: center
}
#article-related TABLE.data THEAD TH.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TD.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TD.rowsep {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data THEAD TH.rowsep {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY {
	BORDER-TOP: #999 1px solid; BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TR {
	BACKGROUND-COLOR: #f6f6f6
}
#article-related TABLE.data TBODY TR.odd {
	BACKGROUND-COLOR: #fff
}
#article-related TABLE.data TBODY TD {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0.5em; PADDING-LEFT: =
0.5em; FONT-SIZE: 90%; PADDING-BOTTOM: 0.15em; PADDING-TOP: 0.15em
}
#article-related TABLE.data TFOOT TD {
	PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; FONT-SIZE: 90%; =
PADDING-BOTTOM: 0.5em; PADDING-TOP: 0.5em; BACKGROUND-COLOR: #fff
}
#foot-er {
	BORDER-TOP-WIDTH: 0px; CLEAR: both; PADDING-RIGHT: 0px; PADDING-LEFT: =
0px; PADDING-BOTTOM: 0px; MARGIN: 20px 0px; PADDING-TOP: 0px
}
#foot-er #footer-journal {
	PADDING-RIGHT: 1%; BORDER-TOP: #000 1px solid; PADDING-LEFT: 1%; =
BACKGROUND: #eee; PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#foot-er #footer-journal:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #foot-er #footer-journal {
	HEIGHT: 1%
}
#foot-er #footer-journal P {
	PADDING-RIGHT: 1em; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: =
0px; MARGIN: 0px 1em 0px 0px; PADDING-TOP: 0px
}
#foot-er #footer-journal P.journal-name {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; FONT-STYLE: italic
}
#foot-er #footer-journal P.issn {
	FONT-SIZE: 100%
}
#foot-er #footer-journal P.eissn {
	FONT-SIZE: 100%
}
#foot-er #footer-journal P.extra {
	FONT-SIZE: 100%
}
#foot-er #footer-links {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%; BACKGROUND: #000; PADDING-BOTTOM: =
5px; PADDING-TOP: 5px
}
#foot-er #footer-links UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#foot-er #footer-links UL LI {
	DISPLAY: inline
}
#foot-er #footer-links UL LI A:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 1em; BACKGROUND: =
#000; FLOAT: left; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0px 1em; =
BORDER-LEFT: #fff 1px solid; COLOR: #fff; PADDING-TOP: 0px; =
TEXT-DECORATION: none
}
#foot-er #footer-links UL LI A:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 1em; BACKGROUND: =
#000; FLOAT: left; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0px 1em; =
BORDER-LEFT: #fff 1px solid; COLOR: #fff; PADDING-TOP: 0px; =
TEXT-DECORATION: none
}
 HTML #foot-er #footer-links UL LI A:link {
	DISPLAY: inline
}
 HTML #foot-er #footer-links UL LI A:visited {
	DISPLAY: inline
}
#foot-er #footer-links UL LI A:hover {
	TEXT-DECORATION: underline
}
#foot-er #footer-links UL LI A.about-npg:link {
	PADDING-LEFT: 0px; FONT-WEIGHT: bold; BORDER-LEFT-WIDTH: 0px; =
MARGIN-LEFT: 0px
}
#foot-er #footer-links UL LI A.about-npg:visited {
	PADDING-LEFT: 0px; FONT-WEIGHT: bold; BORDER-LEFT-WIDTH: 0px; =
MARGIN-LEFT: 0px
}
#foot-er #footer-copyright {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 1%; PADDING-LEFT: 1%; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px; TEXT-ALIGN: left! important
}
 HTML #foot-er #footer-copyright .footer-constrain {
	TEXT-ALIGN: left
}
#foot-er #footer-copyright A {
	COLOR: #b1062e
}
#foot-er #footer-copyright P {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 5px
}
#foot-er #footer-copyright P.logo {
	PADDING-RIGHT: 36px; PADDING-LEFT: 36px; BACKGROUND: =
url(/common/images/npg_logo.gif) no-repeat 0px 50%; PADDING-BOTTOM: 7px; =
MARGIN: 5px 0px 0px; PADDING-TOP: 7px
}
#foot-er #footer-copyright P A:link {
	FONT-WEIGHT: bold; TEXT-DECORATION: none
}
#foot-er #footer-copyright P A:visited {
	FONT-WEIGHT: bold; TEXT-DECORATION: none
}
#foot-er #footer-copyright P A.footer-copyright:link {
	FONT-WEIGHT: normal; COLOR: #000
}
#foot-er #footer-copyright P A.footer-copyright:visited {
	FONT-WEIGHT: normal; COLOR: #000
}
#foot-er #footer-copyright P A:hover {
	TEXT-DECORATION: underline
}
#content .scp {
	FONT-VARIANT: small-caps
}
DIV.ab-ad {
	PADDING-RIGHT: 3px; PADDING-LEFT: 3px; BACKGROUND: #eaeaea; =
MARGIN-BOTTOM: 15px; PADDING-BOTTOM: 3px; PADDING-TOP: 0px; TEXT-ALIGN: =
center
}
DIV.ab-ad H2.head-main {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase; COLOR: #ccc
}
DIV.ab-ad H3.head-main {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase; COLOR: #ccc
}
DIV.ab-ad H4.head-main {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase; COLOR: #ccc
}
DIV.ab-ad H3.head-supported {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 5px 0px 0px; COLOR: #000
}
DIV.ab-ad H4.head-supported {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 5px 0px 0px; COLOR: #000
}
DIV.ab-ad H5.head-supported {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 5px 0px 0px; COLOR: #000
}
DIV.ab-ad H4.head-products {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #e0ebf9; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: =
#333; PADDING-TOP: 5px
}
DIV.ab-ad H5.head-products {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #e0ebf9; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: =
#333; PADDING-TOP: 5px
}
DIV.ab-ad H6.head-products {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #e0ebf9; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: =
#333; PADDING-TOP: 5px
}
DIV.ab-ad H5.head-section {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px; COLOR: #0068b3
}
DIV.ab-ad H6.head-section {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px; COLOR: #0068b3
}
DIV.ab-ad DIV.container {
	BORDER-RIGHT: #e0ebf9 1px solid; BORDER-TOP: #e0ebf9 1px solid; =
MARGIN-TOP: 3px; BORDER-LEFT: #e0ebf9 1px solid; BORDER-BOTTOM: #e0ebf9 =
1px solid; BACKGROUND-COLOR: #fff
}
DIV.ab-ad UL {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fff; =
PADDING-BOTTOM: 5px; MARGIN: 0px; TEXT-TRANSFORM: none; PADDING-TOP: =
5px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
DIV.ab-ad UL UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; MARGIN-BOTTOM: 5px; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
DIV.ab-ad LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 2px; MARGIN: =
0px; PADDING-TOP: 2px
}
DIV.ab-ad A {
	COLOR: #0068b3
}
DIV.ab-ad A.sponsor IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 100%; BORDER-RIGHT-WIDTH: 0px; max-width: 118px
}
DIV.ab-ad P.blurb {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
5px 5px; PADDING-TOP: 0px; TEXT-ALIGN: left
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: 7bit
Content-Location: http://www.nature.com/common/style/header_footer_smallfonts.css

#head-er .accessibility-login A.nature-link {
	FONT: bold 110%/80% Garamond, serif; WIDTH: 5em
}
#global-subject-areas H2 {
	FONT-SIZE: 80%
}
#global-subject-areas H3 {
	FONT-SIZE: 80%
}
#global-subject-areas H4 {
	FONT-SIZE: 80%
}
#global-subject-areas H5 {
	FONT-SIZE: 80%
}
DIV.ab-ad {
	FONT-SIZE: 70%
}
#global-subject-areas H3.view {
	FONT-SIZE: 70%
}
#global-subject-areas H4.view {
	FONT-SIZE: 70%
}
#global-subject-areas H5.view {
	FONT-SIZE: 70%
}
#global-subject-areas UL {
	FONT-SIZE: 70%
}
#head-er .accessibility-login .jumplinks {
	FONT-SIZE: 70%
}
#head-er DIV.logon {
	FONT-SIZE: 70%
}
#head-er .user-services {
	FONT-SIZE: 70%
}
#head-er .publications {
	FONT-SIZE: 70%
}
#head-er .search FORM A {
	FONT-SIZE: 70%
}
#head-er .publications-search LABEL {
	FONT-SIZE: 70%
}
#head-er INPUT {
	FONT-SIZE: 70%
}
#head-er SELECT {
	FONT-SIZE: 70%
}
#foot-er {
	FONT-SIZE: 70%
}
.box#natjob H2.natjob {
	FONT-SIZE: 90%
}
.box#natprod H2.natprod {
	FONT-SIZE: 90%
}
.box#natjob UL.natjob LI H3 {
	FONT-SIZE: 80%
}
.box#natjob DIV.natjobmore {
	FONT-SIZE: 80%
}
.box#natprod DIV.natprodmore INPUT {
	FONT-SIZE: 80%
}
UL.natjob UL {
	FONT-SIZE: 70%
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/nature/style/site.css

#head-er .image-user-services-wrap {
	BACKGROUND-COLOR: #db1a21
}
#head-er .image-user-services IMG.journal-header {
	WIDTH: 419px
}
#head-er .image-user-services {
	BACKGROUND: url(/nature/images/journal_header_bg.jpg) no-repeat right =
top
}
#head-er .user-services A {
	BACKGROUND: url(/common/images/icons/fff/arrow_s.gif) #000 no-repeat =
right center
}
#head-er .user-services A:hover {
	BACKGROUND: url(/common/images/icons/fff/arrow_s.gif) #666 no-repeat =
right center
}
A:link {
	COLOR: #36c
}
A:visited {
	COLOR: #639
}
A:hover {
	COLOR: #db1a21
}
#header-login {
	BACKGROUND: none transparent scroll repeat 0% 0%
}
#header-login IMG.journal-header {
	MARGIN-TOP: 19px; WIDTH: 419px; HEIGHT: 74px
}
#header-login {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI A:hover {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI A.on {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI A.on:visited {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI UL.subnav LI.on {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI UL.subnav A:hover {
	BACKGROUND-COLOR: #db1a21
}
H2.society-resources {
	BACKGROUND-COLOR: #db1a21
}
UL.society-resources A:hover {
	BACKGROUND-COLOR: #db1a21
}
H1.page {
	BACKGROUND-COLOR: #db1a21
}
#articlenav H2 {
	BACKGROUND-COLOR: #db1a21
}
#about #content H2 {
	BACKGROUND-COLOR: #db1a21
}
#article-related #journal-header {
	BACKGROUND-COLOR: #db1a21
}
#article-related A.back-to-article:hover {
	BACKGROUND-COLOR: #db1a21
}
#toc #content H4.area {
	COLOR: #db1a21
}
#aop #content H4.area {
	COLOR: #db1a21
}
#article #content #References OL {
	LIST-STYLE-TYPE: decimal
}
.subnav {
	DISPLAY: none
}
.home .jn-home .subnav {
	DISPLAY: block
}
.about-cover .jn-home .subnav {
	DISPLAY: block
}
.aop .jn-aop .subnav {
	DISPLAY: block
}
.about-aop .jn-aop .subnav {
	DISPLAY: block
}
.supplements .jn-supplements .subnav {
	DISPLAY: block
}
.insights .jn-supplements .subnav {
	DISPLAY: block
}
.outlooks .jn-supplements .subnav {
	DISPLAY: block
}
.collections .jn-supplements .subnav {
	DISPLAY: block
}
.tech-features .jn-supplements .subnav {
	DISPLAY: block
}
.web-focuses .jn-web-focuses .subnav {
	DISPLAY: block
}
.biological-sciences .jn-web-focuses .subnav {
	DISPLAY: block
}
.earth-environment .jn-web-focuses .subnav {
	DISPLAY: block
}
.physical-sciences .jn-web-focuses .subnav {
	DISPLAY: block
}
.science-politics .jn-web-focuses .subnav {
	DISPLAY: block
}
.science-culture .jn-web-focuses .subnav {
	DISPLAY: block
}
.multimedia .jn-multimedia .subnav {
	DISPLAY: block
}
.podcast .jn-multimedia .subnav {
	DISPLAY: block
}
.video .jn-multimedia .subnav {
	DISPLAY: block
}
.google .jn-multimedia .subnav {
	DISPLAY: block
}
.blogs .jn-multimedia .subnav {
	DISPLAY: block
}
.about-journal .jn-about-journal .subnav {
	DISPLAY: block
}
.contact-journal .jn-about-journal .subnav {
	DISPLAY: block
}
.about-editors .jn-about-journal .subnav {
	DISPLAY: block
}
.nature-family .jn-about-journal .subnav {
	DISPLAY: block
}
.first-issue .jn-about-journal .subnav {
	DISPLAY: block
}
.for-advertisers .jn-about-journal .subnav {
	DISPLAY: block
}
.for-librarians .jn-about-journal .subnav {
	DISPLAY: block
}
.for-authors-and-referees .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.getting-published .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.guide-authors .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.publication-policies .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.submissions .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.for-referees .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.publishing .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
MAP.journal-nav UL LI UL.subnav LI {
	BACKGROUND: url(/common/images/nav_dots2.gif) #fcf6f6 no-repeat 11px =
5px
}
.home .jn-home {
	BACKGROUND-COLOR: #db1a21
}
.about-cover .jn-home .subnav .jn-about-cover {
	BACKGROUND-COLOR: #db1a21
}
.aop .jn-aop {
	BACKGROUND-COLOR: #db1a21
}
.about-aop .jn-aop .subnav .jn-about-aop {
	BACKGROUND-COLOR: #db1a21
}
.issue .jn-issue {
	BACKGROUND-COLOR: #db1a21
}
.archive .jn-archive {
	BACKGROUND-COLOR: #db1a21
}
.supplements .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.insights .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.insights .jn-supplements .subnav .jn-insights {
	BACKGROUND-COLOR: #db1a21
}
.outlooks .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.outlooks .jn-supplements .subnav .jn-outlooks {
	BACKGROUND-COLOR: #db1a21
}
.collections .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.collections .jn-supplements .subnav .jn-collections {
	BACKGROUND-COLOR: #db1a21
}
.tech-features .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.tech-features .jn-supplements .subnav .jn-tech-features {
	BACKGROUND-COLOR: #db1a21
}
.web-focuses .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.biological-sciences .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.biological-sciences .jn-web-focuses .subnav .jn-biological-sciences {
	BACKGROUND-COLOR: #db1a21
}
.earth-environment .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.earth-environment .jn-web-focuses .subnav .jn-earth-environment {
	BACKGROUND-COLOR: #db1a21
}
.physical-sciences .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.physical-sciences .jn-web-focuses .subnav .jn-physical-sciences {
	BACKGROUND-COLOR: #db1a21
}
.science-politics .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.science-politics .jn-web-focuses .subnav .jn-science-politics {
	BACKGROUND-COLOR: #db1a21
}
.science-culture .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.science-culture .jn-web-focuses .subnav .jn-science-culture {
	BACKGROUND-COLOR: #db1a21
}
.multimedia .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.podcast .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.podcast .jn-multimedia .subnav .jn-podcast {
	BACKGROUND-COLOR: #db1a21
}
.video .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.video .jn-multimedia .subnav .jn-video {
	BACKGROUND-COLOR: #db1a21
}
.google .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.google .jn-multimedia .subnav .jn-google {
	BACKGROUND-COLOR: #db1a21
}
.blogs .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.blogs .jn-multimedia .subnav .jn-blogs {
	BACKGROUND-COLOR: #db1a21
}
.about-journal .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.contact-journal .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.contact-journal .jn-about-journal .subnav .jn-contact-journal {
	BACKGROUND-COLOR: #db1a21
}
.about-editors .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.about-editors .jn-about-journal .subnav .jn-about-editors {
	BACKGROUND-COLOR: #db1a21
}
.nature-family .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.nature-family .jn-about-journal .subnav .jn-nature-family {
	BACKGROUND-COLOR: #db1a21
}
.first-issue .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.first-issue .jn-about-journal .subnav .jn-first-issue {
	BACKGROUND-COLOR: #db1a21
}
.for-advertisers .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.for-advertisers .jn-about-journal .subnav .jn-for-advertisers {
	BACKGROUND-COLOR: #db1a21
}
.for-librarians .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.for-librarians .jn-about-journal .subnav .jn-for-librarians {
	BACKGROUND-COLOR: #db1a21
}
.for-authors-and-referees .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.getting-published .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.getting-published .jn-for-authors-and-referees .subnav =
.jn-getting-published {
	BACKGROUND-COLOR: #db1a21
}
.guide-authors .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.guide-authors .jn-for-authors-and-referees .subnav .jn-guide-authors {
	BACKGROUND-COLOR: #db1a21
}
.publication-policies .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.publication-policies .jn-for-authors-and-referees .subnav =
.jn-publication-policies {
	BACKGROUND-COLOR: #db1a21
}
.submissions .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.submissions .jn-for-authors-and-referees .subnav .jn-submissions {
	BACKGROUND-COLOR: #db1a21
}
.for-referees .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.for-referees .jn-for-authors-and-referees .subnav .jn-for-referees {
	BACKGROUND-COLOR: #db1a21
}
.publishing .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.publishing .jn-for-authors-and-referees .subnav .jn-scientists {
	BACKGROUND-COLOR: #db1a21
}
.press-releases .jn-press-releases {
	BACKGROUND-COLOR: #db1a21
}
.for-authors .jn-for-authors {
	BACKGROUND-COLOR: #db1a21
}
.for-referees .jn-for-referees {
	BACKGROUND-COLOR: #db1a21
}
.about-the-journal .jn-about-the-journal {
	BACKGROUND-COLOR: #db1a21
}
.about-cover .jn-home .subnav .jn-about-cover {
	BACKGROUND-COLOR: #db1a21
}
.about-aop .jn-aop .subnav .jn-about-aop A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.insights .jn-supplements .subnav .jn-insights A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.outlooks .jn-supplements .subnav .jn-outlooks A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.collections .jn-supplements .subnav .jn-collections A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.tech-features .jn-supplements .subnav .jn-tech-features A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.biological-sciences .jn-web-focuses .subnav .jn-biological-sciences A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.earth-environment .jn-web-focuses .subnav .jn-earth-environment A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.physical-sciences .jn-web-focuses .subnav .jn-physical-sciences A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.science-politics .jn-web-focuses .subnav .jn-science-politics A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.science-culture .jn-web-focuses .subnav .jn-science-culture A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.podcast .jn-multimedia .subnav .jn-podcast A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.video .jn-multimedia .subnav .jn-video A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.google .jn-multimedia .subnav .jn-google A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.blogs .jn-multimedia .subnav .jn-blogs A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.contact-journal .jn-about-journal .subnav .jn-contact-journal A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.about-editors .jn-about-journal .subnav .jn-about-editors A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.nature-family .jn-about-journal .subnav .jn-nature-family A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.first-issue .jn-about-journal .subnav .jn-first-issue A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.for-advertisers .jn-about-journal .subnav .jn-for-advertisers A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.for-librarians .jn-about-journal .subnav .jn-for-librarians A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.getting-published .jn-for-authors-and-referees .subnav =
.jn-getting-published A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.guide-authors .jn-for-authors-and-referees .subnav .jn-guide-authors A =
{
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.publication-policies .jn-for-authors-and-referees .subnav =
.jn-publication-policies A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.submissions .jn-for-authors-and-referees .subnav .jn-submissions A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.for-referees .jn-for-authors-and-referees .subnav .jn-for-referees A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.publishing .jn-for-authors-and-referees .subnav .jn-scientists A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.home .jn-home A:link {
	COLOR: #fff
}
.home .jn-home A:visited {
	COLOR: #fff
}
.aop .jn-aop A:link {
	COLOR: #fff
}
.aop .jn-aop A:visited {
	COLOR: #fff
}
.issue .jn-issue A:link {
	COLOR: #fff
}
.issue .jn-issue A:visited {
	COLOR: #fff
}
.archive .jn-archive A:link {
	COLOR: #fff
}
.archive .jn-archive A:visited {
	COLOR: #fff
}
.supplements .jn-supplements A:link {
	COLOR: #fff
}
.supplements .jn-supplements A:visited {
	COLOR: #fff
}
.insights .jn-supplements A:link {
	COLOR: #fff
}
.insights .jn-supplements A:visited {
	COLOR: #fff
}
.outlooks .jn-supplements A:link {
	COLOR: #fff
}
.outlooks .jn-supplements A:visited {
	COLOR: #fff
}
.collections .jn-supplements A:link {
	COLOR: #fff
}
.collections .jn-supplements A:visited {
	COLOR: #fff
}
.tech-features .jn-supplements A:link {
	COLOR: #fff
}
.tech-features .jn-supplements A:visited {
	COLOR: #fff
}
.web-focuses .jn-web-focuses A:link {
	COLOR: #fff
}
.web-focuses .jn-web-focuses A:visited {
	COLOR: #fff
}
.biological-sciences .jn-web-focuses A:link {
	COLOR: #fff
}
.biological-sciences .jn-web-focuses A:visited {
	COLOR: #fff
}
.earth-environment .jn-web-focuses A:link {
	COLOR: #fff
}
.earth-environment .jn-web-focuses A:visited {
	COLOR: #fff
}
.physical-sciences .jn-web-focuses A:link {
	COLOR: #fff
}
.physical-sciences .jn-web-focuses A:visited {
	COLOR: #fff
}
.science-politics .jn-web-focuses A:link {
	COLOR: #fff
}
.science-politics .jn-web-focuses A:visited {
	COLOR: #fff
}
.science-culture .jn-web-focuses A:link {
	COLOR: #fff
}
.science-culture .jn-web-focuses A:visited {
	COLOR: #fff
}
.multimedia .jn-multimedia A:link {
	COLOR: #fff
}
.multimedia .jn-multimedia A:visited {
	COLOR: #fff
}
.podcast .jn-multimedia A:link {
	COLOR: #fff
}
.podcast .jn-multimedia A:visited {
	COLOR: #fff
}
.video .jn-multimedia A:link {
	COLOR: #fff
}
.video .jn-multimedia A:visited {
	COLOR: #fff
}
.google .jn-multimedia A:link {
	COLOR: #fff
}
.google .jn-multimedia A:visited {
	COLOR: #fff
}
.blogs .jn-multimedia A:link {
	COLOR: #fff
}
.blogs .jn-multimedia A:visited {
	COLOR: #fff
}
.about-journal .jn-about-journal A:link {
	COLOR: #fff
}
.about-journal .jn-about-journal A:visited {
	COLOR: #fff
}
.contact-journal .jn-about-journal A:link {
	COLOR: #fff
}
.contact-journal .jn-about-journal A:visited {
	COLOR: #fff
}
.about-editors .jn-about-journal A:link {
	COLOR: #fff
}
.about-editors .jn-about-journal A:visited {
	COLOR: #fff
}
.nature-family .jn-about-journal A:link {
	COLOR: #fff
}
.nature-family .jn-about-journal A:visited {
	COLOR: #fff
}
.first-issue .jn-about-journal A:link {
	COLOR: #fff
}
.first-issue .jn-about-journal A:visited {
	COLOR: #fff
}
.for-advertisers .jn-about-journal A:link {
	COLOR: #fff
}
.for-advertisers .jn-about-journal A:visited {
	COLOR: #fff
}
.for-librarians .jn-about-journal A:link {
	COLOR: #fff
}
.for-librarians .jn-about-journal A:visited {
	COLOR: #fff
}
.for-authors-and-referees .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.for-authors-and-referees .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.getting-published .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.getting-published .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.guide-authors .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.guide-authors .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.publication-policies .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.publication-policies .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.submissions .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.submissions .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.for-referees .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.for-referees .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.publishing .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.publishing .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.press-releases .jn-press-releases A:link {
	COLOR: #fff
}
.press-releases .jn-press-releases A:visited {
	COLOR: #fff
}
.for-authors .jn-for-authors A:link {
	COLOR: #fff
}
.for-authors .jn-for-authors A:visited {
	COLOR: #fff
}
.for-referees .jn-for-referees A:link {
	COLOR: #fff
}
.for-referees .jn-for-referees A:visited {
	COLOR: #fff
}
.about-the-journal .jn-about-the-journal A:link {
	COLOR: #fff
}
.about-the-journal .jn-about-the-journal A:visited {
	COLOR: #fff
}
.jn-about-the-journal {
	MARGIN-TOP: 1em
}
HR.separator {
	DISPLAY: block; VISIBILITY: hidden
}
#toc #content H4.subject {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 1em 0px -1em; =
TEXT-TRANSFORM: uppercase; COLOR: #db1a21
}
#aop #content H4.subject {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 1em 0px -1em; =
TEXT-TRANSFORM: uppercase; COLOR: #db1a21
}
DIV.ad-top {
	CLEAR: both; PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; =
PADDING-LEFT: 0px; FONT-SIZE: 70%; BACKGROUND: #fff; PADDING-BOTTOM: =
7px; COLOR: #ccc; PADDING-TOP: 7px; TEXT-ALIGN: center
}
DIV.ad-top IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 0px; WIDTH: 100%; HEIGHT: 90px; BORDER-RIGHT-WIDTH: 0px; =
max-width: 728px
}
#logged-in {
	BACKGROUND-COLOR: #fceeee
}
#logged-in A {
	COLOR: #000
}
#login {
	BACKGROUND-COLOR: #fceeee
}
#login A {
	COLOR: #000
}
#login INPUT.button {
	BACKGROUND: #db1a21
}
#search A.adsearch:link {
	COLOR: #000
}
#search A.adsearch:visited {
	COLOR: #000
}
#search A.adsearch:hover {
	COLOR: #db1a21
}
DIV.account-buttons A:link {
	BORDER-RIGHT: #333 0.2em solid; BORDER-TOP: #eceae7 0.2em solid; =
BORDER-LEFT: #eceae7 0.2em solid; COLOR: #fff; BORDER-BOTTOM: #333 0.2em =
solid; BACKGROUND-COLOR: #757575
}
DIV.account-buttons A:visited {
	BORDER-RIGHT: #333 0.2em solid; BORDER-TOP: #eceae7 0.2em solid; =
BORDER-LEFT: #eceae7 0.2em solid; COLOR: #fff; BORDER-BOTTOM: #333 0.2em =
solid; BACKGROUND-COLOR: #757575
}
DIV.account-buttons A:hover {
	BORDER-LEFT-COLOR: #333; BORDER-BOTTOM-COLOR: #eceae7; COLOR: #fff; =
BORDER-TOP-COLOR: #333; BACKGROUND-COLOR: #757575; BORDER-RIGHT-COLOR: =
#eceae7
}
 HTML #breadcrumb DIV {
	PADDING-LEFT: 18.4%
}
#breadcrumb DIV {
	PADDING-LEFT: 18.6%; BACKGROUND: #fceeee
}
H1.page-header {
	FONT-SIZE: 120%; TEXT-TRANSFORM: none; BORDER-BOTTOM-STYLE: none
}
H1.page-header A:link {
	TEXT-DECORATION: none
}
H1.page-header A:visited {
	TEXT-DECORATION: none
}
H1.page-header SPAN.first {
	FONT-WEIGHT: bold; FONT-SIZE: 108%; TEXT-TRANSFORM: lowercase; COLOR: =
#f44; FONT-FAMILY: georgia, garamond; LETTER-SPACING: -0.02em
}
H1.page-header SPAN.second {
	FONT-WEIGHT: bold; FONT-SIZE: 108%; TEXT-TRANSFORM: lowercase; COLOR: =
#000; FONT-FAMILY: georgia, garamond; LETTER-SPACING: -0.02em
}
SPAN.page-header-spacer {
	FONT-SIZE: 120%; PADDING-BOTTOM: 4px
}
 HTML #content DIV.online-only-header {
	TOP: -2.2em
}
#content DIV.online-only-header {
	FLOAT: right; WIDTH: 16em; POSITION: relative; TOP: -2.3em; TEXT-ALIGN: =
right
}
#content DIV.online-only-header SPAN {
	PADDING-LEFT: 15px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/online_only.gif) no-repeat left center; COLOR: =
#666
}
DIV.hr {
	MARGIN: 1em 0px
}
DIV.hr-blank {
	MARGIN: 1em 0px; HEIGHT: 1px
}
HR {
	DISPLAY: none
}
DIV.ad-vert IMG {
	max-width: 160px
}
DIV.ad-vert {
	BACKGROUND: #eaeaea
}
DIV.ad-horiz {
	BORDER-TOP-STYLE: none
}
#content DIV.ad-box {
	TEXT-ALIGN: center
}
#content DIV.ad-box P {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 70%; PADDING-BOTTOM: =
4px; MARGIN: 0px; COLOR: #999; PADDING-TOP: 0px; BACKGROUND-COLOR: =
#eaeaea
}
#content DIV.x300x250 {
	CLEAR: right; FLOAT: right; MARGIN: 15px 0px 0px 10px; WIDTH: 300px! =
important
}
A.backtotop:link {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat 0px 0.6em; =
COLOR: #000; MARGIN-RIGHT: 0px; TEXT-DECORATION: none
}
A.backtotop:visited {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat 0px 0.6em; =
COLOR: #000; MARGIN-RIGHT: 0px; TEXT-DECORATION: none
}
A.backtotop:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#content SPAN.english {
	DISPLAY: block
}
#content SPAN.japanese {
	DISPLAY: block
}
#content .japanese {
	FONT-WEIGHT: normal! important; LINE-HEIGHT: 150%
}
 HTML #content-journalnav #content DIV.issue H2 {
	POSITION: relative
}
#content H2 SPAN.japanese {
	FONT-SIZE: 130%! important
}
#article #content H2#atl SPAN.english {
	FONT-SIZE: 90%
}
#content H4 SPAN.japanese {
	FONT-SIZE: 120%! important
}
#content H4 SPAN.english {
	FONT-SIZE: 90%! important; COLOR: #2d2d2d
}
#content DIV.container DIV.entry P.links A.japanese:link {
	FONT-SIZE: 120%! important
}
#content DIV.container DIV.entry P.links A.japanese:visited {
	FONT-SIZE: 120%! important
}
#content P.japanese {
	FONT-SIZE: 100%! important
}
#content P.english {
	FONT-WEIGHT: normal! important
}
#content DIV.no-header {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0px; PADDING-LEFT: 0px; MARGIN-BOTTOM: =
1em; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#content DIV.no-header-art {
	PADDING-RIGHT: 0px; MARGIN-TOP: -2em; PADDING-LEFT: 0px; MARGIN-BOTTOM: =
1em; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#content DIV.no-header2 {
	PADDING-RIGHT: 1px; MARGIN-TOP: 2em; PADDING-LEFT: 1px; PADDING-BOTTOM: =
1px; PADDING-TOP: 1px
}
#content DIV.no-header3 {
	PADDING-RIGHT: 1px; MARGIN-TOP: 1em; PADDING-LEFT: 1px; MARGIN-BOTTOM: =
1em; PADDING-BOTTOM: 1px; PADDING-TOP: 1px
}
#content P.links A.fulltext {
	FONT-WEIGHT: bold
}
 HTML #content TABLE.data {
	FONT-SIZE: 110%; MARGIN: 1em 0px 0px
}
#content TABLE.data {
	CLEAR: both; BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #999 1px solid; PADDING-LEFT: 10px; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #999 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #999 1px =
solid
}
#content TABLE.data TD {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 3px
}
#content TABLE.data TH {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 3px
}
 HTML #content TABLE.data CAPTION {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 0px
}
#content TABLE.data CAPTION {
	PADDING-RIGHT: 0px; PADDING-LEFT: 20px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 5px; MARGIN: 1em 0px 0px; PADDING-TOP: 0px; =
TEXT-ALIGN: left
}
 HTML #content TABLE.data THEAD TH {
	BORDER-TOP-WIDTH: 0px
}
 HTML #content TABLE.data THEAD TD {
	BORDER-TOP-WIDTH: 0px
}
#content TABLE.data THEAD TH {
	BORDER-TOP: #d6d6d6 1px solid; BORDER-BOTTOM: #d6d6d6 1px solid
}
#content TABLE.data THEAD TD {
	BORDER-TOP: #d6d6d6 1px solid; BORDER-BOTTOM: #d6d6d6 1px solid
}
#content TABLE.data TR.odd {
	BACKGROUND-COLOR: #efefef
}
#content TABLE.data TH {
	FONT-WEIGHT: bold; FONT-SIZE: 80%
}
#content TABLE.data TD {
	FONT-SIZE: 80%
}
UL.anchor {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; PADDING-BOTTOM: =
0px; MARGIN: 1em 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
UL.anchor A:link {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat 0px 0.5em
}
UL.anchor A:visited {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat 0px 0.5em
}
UL.anchor A:hover {
	BACKGROUND: url(/common/images/icons/c03/arrow_down.gif) no-repeat 0px =
0.5em
}
UL.anchor A.out:link {
	BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
UL.anchor A.out:visited {
	BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
UL.anchor A.out:hover {
	BACKGROUND: url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em
}
#content UL.anchor UL {
	LIST-STYLE-TYPE: none
}
#content DIV.prevnext {
	CLEAR: both; BORDER-RIGHT: black 1px solid; BORDER-TOP: black 0px =
solid; BACKGROUND: #fff; BORDER-LEFT: black 1px solid; BORDER-BOTTOM: =
black 1px solid; TEXT-ALIGN: center
}
 HTML #content DIV.prevnext {
	HEIGHT: 1%
}
#content DIV.prevnext .hide {
	DISPLAY: none
}
#content DIV.prevnext A:link {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#content DIV.prevnext A:visited {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#content DIV.prevnext A:hover {
	COLOR: #db1a21; TEXT-DECORATION: none
}
#content A.previous:link {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#content A.previous:visited {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#content A.previous:hover {
	BACKGROUND: url(/common/images/arrow_red_left.gif) no-repeat left =
center
}
#content A.japanese:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/fff/japanese.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#content A.japanese:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/fff/japanese.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#content A.japanese:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/fff/japanese.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#content A.english:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; PADDING-BOTTOM: 2px; =
PADDING-TOP: 2px
}
#content A.english:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; PADDING-BOTTOM: 2px; =
PADDING-TOP: 2px
}
#content A.english:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; PADDING-BOTTOM: 2px; =
PADDING-TOP: 2px
}
#content A.next:link {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black.gif) no-repeat right center; FLOAT: =
right; PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: =
10px; PADDING-TOP: 2px
}
#content A.next:visited {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black.gif) no-repeat right center; FLOAT: =
right; PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: =
10px; PADDING-TOP: 2px
}
#content A.next:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat right center
}
#content OL.norm {
	FONT-SIZE: 90%
}
#content UL.norm {
	FONT-SIZE: 90%
}
.icon-inline {
	BACKGROUND-POSITION: left center; PADDING-LEFT: 17px; =
BACKGROUND-REPEAT: no-repeat
}
#content .download-pdf {
	BACKGROUND-IMAGE: url(/common/images/download_pdf.gif)
}
#content DIV.divider {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 1em; MARGIN: =
0px; PADDING-TOP: 1em
}
H2.npg-resources {
	BACKGROUND-COLOR: #757575
}
UL.npg-resources A:hover {
	BACKGROUND-COLOR: #757575
}
#extranav DIV.subscribe-to-nature {
	MARGIN-BOTTOM: 1em; BACKGROUND-COLOR: #eaeaea; TEXT-ALIGN: center
}
#extranav DIV.subscribe-to-nature IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 100%; BORDER-RIGHT-WIDTH: 0px
}
#extranav DIV.produced-with-support {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; MARGIN-BOTTOM: 1em; =
PADDING-BOTTOM: 5px; BORDER-LEFT: #666 1px solid; PADDING-TOP: 5px; =
BORDER-BOTTOM: #666 1px solid
}
#extranav DIV.produced-with-support IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 100%; BORDER-RIGHT-WIDTH: 0px
}
#extranav DIV.produced-with-support H2 {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px 0px 5px; COLOR: #666
}
#extranav DIV.extra {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: black =
1px solid; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; MARGIN: 1em 0px; =
BORDER-LEFT: black 1px solid; PADDING-TOP: 5px; BORDER-BOTTOM: black 1px =
solid
}
#extranav DIV.pink {
	BACKGROUND-COLOR: #fceeee
}
#extranav DIV.pink LI {
	BORDER-BOTTOM: #fceeee 1px solid
}
#extranav DIV.grey {
	BACKGROUND-COLOR: #eaeaea
}
#extranav DIV.grey LI {
	BORDER-BOTTOM: #eaeaea 1px solid
}
#extranav DIV.blue {
	BACKGROUND-COLOR: #f7f9fd
}
#extranav DIV.blue LI {
	BORDER-BOTTOM: #f7f9fd 1px solid
}
#extranav DIV.extra H2 {
	FONT-SIZE: 70%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px 0px 0.5em; COLOR: #db1a21; TEXT-ALIGN: left
}
#extranav DIV.extra UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; BACKGROUND-COLOR: =
transparent
}
#extranav DIV.extra LI {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
2px; PADDING-TOP: 2px; BACKGROUND-COLOR: transparent
}
#extranav DIV.extra LI A:link {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em; COLOR: #36c; =
TEXT-DECORATION: underline
}
#extranav DIV.extra LI A:visited {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em; COLOR: #36c; =
TEXT-DECORATION: underline
}
#extranav DIV.extra LI A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#extranav DIV.extra UL LI.more A:link {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#extranav DIV.extra UL LI.more A:visited {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#extranav DIV.books {
	BORDER-RIGHT: #fcc 1px solid; BORDER-TOP: #fcc 1px solid; BORDER-LEFT: =
#fcc 1px solid; BORDER-BOTTOM: #fcc 1px solid
}
#extranav DIV.books H3 {
	FONT-SIZE: 70%; MARGIN-BOTTOM: 0px
}
#extranav DIV.books H4 {
	DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 70%
}
#extranav DIV.books DIV.image {
	MARGIN-TOP: 10px; TEXT-ALIGN: center
}
#extranav DIV.books UL {
	DISPLAY: inline
}
#extranav DIV.books UL LI {
	DISPLAY: inline
}
#extranav DIV.books DIV.border-top {
	BORDER-TOP: #fcc 1px solid; PADDING-TOP: 15px
}
#extranav DIV.books LI A:link {
	DISPLAY: inline; BACKGROUND: none transparent scroll repeat 0% 0%; =
BORDER-LEFT: #000 1px solid
}
#extranav DIV.books LI A:visited {
	DISPLAY: inline; BACKGROUND: none transparent scroll repeat 0% 0%; =
BORDER-LEFT: #000 1px solid
}
#extranav DIV.books LI A:hover {
	DISPLAY: inline; BACKGROUND: none transparent scroll repeat 0% 0%; =
BORDER-LEFT: #000 1px solid
}
#extranav DIV.books LI A.first:link {
	BORDER-LEFT-WIDTH: 0px
}
#extranav DIV.books LI A.first:visited {
	BORDER-LEFT-WIDTH: 0px
}
#extranav DIV.books LI A.first:hover {
	BORDER-LEFT-WIDTH: 0px
}
.collapse {
	WIDTH: 100%
}
DIV.nature-marketing {
	CLEAR: both; BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #999 1px solid; MARGIN-TOP: 1em; PADDING-LEFT: 10px; =
BACKGROUND: #fceeee; PADDING-BOTTOM: 10px; BORDER-LEFT: #999 1px solid; =
PADDING-TOP: 10px; BORDER-BOTTOM: #999 1px solid
}
DIV.nature-marketing H1 {
	FONT-SIZE: 90%; MARGIN: 0px
}
DIV.nature-marketing IMG {
	FLOAT: right
}
DIV.nature-marketing P {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
DIV.nature-marketing A.subscribe {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em; COLOR: =
#db1a21
}
H2.page {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
H3.page {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
MAP.journal-nav UL LI {
	BACKGROUND-COLOR: #fceeee
}
#home #journalnav .image-holder {
	TEXT-ALIGN: center
}
#home #journalnav .image-holder IMG {
	MARGIN-BOTTOM: 10px
}
#home #journalnav .google {
	BORDER-RIGHT: #ccc 1px solid; BORDER-TOP: #ccc 1px solid; MARGIN: 20px =
0px; BORDER-LEFT: #ccc 1px solid; BORDER-BOTTOM: #ccc 1px solid; =
TEXT-ALIGN: center
}
#home #content DIV.issue {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #666 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #666 1px =
solid
}
#home #content DIV.issue DIV.cover {
	FLOAT: left; WIDTH: 152px! important; MARGIN-RIGHT: 10px
}
#home #content DIV.issue DIV.issue-links {
	MARGIN-LEFT: 162px
}
#home #content DIV.issue P {
	FONT-SIZE: 90%
}
#home #content DIV.issue IMG {
	BORDER-RIGHT: #666 1px solid; BORDER-TOP: #666 1px solid; FLOAT: left; =
BORDER-LEFT: #666 1px solid; WIDTH: 150px! important; BORDER-BOTTOM: =
#666 1px solid; HEIGHT: 200px! important
}
#home #content DIV.issue H1 {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px
}
#home #content DIV.issue-links UL.issue-links {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 10px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#home #content DIV.issue-links UL.issue-links LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 4px; PADDING-TOP: 4px
}
#home #content DIV.issue H1 SPAN.title {
	DISPLAY: block; FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #c33
}
#home #content DIV.issue H1 SPAN.issue {
	FONT-SIZE: 90%
}
#home #content DIV.issue UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#home #content DIV.issue H2 {
	FONT-SIZE: 70%; MARGIN: 0px; COLOR: #c33
}
#home #content DIV.article {
	PADDING-BOTTOM: 1em; MARGIN: 1em 0px
}
#home #content DIV.article .image {
	FLOAT: left; WIDTH: 163px! important; MARGIN-RIGHT: 10px
}
#home #content DIV.article .image IMG {
	BORDER-RIGHT: #666 1px solid; BORDER-TOP: #666 1px solid; FLOAT: left; =
BORDER-LEFT: #666 1px solid; WIDTH: 161px! important; BORDER-BOTTOM: =
#666 1px solid
}
#home #content DIV.article .image2 IMG {
	BORDER-RIGHT: #666 0px solid; BORDER-TOP: #666 0px solid; FLOAT: left; =
BORDER-LEFT: #666 0px solid; WIDTH: 161px! important; BORDER-BOTTOM: =
#666 0px solid
}
#home #content DIV.article .text {
	MARGIN-LEFT: 173px
}
#home #content DIV.article H1 {
	FONT-WEIGHT: bold; FONT-SIZE: 100%
}
#home #content DIV.article H1 SPAN.title {
	DISPLAY: block; FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #c33
}
#home #content DIV.article H1 SPAN.atl {
	FONT-SIZE: 90%
}
#home #content DIV.article P {
	FONT-SIZE: 90%
}
#home #content .featurebox {
	MARGIN-BOTTOM: 20px
}
#home #content DIV.left {
	FLOAT: left; WIDTH: 48%
}
#home #content DIV.right {
	FLOAT: right; WIDTH: 48%
}
#home #content .featurebox UL {
	CLEAR: both; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 80%; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none
}
#home #content .featurebox A.more {
	MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#home #content .featurebox H1 {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-SIZE: 70%; BACKGROUND: =
#db1a21; PADDING-BOTTOM: 3px; TEXT-TRANSFORM: uppercase; COLOR: #fff; =
PADDING-TOP: 3px
}
#home #content .news H1 {
	MARGIN: 0px 0px 10px
}
#home #content .highlight H1 {
	MARGIN: 0px 0px 10px
}
#home #content .news H2 {
	FONT-SIZE: 70%; MARGIN: 1em 0px 0.5em; TEXT-TRANSFORM: uppercase
}
#home #content .highlight H2 {
	FONT-SIZE: 70%; MARGIN: 1em 0px 0.5em; TEXT-TRANSFORM: uppercase
}
#home #content .news A.imagelink {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN-LEFT: 60px
}
#home #content .highlight A.imagelink {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN-LEFT: 60px
}
#home #content .news IMG.newsimage {
	FLOAT: left; WIDTH: 50px; HEIGHT: 50px
}
#home #content .highlight IMG.newsimage {
	FLOAT: left; WIDTH: 50px; HEIGHT: 50px
}
#home #content .news UL {
	MARGIN: 1em 0px 0px
}
#home #content .news LI {
	MARGIN: 1em 0px
}
#home #content .webfocus H1 {
	MARGIN-BOTTOM: 1px
}
#home #content .topten H1 {
	MARGIN-BOTTOM: 1px
}
#home #content .webfocus .title {
	MARGIN-TOP: 0px
}
#home #content .webfocus H2 {
	PADDING-RIGHT: 5px; PADDING-LEFT: 70px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; MIN-HEIGHT: 55px! important; PADDING-BOTTOM: 0px; MARGIN: 0px; =
PADDING-TOP: 5px
}
#home #content .topten P.header {
	PADDING-RIGHT: 5px; PADDING-LEFT: 70px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; MIN-HEIGHT: 55px! important; PADDING-BOTTOM: 0px; MARGIN: 0px; =
PADDING-TOP: 5px
}
#home #content .webfocus P {
	FONT-SIZE: 80%; MARGIN: 1em 0px
}
#home #content .topten H2 {
	FONT-SIZE: 80%; MARGIN: 1em 0px; TEXT-TRANSFORM: uppercase
}
#home #content .topten OL {
	PADDING-LEFT: 23px; FONT-SIZE: 80%; MARGIN: 0px 0px 20px
}
#home #content .topten LI {
	MARGIN: 1em 0px
}
#home #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#home #content H4 SPAN.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#home #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#home #content P.norm {
	FONT-SIZE: 90%
}
#archive #content P {
	FONT-SIZE: 90%
}
#archive #content H3 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; PADDING-BOTTOM: 0.3em; MARGIN: 0px; =
PADDING-TOP: 0.3em
}
#archive #content H3 SPAN {
	FONT-WEIGHT: normal; FONT-SIZE: 80%
}
#archive #content H3 A:link {
	PADDING-LEFT: 15px; BACKGROUND: url(/common/images/archive_plus.gif) =
no-repeat left center
}
#archive #content H3 A:visited {
	PADDING-LEFT: 15px; BACKGROUND: url(/common/images/archive_plus.gif) =
no-repeat left center
}
#archive #content H3 A:hover {
	BACKGROUND: url(/common/images/archive_plus_red.gif) no-repeat left =
center
}
#archive #content H3.open A:link {
	BACKGROUND: url(/common/images/archive_minus.gif) no-repeat left center
}
#archive #content H3.open A:visited {
	BACKGROUND: url(/common/images/archive_minus.gif) no-repeat left center
}
#archive #content H3.open A:hover {
	BACKGROUND: url(/common/images/archive_minus_red.gif) no-repeat left =
center
}
#archive #content H3.open {
	BACKGROUND: #f7f9fd
}
#archive #content H3.open SPAN {
	FONT-WEIGHT: bold
}
#archive #content H4 {
	PADDING-LEFT: 15px; FONT-SIZE: 80%; BACKGROUND: #f7f9fd; =
PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #36c; PADDING-TOP: 0.2em
}
#archive #content UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: #f7f9fd; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none
}
#archive #content UL.listlinks {
	FONT-SIZE: 90%; BACKGROUND: #fff; MARGIN-BOTTOM: 2em
}
#archive #content UL.listlinks A {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat left center
}
#archive #content UL.listlinks A:hover {
	BACKGROUND: url(/common/images/arrow_red_down.gif) no-repeat left =
center
}
#archive #content DIV.container LI {
	MARGIN-LEFT: 15px
}
#archive #content DIV.container LI A:link {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#archive #content DIV.container LI A:visited {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#archive #content DIV.container LI A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#archive #content H3.abuts-h2-above {
	MARGIN-TOP: 1em
}
#archive #content H3.abuts-h2-below {
	MARGIN-BOTTOM: 1em
}
#toc #content H1.page-header SPAN.focus {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 5px; FONT-SIZE: 60%; PADDING-BOTTOM: 1px; =
BORDER-LEFT: #000 1px solid; PADDING-TOP: 1px; BORDER-BOTTOM: #000 1px =
solid; POSITION: relative; TOP: -2px
}
#toc #content H1.page-header {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-SIZE: 100%; PADDING-BOTTOM: =
1px; PADDING-TOP: 1px; POSITION: relative; TOP: -2px
}
#toc #content DIV.issue {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #666 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #666 1px =
solid
}
#toc #content DIV.issue P {
	FONT-SIZE: 90%
}
#toc #content P.norm {
	FONT-SIZE: 90%
}
#toc #content DIV.issue IMG {
	BORDER-RIGHT: #666 1px solid; BORDER-TOP: #666 1px solid; FLOAT: left; =
BORDER-LEFT: #666 1px solid; WIDTH: 150px! important; MARGIN-RIGHT: =
10px; BORDER-BOTTOM: #666 1px solid; HEIGHT: 200px! important
}
#toc #content DIV.issue IMG.first-toc {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: none; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 0px 0px 10px; WIDTH: 413px! important; =
HEIGHT: 165px! important; BORDER-RIGHT-WIDTH: 0px
}
#toc #content DIV.issue DIV.first-toc-centre {
	TEXT-ALIGN: center
}
#toc #content DIV.issue P.mission {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 1em; PADDING-TOP: 0px
}
#toc #content DIV.issue DIV.issue-links {
	FLOAT: left; WIDTH: 60%
}
#toc #content DIV.issue UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
 HTML #toc #content DIV.issue DIV.wrapper {
	WIDTH: 49%
}
#toc #content DIV.issue DIV.wrapper {
	FLOAT: left; MARGIN: 0px; WIDTH: 50%
}
#toc #content DIV.issue UL.second {
	MARGIN-LEFT: 10px
}
#toc #content DIV.issue H2 {
	MARGIN-TOP: 0px; FONT-SIZE: 100%; COLOR: #c33
}
#toc #content DIV.issue H2.insight {
	MARGIN-BOTTOM: 0px
}
#toc #content DIV.issue P.volume {
	MARGIN-TOP: 0px; FONT-SIZE: 90%
}
#toc #content DIV.issue H2 SPAN.free {
	FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #009c00
}
#toc #content DIV.issue H3 {
	FONT-SIZE: 90%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px; COLOR: #000
}
#toc #content DIV.issue H3.also {
	CLEAR: both; PADDING-TOP: 1em
}
#toc #content DIV.news {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 15px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 15px; PADDING-BOTTOM: 15px; MARGIN: 1em 0px; =
BORDER-LEFT: #000 1px solid; PADDING-TOP: 15px; BORDER-BOTTOM: #000 1px =
solid
}
#toc #content DIV.news DIV {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fff; =
PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 5px; opacity: 0.92
}
#toc #content DIV.news H2 {
	MARGIN: 0px; FONT: 170% georgia, serif; COLOR: #ca4439
}
#toc #content DIV.news H2 SPAN {
	COLOR: #fdb7ac
}
#toc #content DIV.news P {
	FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#toc #content DIV.news A.special {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em; COLOR: =
#db1a21
}
#toc #content UL.anchor A {
	DISPLAY: block
}
#toc #content UL.anchor A.online-only {
	PADDING-LEFT: 25px; BACKGROUND: =
url(/common/images/icons/online_only_anchor.gif) no-repeat left 4px
}
#toc #content P.online-only {
	PADDING-RIGHT: 0px; PADDING-LEFT: 15px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/online_only.gif) no-repeat left center; =
PADDING-BOTTOM: 3px; MARGIN: 1em 0px; COLOR: #777; PADDING-TOP: 0px
}
#toc #content SPAN.online-only {
	PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/online_only.gif) no-repeat left center
}
#toc #content DIV.feature {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #999 1px =
solid; PADDING-LEFT: 10px; MARGIN-BOTTOM: 2em; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #999 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #999 1px =
solid
}
#toc #content DIV.feature H3 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: =
0.4em; MARGIN: 0px; COLOR: #c33; PADDING-TOP: 0px
}
#toc #content DIV.feature H4 {
	FONT-SIZE: 100%; MARGIN: 0.5em 0px 1em; FONT-FAMILY: Georgia, serif
}
#toc #content DIV.feature H4 SPAN {
	BORDER-RIGHT: #6c481f 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: =
#6c481f 1px solid; PADDING-LEFT: 2px; FONT-SIZE: 70%; BACKGROUND: =
#ebe3db; PADDING-BOTTOM: 1px; BORDER-LEFT: #6c481f 1px solid; COLOR: =
#6c481f; MARGIN-RIGHT: 3px; PADDING-TOP: 1px; BORDER-BOTTOM: #6c481f 1px =
solid; FONT-FAMILY: Verdana, arial, helvetica, sans-serif
}
#toc #content DIV.feature H4 A:link {
	COLOR: #6c481f; TEXT-DECORATION: none
}
#toc #content DIV.feature H4 A:visited {
	COLOR: #6c481f; TEXT-DECORATION: none
}
#toc #content DIV.feature H4 A:hover {
	COLOR: #db1a21; TEXT-DECORATION: none
}
#toc #content DIV.feature IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 60px; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px
}
#toc #content DIV.feature P {
	FONT-SIZE: 90%; MARGIN-LEFT: 70px
}
#toc #content DIV.feature P.no-image {
	MARGIN-LEFT: 0px
}
#toc #content DIV.clearfix P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#toc #content H3 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px 0px 1em; COLOR: #db1a21; PADDING-TOP: =
3px
}
#toc #content H4 {
	FONT-SIZE: 100%; MARGIN: 0px
}
#toc #content H4 SPAN.page {
	FONT-SIZE: 90%; COLOR: #999
}
#toc #content H4 SPAN.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#toc #content H4 SPAN.artsubhead {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 70%; TEXT-TRANSFORM: =
uppercase
}
#toc #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#toc #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#toc #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#toc #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#toc #content P.seealso {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px 0px
}
#toc #content P.seealso SPAN.seealso {
	FONT-WEIGHT: bold; COLOR: #c33
}
#toc #content A.more-review {
	MARGIN-TOP: 2em; DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#toc #content DIV.insight {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; PADDING-BOTTOM: 10px; =
MARGIN: 0px; BORDER-LEFT: #666 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #666 1px solid
}
#toc #content DIV.insight H3 {
	MARGIN-TOP: 0px; PADDING-TOP: 0px
}
#toc #content DIV.insight H3 SPAN {
	FONT-SIZE: 80%; TEXT-TRANSFORM: uppercase; COLOR: #009c00
}
#toc #content DIV.insight P.produced {
	FONT-SIZE: 70%; FLOAT: left; COLOR: #666
}
#toc #content DIV.insight IMG.supporters {
	FLOAT: left; MARGIN-BOTTOM: 10px; MARGIN-LEFT: 20px
}
#toc #content DIV.insight A.backtotop {
	MARGIN-TOP: 0px
}
#toc #content DIV.insight A.fulltoc {
	DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_red.gif) no-repeat left center; MARGIN: 0px 0px =
2em; COLOR: #db1a21
}
#toc #content DIV.insight A.fulltoc:hover {
	BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
COLOR: #36c
}
#aop #content H2 {
	MARGIN-BOTTOM: 1em
}
#aop #content H3 {
	FONT-SIZE: 100%; MARGIN: 0px; COLOR: #000
}
#aop #content H3.category {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 70%; TEXT-TRANSFORM: =
uppercase
}
#aop #content H4.atl {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; MARGIN-BOTTOM: =
0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#aop #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#aop #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#aop #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#aop #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#aop #content P.seealso {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px 0px
}
#aop #content P.seealso SPAN.seealso {
	FONT-WEIGHT: bold; COLOR: #c33
}
#aop #content P.footer {
	FONT-SIZE: 90%
}
#aop #content P.intro {
	FONT-SIZE: 90%
}
#aop #content A.about-aop {
	FONT-SIZE: 90%
}
DIV.reg-rec UL {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 6px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 6px; PADDING-BOTTOM: 6px; MARGIN: 0px; BORDER-LEFT: =
#666 1px solid; PADDING-TOP: 6px; BORDER-BOTTOM: #666 1px solid; =
LIST-STYLE-TYPE: none; BACKGROUND-COLOR: #fceeee
}
DIV.reg-rec UL LI {
	DISPLAY: block; FONT-SIZE: 70%; MARGIN: 4px 0px
}
DIV.reg-rec UL.toc LI {
	BORDER-BOTTOM: #f7f9fd 1px solid
}
DIV.reg-rec UL LI.first {
	MARGIN-TOP: 0.1em
}
DIV.reg-rec UL LI.last {
	MARGIN-BOTTOM: 0px
}
DIV.reg-rec UL A:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 22px; PADDING-BOTTOM: =
0px; COLOR: #000; PADDING-TOP: 0px; TEXT-DECORATION: none
}
DIV.reg-rec UL A:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 22px; PADDING-BOTTOM: =
0px; COLOR: #000; PADDING-TOP: 0px; TEXT-DECORATION: none
}
DIV.reg-rec UL A:hover {
	TEXT-DECORATION: underline
}
DIV.reg-rec UL A.e-alerts {
	BACKGROUND: url(/common/images/icons/fceeee/envelope.gif) no-repeat 0px =
3px
}
DIV.reg-rec UL A.recommend {
	BACKGROUND: url(/common/images/icons/fceeee/tick.gif) no-repeat 0px 1px
}
DIV.reg-rec UL A.newsfeeds {
	BACKGROUND: url(/common/images/icons/fceeee/newsfeeds.gif) no-repeat =
0px 0px; PADDING-BOTTOM: 2px
}
DIV.reg-rec UL A.purchase {
	BACKGROUND: url(/common/images/icons/f7f9fd/purchase.gif) no-repeat 0px =
0px; PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
DIV.reg-rec UL A.bookmark {
	BACKGROUND: url(/common/images/icons/f7f9fd/bookmark.gif) no-repeat 0px =
0px; PADDING-BOTTOM: 1px; PADDING-TOP: 1px
}
 HTML DIV.reg-rec UL A.japanese {
	BACKGROUND: url(/common/images/icons/f7f9fd/japanese.gif) no-repeat 0px =
3px
}
DIV.reg-rec UL A.japanese {
	BACKGROUND: url(/common/images/icons/f7f9fd/japanese.gif) no-repeat 0px =
1px; PADDING-BOTTOM: 1px; PADDING-TOP: 1px
}
DIV.reg-rec UL.toc {
	BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #f7f9fd
}
#articlenav {
	DISPLAY: block; MARGIN-BOTTOM: 20px
}
#articlenav H2 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
70%; BACKGROUND: #db1a21; PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #fff; =
PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav DIV.prevnext {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 70%; BACKGROUND: =
#fceeee; PADDING-BOTTOM: 3px; MARGIN: 0px; PADDING-TOP: 3px; TEXT-ALIGN: =
center
}
#articlenav DIV.prevnext A.prev {
	PADDING-LEFT: 7px; BACKGROUND: url(/common/images/arrow_black_left.gif) =
no-repeat left center
}
#articlenav DIV.prevnext A.next {
	PADDING-RIGHT: 7px; BACKGROUND: url(/common/images/arrow_black.gif) =
no-repeat right center
}
#articlenav DIV.prevnext A:link {
	COLOR: #000; TEXT-DECORATION: none
}
#articlenav DIV.prevnext A:visited {
	COLOR: #000; TEXT-DECORATION: none
}
#articlenav DIV.prevnext A:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 7px; MARGIN: 1px =
0px 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; BACKGROUND-COLOR: =
#fceeee; TEXT-ALIGN: left
}
#articlenav UL LI {
	MARGIN: 0px; BORDER-BOTTOM: #fceeee 1px solid; BACKGROUND-COLOR: =
#fceeee
}
 HTML #articlenav UL A:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 14px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 14px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 14px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
#articlenav UL A:link {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 14px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_black.gif) no-repeat 5px 8px; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #000; PADDING-TOP: 3px; =
TEXT-DECORATION: none
}
#articlenav UL A:visited {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 14px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_black.gif) no-repeat 5px 8px; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #000; PADDING-TOP: 3px; =
TEXT-DECORATION: none
}
#articlenav UL A:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.page {
	BACKGROUND: url(/common/images/arrow_black_down.gif) no-repeat 4px 8px
}
#articlenav UL A.page:visited {
	BACKGROUND: url(/common/images/arrow_black_down.gif) no-repeat 4px 8px
}
#articlenav UL A.page:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
 HTML #articlenav A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav A.toc:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
#articlenav LI.toc {
	TEXT-ALIGN: center
}
#articlenav A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 3px; PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 3px; PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav A.toc:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 3px; PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav LI.fulltext {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.download-pdf {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.sendtofriend {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.export {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.permissions {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.save {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.purchase-article {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.purchase-issue {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.subscribe {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
 HTML #articlenav UL A.fulltext:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.fulltext:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.fulltext:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.download-pdf:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.download-pdf:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.download-pdf:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.sendtofriend:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.sendtofriend:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.sendtofriend:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.export:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.export:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.export:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.permissions:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.permissions:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.permissions:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.save:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.save:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.save:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-article:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-article:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-article:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-issue:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-issue:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-issue:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.subscribe:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.subscribe:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.subscribe:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
#articlenav UL A.fulltext:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.fulltext:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.sendtofriend:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.sendtofriend:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.export:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.export:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.permissions:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.permissions:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.save:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.save:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-article:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-article:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-issue:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-issue:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.subscribe:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.subscribe:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 3px
}
#articlenav UL A.fulltext:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.download-pdf:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.sendtofriend:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.export:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.permissions:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.save:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.purchase-article:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.purchase-issue:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.subscribe:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.fulltext:link {
	BACKGROUND: url(/common/images/fulltext.gif) #fff no-repeat 5px 4px
}
#articlenav UL A.fulltext:visited {
	BACKGROUND: url(/common/images/fulltext.gif) #fff no-repeat 5px 4px
}
#articlenav UL A.fulltext:hover {
	BACKGROUND: url(/common/images/fulltext.gif) #fff no-repeat 5px 4px
}
#articlenav UL A.download-pdf:link {
	BACKGROUND: url(/common/images/icons/fff/pdf.gif) #fff no-repeat 5px =
4px
}
#articlenav UL A.download-pdf:visited {
	BACKGROUND: url(/common/images/icons/fff/pdf.gif) #fff no-repeat 5px =
4px
}
#articlenav UL A.download-pdf:hover {
	BACKGROUND: url(/common/images/icons/fff/pdf.gif) #fff no-repeat 5px =
4px
}
#articlenav UL A.sendtofriend:link {
	BACKGROUND: url(/common/images/send_to_a_friend.gif) #fff no-repeat 5px =
6px
}
#articlenav UL A.sendtofriend:visited {
	BACKGROUND: url(/common/images/send_to_a_friend.gif) #fff no-repeat 5px =
6px
}
#articlenav UL A.sendtofriend:hover {
	BACKGROUND: url(/common/images/send_to_a_friend.gif) #fff no-repeat 5px =
6px
}
#articlenav UL A.export:link {
	BACKGROUND: url(/common/images/icons/fff/export.gif) #fff no-repeat 5px =
1px
}
#articlenav UL A.export:visited {
	BACKGROUND: url(/common/images/icons/fff/export.gif) #fff no-repeat 5px =
1px
}
#articlenav UL A.export:hover {
	BACKGROUND: url(/common/images/icons/fff/export.gif) #fff no-repeat 5px =
1px
}
#articlenav UL A.permissions:link {
	BACKGROUND: url(/common/images/icons/fff/permissions.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.permissions:visited {
	BACKGROUND: url(/common/images/icons/fff/permissions.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.permissions:hover {
	BACKGROUND: url(/common/images/icons/fff/permissions.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.save:link {
	BACKGROUND: url(/common/images/icons/fff/connotea1.gif) #fff no-repeat =
5px 1px
}
#articlenav UL A.save:visited {
	BACKGROUND: url(/common/images/icons/fff/connotea1.gif) #fff no-repeat =
5px 1px
}
#articlenav UL A.save:hover {
	BACKGROUND: url(/common/images/icons/fff/connotea1.gif) #fff no-repeat =
5px 1px
}
#articlenav UL A.purchase-article:link {
	BACKGROUND: url(/common/images/icons/fff/purchase_article.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-article:visited {
	BACKGROUND: url(/common/images/icons/fff/purchase_article.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-article:hover {
	BACKGROUND: url(/common/images/icons/fff/purchase_article.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-issue:link {
	BACKGROUND: url(/common/images/icons/fff/purchase_issue.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-issue:visited {
	BACKGROUND: url(/common/images/icons/fff/purchase_issue.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-issue:hover {
	BACKGROUND: url(/common/images/icons/fff/purchase_issue.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.subscribe:link {
	BACKGROUND: url(/common/images/icons/fff/subscribe.gif) #fff no-repeat =
5px 3px
}
#articlenav UL A.subscribe:visited {
	BACKGROUND: url(/common/images/icons/fff/subscribe.gif) #fff no-repeat =
5px 3px
}
#articlenav UL A.subscribe:hover {
	BACKGROUND: url(/common/images/icons/fff/subscribe.gif) #fff no-repeat =
5px 3px
}
#articlenav LI.last {
	PADDING-BOTTOM: 5px
}
#articlenav UL.supplementary {
	PADDING-TOP: 7px
}
#articlenav UL A.on {
	BACKGROUND: url(/common/images/arrow_white.gif) #db1a21 no-repeat 5px =
8px; COLOR: #fff
}
#articlenav UL A.on:visited {
	BACKGROUND: url(/common/images/arrow_white.gif) #db1a21 no-repeat 5px =
8px; COLOR: #fff
}
#articlenav UL A.on:hover {
	COLOR: #fff; TEXT-DECORATION: underline
}
#article #content DIV {
	PADDING-BOTTOM: 1.5em
}
#article #content DIV.hr {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px
}
#article #content H2.nibs {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
#article #content H3 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
#article #content H3.norm {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: none transparent =
scroll repeat 0% 0%; PADDING-BOTTOM: 0px; MARGIN: 1em 0px 0px; COLOR: =
#000; PADDING-TOP: 0px
}
#article #content H4.norm {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 1em 0px 0px
}
#article #content H3.location {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; BACKGROUND: none transparent =
scroll repeat 0% 0%; MARGIN: 1em 0px 0px; COLOR: #000
}
#article #content H5.norm {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content H5.norm {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content DIV P.norm {
	FONT-SIZE: 90%; MARGIN: 1em 0px
}
#article #content DIV Q.pullquote {
	PADDING-RIGHT: 10%; BORDER-TOP: #eaeaea 1px solid; DISPLAY: block; =
PADDING-LEFT: 10%; FONT-SIZE: 90%; PADDING-BOTTOM: 0.5em; MARGIN: 1em =
0px 0px; PADDING-TOP: 0.5em; BORDER-BOTTOM: #eaeaea 1px solid; =
TEXT-ALIGN: center
}
#article #content DIV BLOCKQUOTE.pullquote {
	PADDING-RIGHT: 10%; BORDER-TOP: #eaeaea 1px solid; PADDING-LEFT: 10%; =
FONT-SIZE: 90%; PADDING-BOTTOM: 0px; MARGIN: 1em 0px 0px; PADDING-TOP: =
0px; BORDER-BOTTOM: #eaeaea 1px solid; TEXT-ALIGN: center
}
#article #content P.follows-h4 {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article #content P.follows-h5 {
	DISPLAY: inline; FONT-SIZE: 90%
}
#article #content DL {
	FONT-SIZE: 90%
}
#article #content #subjectcategories {
	FONT-SIZE: 70%
}
#article #content #cite {
	FONT-SIZE: 70%
}
#article #content .cite {
	FONT-SIZE: 70%
}
#article #content #errorcor {
	FONT-SIZE: 70%
}
#article #content #errorcor A {
	COLOR: #c03
}
#article #content #artsubhead {
	DISPLAY: block; FONT-SIZE: 70%
}
#article #content #atl {
	FONT-WEIGHT: normal; FONT-SIZE: 130%
}
#article #content #artnote {
	FONT-SIZE: 90%
}
#article #content #aug {
	FONT-SIZE: 90%
}
#article #content P.caff {
	FONT-SIZE: 70%
}
#article #content P.aunote {
	FONT-SIZE: 70%
}
#article #content P.tlnote {
	FONT-SIZE: 70%
}
#article #content P.prdates {
	FONT-SIZE: 70%
}
#article #content P.footnote {
	FONT-SIZE: 90%
}
#article #content P.endnote {
	FONT-SIZE: 90%
}
#article #content P.closenote {
	FONT-SIZE: 90%
}
#article #content P.lead {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content #affiliations-notes {
	MARGIN-TOP: 1em; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px
}
#article #content #articlebody {
	MARGIN-TOP: -1em; PADDING-TOP: 0.5em
}
#article #affiliations-notes OL {
	PADDING-LEFT: 0px; LIST-STYLE-POSITION: inside; FONT-SIZE: 70%; =
MARGIN-LEFT: 0px
}
#article #affiliations-notes {
	MARGIN-TOP: -1em
}
#article #content #abs {
	MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: =
0px
}
#article #content #abs H4.abs {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content #abs P.follows-h4 {
	DISPLAY: inline; FONT-SIZE: 90%
}
#article #content #abs DIV {
	MARGIN-TOP: 1em; PADDING-BOTTOM: 0px
}
#article #content DIV.keyw-abbr H4.keywords {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%
}
#article #content DIV.keyw-abbr P.keywords {
	DISPLAY: inline; FONT-SIZE: 70%
}
#article #content DIV.keyw-abbr H4.abbreviations {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%
}
#article #content DIV.keyw-abbr P.abbreviations {
	DISPLAY: inline; FONT-SIZE: 70%
}
#article DIV.figure-table {
	PADDING-RIGHT: 10px; MARGIN-TOP: 2em; PADDING-LEFT: 10px; =
PADDING-BOTTOM: 10px; PADDING-TOP: 10px; BACKGROUND-COLOR: #fceeee
}
#article DIV.figure-table H5 {
	DISPLAY: block; MARGIN-BOTTOM: 10px
}
#article DIV.figure-table H4.nibs {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; FONT-SIZE: 90%; =
PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; PADDING-TOP: 0px
}
#article DIV.figure-table IMG.thumb {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 10px 10px 0px 0px; WIDTH: 150px; =
BORDER-RIGHT-WIDTH: 0px
}
#article DIV.figure-table P {
	FONT-SIZE: 70%; MARGIN: 10px 0px 10px 160px
}
#article DIV.figure-table A.full {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 25px; BACKGROUND: =
url(/common/images/full_figure.gif) no-repeat left center; =
PADDING-BOTTOM: 4px; PADDING-TOP: 0px
}
#article DIV.figure-table A.high-res {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 25px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/icons/fceeee/high_res.gif) no-repeat left =
center; PADDING-BOTTOM: 4px; MARGIN-LEFT: 160px; PADDING-TOP: 0px
}
#article #content SPAN.journal {
	FONT-STYLE: italic
}
#article #content SPAN.jnumber {
	FONT-WEIGHT: bold
}
#article #content #more DIV.box {
	PADDING-RIGHT: 10px; MARGIN-TOP: 1px; PADDING-LEFT: 10px; BACKGROUND: =
#eaeaea; PADDING-BOTTOM: 20px; PADDING-TOP: 10px
}
#article #content #more DIV.container {
	PADDING-RIGHT: 0px; MARGIN-TOP: 1.5em; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#article #content #more P.intro {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more H4.area {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more P.title {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#article #content #more P.source {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more P.source SPAN.journal {
	FONT-STYLE: italic
}
#article #content #more P.seeall {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more P.seeall A {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_red.gif) =
no-repeat left center; COLOR: #c03
}
#article #content #acknowledgements H4 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content .inline {
	DISPLAY: inline
}
#article #content #acknowledgements H4.footnotes {
	MARGIN-BOTTOM: 0px
}
#article #content #acknowledgements P.pubdate {
	FONT-SIZE: 70%
}
#article #content #acknowledgements P.follows-h4 {
	DISPLAY: inline; FONT-SIZE: 90%
}
#article #content UL.none {
	LIST-STYLE-TYPE: none
}
#article #content #References LI {
	MARGIN-BOTTOM: 0.5em
}
#article #content DIV.ad-right {
	FLOAT: right; PADDING-BOTTOM: 10px; MARGIN: 0px 0px 0px 10px; WIDTH: =
300px! important
}
#article #content DIV.ad-right P {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 70%; PADDING-BOTTOM: =
3px; MARGIN: 0px; COLOR: #ccc; PADDING-TOP: 0px; TEXT-ALIGN: center
}
#article #content DIV.ad-right IMG {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; DISPLAY: block; =
PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: =
0px
}
#article #content DIV.image-legend {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 0px; BACKGROUND: #fceeee; FLOAT: right; =
PADDING-BOTTOM: 0px; MARGIN: 10px 0px 10px 10px; BORDER-LEFT: #000 1px =
solid; WIDTH: 180px! important; PADDING-TOP: 0px; BORDER-BOTTOM: #000 =
1px solid
}
#article #content DIV.image-legend P {
	PADDING-RIGHT: 5px; BORDER-TOP: #000 1px solid; PADDING-LEFT: 5px; =
FONT-SIZE: 70%; PADDING-BOTTOM: 5px; MARGIN: 0px; PADDING-TOP: 5px
}
#article #content DIV.image-legend IMG {
	BORDER-TOP-WIDTH: 0px; DISPLAY: block; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 180px; BORDER-RIGHT-WIDTH: 0px
}
#article #content DIV.image-legend SPAN {
	FONT-STYLE: italic
}
#article #content P.beforeimage-full {
	MARGIN-BOTTOM: 1em
}
#article #content DIV.image-full {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #000 1px =
solid; MARGIN-TOP: 0px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
#fceeee; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: =
10px; BORDER-BOTTOM: #000 1px solid; TEXT-ALIGN: center
}
#article #content DIV.image-full IMG {
	BORDER-RIGHT: #000 1px solid; BORDER-TOP: #000 1px solid; BORDER-LEFT: =
#000 1px solid; BORDER-BOTTOM: #000 1px solid; max-width: 427px
}
#article #content DIV.image-full P {
	TEXT-ALIGN: left
}
#article #content DIV.image-full SPAN {
	FONT-STYLE: italic
}
#article #content P.norm {
	FONT-SIZE: 90%
}
#article #content P.abstract {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content H3.norm SPAN.reviewed {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 80%
}
#article #content P.book-aug {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content P.book-pub {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content H3.listing {
	MARGIN-TOP: 1em; BACKGROUND: none transparent scroll repeat 0% 0%; =
COLOR: #000
}
#article #content H3 SPAN.atl {
	FONT-WEIGHT: bold
}
#article #content H3 SPAN.artsubhead {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 80%; TEXT-TRANSFORM: =
uppercase
}
#article #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#article #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content P.seealso {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px 0px
}
#article #content P.seealso SPAN.seealso {
	FONT-WEIGHT: bold; COLOR: #c33
}
#article #content P.aug-explain {
	FONT-SIZE: 70%; FONT-STYLE: italic
}
#article #content OL.questions P.question {
	FONT-WEIGHT: bold
}
#article #content OL.questions {
	PADDING-LEFT: 0px; LIST-STYLE-POSITION: inside; MARGIN-LEFT: 0px
}
#article #content BLOCKQUOTE IMG.quoteleft {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 12px; MARGIN-RIGHT: 5px; HEIGHT: 10px; BORDER-RIGHT-WIDTH: =
0px
}
#article #content BLOCKQUOTE IMG.quoteright {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN-LEFT: 5px; WIDTH: 12px; HEIGHT: 10px; BORDER-RIGHT-WIDTH: =
0px
}
#article #content BLOCKQUOTE.full {
	MARGIN-TOP: 1em; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/dots_vertical.gif) repeat-y left top; MARGIN-LEFT: =
15px
}
#article #content BLOCKQUOTE.full P {
	MARGIN: 0px
}
#article #content BLOCKQUOTE.full P.quote-source {
	FONT-WEIGHT: bold
}
#article #content BLOCKQUOTE.box {
	BORDER-RIGHT: #000 1px solid; BORDER-TOP: #000 1px solid; FLOAT: right; =
MARGIN: 0px 0px 10px 10px; BORDER-LEFT: #000 1px solid; WIDTH: 180px! =
important; BORDER-BOTTOM: #000 1px solid
}
#article #content BLOCKQUOTE.box P.quote {
	MARGIN: 10px
}
#article #content BLOCKQUOTE.box P.quote-source {
	PADDING-RIGHT: 10px; BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; =
BACKGROUND: #fceeee; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 10px; =
PADDING-TOP: 10px
}
#article A.arrow-back {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat left center
}
#article A.arrow-back:visited {
	BACKGROUND: url(/common/images/arrow_purple_right.gif) no-repeat left =
center
}
#article A.arrow-back:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#article A.arrow-down {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat left center
}
#article A.arrow-down:visited {
	BACKGROUND: url(/common/images/arrow_purple_down.gif) no-repeat left =
center
}
#article A.arrow-down:hover {
	BACKGROUND: url(/common/images/arrow_red_down.gif) no-repeat left =
center
}
#article-related DIV.prevnext {
	BORDER-TOP: #000 1px solid
}
#article-related DIV.prevnext A:link {
	COLOR: #000
}
#article-related DIV.prevnext A:visited {
	COLOR: #000
}
#article-related DIV.prevnext A:hover {
	COLOR: #db1a21
}
#article-related A.previous:link {
	BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center
}
#article-related A.previous:visited {
	BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center
}
#article-related A.previous:hover {
	BACKGROUND: url(/common/images/arrow_red_left.gif) no-repeat left =
center
}
#article-related A.index:link {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat left =
center
}
#article-related A.index:visited {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat left =
center
}
#article-related A.index:hover {
	BACKGROUND: url(/common/images/arrow_red_up.gif) no-repeat left center
}
#article-related A.next:link {
	BACKGROUND: url(/common/images/arrow_black.gif) no-repeat right center
}
#article-related A.next:visited {
	BACKGROUND: url(/common/images/arrow_black.gif) no-repeat right center
}
#article-related A.next:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat right center
}
#article-related DIV.container-sendfriend {
	BACKGROUND: #fceeee
}
#article-related DIV.container-figtab {
	BACKGROUND: #fceeee
}
#article-related DIV.container-image {
	BACKGROUND: #fceeee
}
#article-related DIV.container-image-text {
	BACKGROUND: #fceeee
}
#article-related DIV.container-more {
	BACKGROUND: #fceeee
}
#article-related DIV.container-image-box {
	BACKGROUND: #fceeee
}
#article-related DIV.container-text-box {
	BACKGROUND: #fceeee
}
#article-related DIV.container-figtab A.full {
	BACKGROUND: url(/common/images/icons/fceeee/high_res.gif) no-repeat 0px =
0px; PADDING-BOTTOM: 3px
}
#article-related DIV.container-figtab A.pp {
	BACKGROUND: url(/common/images/icons/fceeee/powerpoint.gif) no-repeat =
0px 0px
}
#article-related DIV.container-extra {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 0px solid
}
#article-related DIV.container-cite {
	CLEAR: both
}
#article-related DIV.container-image {
	BORDER-TOP: #000 1px solid
}
#article-related DIV.container-text-box {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 10px; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px =
solid; PADDING-TOP: 10px
}
#article-related DIV.container-image-box {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
TEXT-ALIGN: center
}
#article-related DIV.container-image-box P {
	FONT-SIZE: 70%; FONT-STYLE: italic
}
#article-related DIV.container-text-box P {
	FONT-SIZE: 90%
}
#article-related DIV.container-sendfriend {
	FONT-SIZE: 90%
}
#article-related DIV.container-extra H2.norm {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-cite H2.norm {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-extra H2.note {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper H2.note {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite H2.note {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-extra P.note {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-extra P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite P.note {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.note {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.aug {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.journal {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-extra P.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite P.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.wrapper P.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related P.viewing {
	FONT-SIZE: 90%; MARGIN: 1em 0px
}
#article-related P.pubmed {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-more A.article {
	MARGIN-TOP: 1em
}
#article-related DIV.container-more {
	BORDER-BOTTOM-WIDTH: 0px
}
#article-related DIV.no-nav {
	BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more UL.auth {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 1em
}
#article-related DIV.container-more UL.auth LI {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0.2em; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#article-related DIV.container-products {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
PADDING-LEFT: 10px; BACKGROUND: #fceeee; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #000 1px =
solid
}
#article-related DIV.container-products H2 {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-products UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; =
LIST-STYLE-TYPE: none
}
#article-related DIV.container-products UL LI {
	MARGIN-TOP: 0.5em
}
#article-related DIV.container-products UL A:link {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat left center
}
#article-related DIV.container-products UL A:visited {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat left center
}
#article-related DIV.container-products UL A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#article-related DIV.alphabet {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
PADDING-BOTTOM: 3px; BORDER-LEFT: #000 1px solid; COLOR: #999; =
PADDING-TOP: 3px; BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.alphabet A:link {
	COLOR: #000
}
#article-related DIV.alphabet A:visited {
	COLOR: #000
}
#article-related DIV.alphabet A:hover {
	COLOR: #db1a21
}
#article-related DIV.alphabet SPAN {
	COLOR: #000
}
#article-related DIV.cooperation {
	FONT-SIZE: 70%; FLOAT: left; MARGIN: 1em 0px 10px; COLOR: #999
}
#article-related DIV.cooperation A.natprod {
	FONT: bold 110% georgia; LETTER-SPACING: -0.04em; TEXT-DECORATION: none
}
#article-related DIV.cooperation A.natprod SPAN.first {
	COLOR: #f44
}
#article-related DIV.cooperation A.natprod SPAN.second {
	COLOR: #444
}
#article-related A.pp {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: =
25px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/fceeee/powerpoint.gif) no-repeat 0px 0px; =
PADDING-BOTTOM: 4px; PADDING-TOP: 0px
}
#article-related DIV.download-plugins {
	MARGIN-TOP: 1em; FLOAT: left
}
#article-related A.download-plugins:link {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 10px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: =
url(/common/images/arrow_blue_down.gif) no-repeat left center; =
BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; =
BORDER-RIGHT-WIDTH: 0px
}
#article-related A.download-plugins:visited {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 10px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: =
url(/common/images/arrow_blue_down.gif) no-repeat left center; =
BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; =
BORDER-RIGHT-WIDTH: 0px
}
#article-related A.download-plugins:hover {
	BACKGROUND: url(/common/images/arrow_red_down.gif) no-repeat left =
center
}
#article-related DIV.container-supplementary {
	BACKGROUND-COLOR: #fceeee
}
#article-related DIV.container-supplementary P {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: 0px
}
#article-related DIV.container-supplementary H2 {
	PADDING-BOTTOM: 0px; COLOR: #000; PADDING-TOP: 0px
}
#article-related DIV.container-supplementary DIV.wrapper {
	PADDING-BOTTOM: 1em; MARGIN: 0px; PADDING-TOP: 1em; BORDER-BOTTOM: =
black 1px solid
}
#article-related DIV.container-supplementary DIV.first {
	BORDER-TOP: black 1px solid
}
#article-related DIV.container-supplementary P.links {
	MARGIN-TOP: 0.5em; FONT-SIZE: 70%
}
#article-related #browser-plugins {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related #browser-plugins H2 {
	CLEAR: both; FONT-SIZE: 90%; MARGIN: 0px; COLOR: #db1a21
}
#article-related #browser-plugins H3 {
	FONT-SIZE: 90%; MARGIN: 1em 0px 0px; COLOR: #000
}
#article-related #browser-plugins DIV {
	FLOAT: left; MARGIN-LEFT: 3%; WIDTH: 30%
}
#article-related #browser-plugins DIV.first {
	MARGIN-LEFT: 0px
}
#article-related #browser-plugins UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#article-related #browser-plugins LI A:link {
	PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
#article-related #browser-plugins LI A:visited {
	PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
#article-related #browser-plugins LI A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em
}
.icon {
	PADDING-RIGHT: 0px; BACKGROUND-POSITION: left center; DISPLAY: block; =
PADDING-LEFT: 20px; PADDING-BOTTOM: 2px; PADDING-TOP: 2px; =
BACKGROUND-REPEAT: no-repeat
}
.i-audio {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/audio.gif)
}
.i-audio-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/audio_grey.gif)
}
.i-bitmap {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/bitmap.gif)
}
.i-bitmap-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/bitmap_grey.gif)
}
.i-compressed {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/compressed.gif)
}
.i-compressed-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/compressed_grey.gif)
}
.i-markup {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/markup.gif)
}
.i-markup-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/markup_grey.gif)
}
.i-movie {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/movie.gif)
}
.i-movie-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/movie_grey.gif)
}
.i-pdf {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/pdf.gif)
}
.i-pdf-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/pdf_grey.gif)
}
.i-postscript {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/postscript.gif)
}
.i-postscript-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/postscript_grey.gif)
}
.i-powerpoint {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/powerpoint.gif)
}
.i-powerpoint-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/powerpoint_grey.gif)
}
.i-svg {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/svg.gif)
}
.i-sif {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/sif.gif)
}
.i-sif-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/sif.gif)
}
.i-svg-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/svg_grey.gif)
}
.i-text {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/text.gif)
}
.i-text-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/text_grey.gif)
}
.i-word {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/word.gif)
}
.i-word-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/word_grey.gif)
}
.i-xls {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/xls.gif)
}
.i-xls-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/xls_grey.gif)
}
.i-microarray {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/microarray.gif)
}
.i-chemical-structures {
	BACKGROUND-IMAGE: =
url(/common/images/icons/fceeee/chemical_structures.gif)
}
.plugin-audio {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/audio.gif)
}
.plugin-audio-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/audio_grey.gif)
}
.plugin-bitmap {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/bitmap.gif)
}
.plugin-bitmap-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/bitmap_grey.gif)
}
.plugin-compressed {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/compressed.gif)
}
.plugin-compressed-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/compressed_grey.gif)
}
.plugin-markup {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/markup.gif)
}
.plugin-markup-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/markup_grey.gif)
}
.plugin-movie {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/movie.gif)
}
.plugin-movie-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/movie_grey.gif)
}
.plugin-pdf {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/pdf.gif)
}
.plugin-pdf-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/pdf_grey.gif)
}
.plugin-postscript {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/postscript.gif)
}
.plugin-postscript-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/postscript_grey.gif)
}
.plugin-powerpoint {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/powerpoint.gif)
}
.plugin-powerpoint-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/powerpoint_grey.gif)
}
.plugin-sif {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/sif.gif)
}
.plugin-svg {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/svg.gif)
}
.plugin-svg-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/svg_grey.gif)
}
.plugin-word {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/word.gif)
}
.plugin-word-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/word_grey.gif)
}
.plugin-xls {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/xls.gif)
}
.plugin-xls-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/xls_grey.gif)
}
.plugin-microarray {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/microarray.gif)
}
.plugin-chemical-structures {
	BACKGROUND-IMAGE: =
url(/common/images/icons/eaeaea/chemical_structures.gif)
}
.plugin-text {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/text.gif)
}
 HTML #content #related-links {
	PADDING-TOP: 5px
}
#content #related-links {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; MARGIN-TOP: 1em; PADDING-LEFT: 10px; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid; BACKGROUND-COLOR: #f7fbff
}
#content #related-links H3 {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0px; PADDING-LEFT: 0px; BACKGROUND: =
none transparent scroll repeat 0% 0%; PADDING-BOTTOM: 0px; =
TEXT-TRANSFORM: uppercase; PADDING-TOP: 0px
}
#content #related-links H4 {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 1em 0px 0px; =
TEXT-TRANSFORM: uppercase
}
#content #related-links P.explain {
	FONT-SIZE: 70%; MARGIN: 0px 0px 1.5em
}
#content #related-links UL.norm {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#content #related-links UL.norm A:link {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #related-links UL.norm A:visited {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #related-links UL.norm A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#content #nature-products {
	PADDING-BOTTOM: 0px! important
}
#content #nature-products H3 {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px! important; =
BORDER-TOP: black 1px solid; PADDING-LEFT: 10px! important; BACKGROUND: =
none transparent scroll repeat 0% 0%; PADDING-BOTTOM: 5px! important; =
MARGIN: 0px; FONT: bold 100% georgia; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 5px! important; BORDER-BOTTOM: black 1px solid; =
LETTER-SPACING: -0.04em
}
#content #nature-products H3 A {
	TEXT-DECORATION: none
}
#content #nature-products H3 SPAN.first {
	COLOR: #f44
}
#content #nature-products H3 SPAN.second {
	COLOR: #444
}
#content #nature-products DIV.natpro {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: black =
0px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; PADDING-BOTTOM: =
10px; BORDER-LEFT: black 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: =
black 1px solid
}
#content #nature-products DIV.natpro SPAN {
	MARGIN-TOP: 4px; DISPLAY: block; FONT-SIZE: 70%
}
#content #nature-products DIV.natpro H4 {
	FONT-WEIGHT: normal; FONT-SIZE: 80%; BACKGROUND: =
url(/common/images/in_cooperation_biocompare.gif) no-repeat right =
center; PADDING-BOTTOM: 0.5em; PADDING-TOP: 0.5em; BORDER-BOTTOM: black =
1px solid
}
#content #nature-products DIV.natpro UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; PADDING-BOTTOM: =
0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#content #nature-products DIV.natpro UL A:link {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #nature-products DIV.natpro UL A:visited {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #nature-products DIV.natpro UL A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#content #nature-products A.natpromore {
	DISPLAY: block; FONT-SIZE: 70%; FLOAT: right; COLOR: #c03; =
TEXT-DECORATION: underline
}
#content DIV#more-like-this {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: black =
1px solid; PADDING-LEFT: 10px; BACKGROUND: #f7fbff; PADDING-BOTTOM: =
10px; MARGIN: 0px; BORDER-LEFT: black 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: black 1px solid
}
#content DIV#more-like-this H3 {
	BACKGROUND: none transparent scroll repeat 0% 0%
}
#content DIV#more-like-this DIV.wrapper {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; MARGIN-BOTTOM: 1.5em; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#content DIV#more-like-this P.explain {
	FONT-SIZE: 70%; MARGIN: 0px 0px 1.5em
}
#content DIV#more-like-this A.article {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#content DIV#more-like-this P.journal {
	FONT-SIZE: 70%; MARGIN: 0px; FONT-STYLE: italic
}
#content DIV#more-like-this P.journal SPAN {
	FONT-STYLE: normal
}
#content DIV#more-like-this H4.area {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase
}
#content DIV#more-like-this A.allmatches:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#content DIV#more-like-this A.allmatches:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#content DIV#more-like-this A.allmatches:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#index-archive #content A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#index-archive #content A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#index-archive #content H2.supp {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px 0px 1em; COLOR: #db1a21; PADDING-TOP: =
3px
}
#index-archive #content DIV.supp {
	MARGIN: 0px
}
#index-archive #content DIV.supp-noimage {
	MARGIN: 0px
}
#index-archive #content DIV.supp H3 {
	FONT-SIZE: 100%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px 0px 0px 70px
}
#index-archive #content DIV.supp-noimage H3 {
	FONT-SIZE: 100%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px
}
#index-archive #content H3 A.atl {
	FONT-SIZE: 90%
}
#index-archive #content DIV.supp IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 60px; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px
}
#index-archive #content DIV.supp P.norm {
	FONT-SIZE: 90%; MARGIN: 0px 0px 0px 70px
}
#index-archive #content DIV.supp P.support {
	FONT-SIZE: 70%; MARGIN: 0px 0px 0px 70px; COLOR: #666
}
#index-archive #content DIV.supp P.doi {
	FONT-SIZE: 70%; MARGIN: 0px 0px 0px 70px
}
#content SPAN.free-access {
	FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #090
}
#index-archive #content DIV.archive A.fulltoc {
	DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 90%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center; MARGIN: 0px =
0px 2em
}
#index-archive #content DIV.archive A.fulltoc:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
UL.sup-anchor {
	FLOAT: left
}
DIV.sup-box {
	WIDTH: 99%; HEIGHT: 110px
}
DIV.sup-reprints {
	BORDER-RIGHT: #746cb0 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: =
#746cb0 1px solid; PADDING-LEFT: 5px; FONT-SIZE: 80%; BACKGROUND: =
#f3fafc; FLOAT: right; PADDING-BOTTOM: 5px; MARGIN: 15px 5px 5px; =
BORDER-LEFT: #746cb0 1px solid; PADDING-TOP: 5px; BORDER-BOTTOM: #746cb0 =
1px solid
}
DIV.sup-reprints UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
DIV.sup-reprints UL LI.sup-heading {
	FONT-WEIGHT: bold; MARGIN-BOTTOM: 5px; COLOR: #000
}
#summary #content A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#summary #content A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#summary #content A.toc:hover {
	BACKGROUND: url(/common/images/arrow_red_up.gif) no-repeat left center
}
#summary #content DIV.prevnext {
	BORDER-TOP: #000 1px solid; MARGIN-TOP: 2em
}
#summary #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#summary #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#sponsor #content IMG.highlit-sponsor {
	FLOAT: left; MARGIN: 0px 10px 10px 0px
}
#sponsor #content P.norm {
	FONT-SIZE: 90%
}
#sponsor #content DIV.container {
	BACKGROUND: url(/common/images/eaeaea.gif) repeat-y center top
}
#sponsor #content DIV.container DIV {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 20px; WIDTH: =
45%; PADDING-TOP: 20px
}
#sponsor #content DIV.container DIV IMG {
	WIDTH: 100%
}
#sponsor #content DIV.container .left {
	FLOAT: left; TEXT-ALIGN: center
}
#sponsor #content DIV.container .right {
	FLOAT: right; TEXT-ALIGN: center
}
#sponsor #content DIV.divider {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: =
url(/nature_CSS/images/divider_sponsor.gif) no-repeat center top; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; HEIGHT: 1px
}
#footer-sponsor {
	TEXT-ALIGN: center
}
#press #content P.norm {
	FONT-SIZE: 90%
}
#press #content DIV.prevnext {
	BORDER-TOP: black 1px solid
}
#press #content H2 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px 0px 0.5em; COLOR: =
#db1a21
}
#press #content H3 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 1em 0px 0px
}
#press #content UL.anchor {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#press #content H4 {
	FONT-SIZE: 100%; MARGIN: 0px
}
#press #content H4 SPAN.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#press #content H4 SPAN.artsubhead {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 70%; TEXT-TRANSFORM: =
uppercase
}
#press #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#press #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#press #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#press #content P.doi-top {
	FONT-SIZE: 70%; MARGIN: 1em 0px
}
#press #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#press #content UL.no-h3 {
	PADDING-TOP: 1em
}
#request-copy #content P.norm {
	FONT-SIZE: 90%
}
#request-copy #content P.norm {
	FONT-SIZE: 90%
}
#request-copy #content LABEL {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#request-copy #content LABEL.terms-cond {
	FONT-WEIGHT: normal
}
#request-copy #content .wrapper INPUT {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0px; MARGIN: 0.2em 0px 0.5em; WIDTH: auto; PADDING-TOP: 0px
}
#request-copy #content TEXTAREA {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0px; MARGIN: 0.2em 0px 0.5em; WIDTH: auto; PADDING-TOP: 0px
}
#request-copy #content INPUT.terms-cond {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0.5em 0px 0px; PADDING-TOP: 0px
}
#request-copy #content .wrapper INPUT {
	WIDTH: 100%
}
#request-copy #content TEXTAREA {
	WIDTH: 100%
}
#request-copy #content FORM {
	PADDING-RIGHT: 15px; PADDING-LEFT: 15px; PADDING-BOTTOM: 10px; =
PADDING-TOP: 10px; BACKGROUND-COLOR: #fceeee
}
#request-copy #content .wrapper SELECT {
	DISPLAY: block; MARGIN: 0.2em 0px 0.5em
}
#request-copy #content INPUT.button {
	MARGIN-TOP: 1em; DISPLAY: block
}
#topten #content P.intro {
	FONT-SIZE: 90%
}
#topten #content H2 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 3px; MARGIN: 0px 0px 1em; COLOR: #db1a21; =
PADDING-TOP: 3px
}
#topten #content P.content {
	PADDING-BOTTOM: 0.2em; MARGIN: 0px; PADDING-TOP: 0.2em
}
#topten #content P.author {
	PADDING-BOTTOM: 0.2em; MARGIN: 0px; PADDING-TOP: 0.2em
}
#topten #content P.issue {
	FONT-SIZE: 80%; PADDING-BOTTOM: 0.2em; MARGIN: 0px
}
#topten #content OL {
	MARGIN-TOP: 0px; PADDING-LEFT: 0px; MARGIN-LEFT: 0px
}
#topten #content OL LI {
	LIST-STYLE-POSITION: inside; FONT-SIZE: 90%; PADDING-BOTTOM: 1em
}
#topten #content P.links {
	FONT-SIZE: 80%; MARGIN: 0px
}
#topten #content H3.art {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px
}
#info #content UL.index A {
	FONT-WEIGHT: bold
}
#info #content UL.index P {
	MARGIN-TOP: 0px
}
#info #content UL.subnav {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0px; MARGIN: 0px 0px 0px 30px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#info #content P.norm {
	FONT-SIZE: 90%
}
#info #content UL {
	FONT-SIZE: 90%
}
#info #content P.no-top-margin {
	MARGIN-TOP: 0px; FONT-SIZE: 90%
}
#info #content UL.no-top-margin {
	MARGIN-TOP: 0px
}
#info #content H2 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
#info #content H3.norm {
	FONT-SIZE: 90%; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px
}
#info #content DIV.illust IMG {
	BORDER-TOP-STYLE: none; BORDER-RIGHT-STYLE: none; BORDER-LEFT-STYLE: =
none; BORDER-BOTTOM-STYLE: none
}
#info #content UL.illust {
	LIST-STYLE-TYPE: none
}
#info #content UL.illust {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#info #content UL.illust LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#info #content DIV.illust {
	TEXT-ALIGN: center
}
#info #content UL.subnav A {
	BACKGROUND: url(/common/images/nav_dots_36c.gif) no-repeat 0px 3px
}
#info #content UL.subnav A:visited {
	BACKGROUND: url(/common/images/nav_dots_639.gif) no-repeat 0px 3px
}
#info #content UL.subnav A:hover {
	BACKGROUND: url(/common/images/nav_dots_db1a21.gif) no-repeat 0px 3px
}
#info #content .natureeditorial P {
	MARGIN-TOP: 0px; FONT-SIZE: 90%
}
#info #content .l {
	CLEAR: left; FLOAT: left; WIDTH: 48%
}
#info #content .r {
	FLOAT: right; WIDTH: 48%
}
#info #content DIV.col2 {
	MARGIN: 10px 0px
}
#info #content DIV.col2 H3 {
	FONT-SIZE: 90%
}
#info #content DIV.col2 H3.col {
	CLEAR: left; FONT-WEIGHT: normal; FONT-SIZE: 90%; FLOAT: left; MARGIN: =
0px; WIDTH: 40%; FONT-STYLE: italic
}
#info #content DIV.col2 H4.col {
	CLEAR: left; FONT-WEIGHT: normal; FONT-SIZE: 90%; FLOAT: left; MARGIN: =
0px; WIDTH: 40%; FONT-STYLE: italic
}
#info #content DIV.col2 H4.col {
	FONT-STYLE: normal
}
#info #content DIV.col2 P.col {
	FONT-SIZE: 90%; FLOAT: left; MARGIN: 0px; WIDTH: 55%
}
#subscribe-now #content DIV.container {
	BORDER-RIGHT: #ccc 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #ccc 1px =
solid; PADDING-LEFT: 10px; MARGIN-BOTTOM: 1em; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #ccc 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #ccc 1px =
solid; BACKGROUND-COLOR: #fafafa
}
#subscribe-now #content DIV.container DIV.column1 {
	PADDING-RIGHT: 1%; BACKGROUND: url(/common/images/eaeaea.gif) repeat-y =
right top; FLOAT: left; WIDTH: 47%
}
#subscribe-now #content DIV.container DIV.column2 {
	PADDING-LEFT: 1%; FLOAT: right; WIDTH: 49%
}
#subscribe-now #content .button {
	BACKGROUND: #db1a21
}
#subscribe-now #content P.intro {
	FONT-SIZE: 90%
}
#subscribe-now #content P.small {
	FONT-SIZE: 70%
}
#subscribe-now #content UL {
	FONT-SIZE: 90%
}
#subscribe-now #content DIV.container P {
	FONT-SIZE: 90%; MARGIN-BOTTOM: 0.5em
}
#subscribe-now #content DIV.container H2 {
	MARGIN-TOP: 0px; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#subscribe-now #content DIV.container H3.first {
	MARGIN-TOP: 0px
}
#subscribe-now #content DIV.container A.register {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 8px; BORDER-TOP: #eaeaea =
1px solid; PADDING-LEFT: 8px; FONT-WEIGHT: bold; FONT-SIZE: 100%; =
BACKGROUND: #db1a21; PADDING-BOTTOM: 2px; BORDER-LEFT: #eaeaea 1px =
solid; COLOR: #fff; PADDING-TOP: 2px; BORDER-BOTTOM: #999 1px solid; =
TEXT-DECORATION: none
}
#subscribe-now #content DIV.container SPAN.freeaccount {
	FONT-WEIGHT: bold
}
#article-related #content DIV.comic {
	BORDER-RIGHT: #fff 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #fff 1px =
solid; PADDING-LEFT: 0px; BORDER-LEFT: #fff 1px solid; BACKGROUND-COLOR: =
#fff
}
#article-related #content DIV.container-comic H2.at1 {
	MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px
}
#article-related #content DIV.container-comic P.atl {
	MARGIN-TOP: 0px; FONT-SIZE: 90%; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: =
0px; PADDING-TOP: 0px
}
#article-related #content DIV.container-comic P.doi {
	MARGIN-TOP: 0px; FONT-SIZE: 80%! important; PADDING-TOP: 0px
}
SPAN.interviewee {
	FONT-WEIGHT: bold
}
SPAN.interviewer {
	FONT-WEIGHT: bold
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/restrict_width/930px.css

#head-er .accessibility-login {
	MARGIN: 0px auto; max-width: 930px
}
#head-er .image-user-services {
	MARGIN: 0px auto; max-width: 930px
}
#head-er .publications-search {
	MARGIN: 0px auto; max-width: 930px
}
DIV.footer-constrain {
	MARGIN: 0px auto; max-width: 930px
}
 HTML #head-er .accessibility-login-wrap {
	TEXT-ALIGN: center
}
 HTML #head-er .image-user-services-wrap {
	TEXT-ALIGN: center
}
 HTML #head-er .publications-search-wrap {
	TEXT-ALIGN: center
}
 HTML DIV.footer-constrain {
	TEXT-ALIGN: center
}
#breadcrumb {
	MARGIN-LEFT: 0px; MARGIN-RIGHT: 0px
}
#constrain {
	CLEAR: both; PADDING-RIGHT: 1%; PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px; TEXT-ALIGN: center
}
#constrain .constrain {
	MARGIN-LEFT: auto; MARGIN-RIGHT: auto; TEXT-ALIGN: left; max-width: =
930px
}
BODY DIV.margin-provider#content {
	MARGIN: 0px
}
#content-journalnav {
	MARGIN-LEFT: 0px
}
#content-extranav {
	MARGIN-RIGHT: 0px
}
#extranav {
	MARGIN-RIGHT: 0px
}
#journalnav {
	MARGIN-LEFT: 0px
}
#article-related #content {
	MARGIN-LEFT: 0px; MARGIN-RIGHT: 0px
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/print.css

#header {
	DISPLAY: none
}
#breadcrumb {
	DISPLAY: none
}
.no-css {
	DISPLAY: none
}
#journalnav {
	DISPLAY: none
}
#journal-header {
	DISPLAY: none
}
#extranav {
	DISPLAY: none
}
#footer {
	DISPLAY: none
}
#footer-sponsor {
	DISPLAY: none
}
#npglogo {
	DISPLAY: none
}
#footer-copyright {
	CLEAR: both; BORDER-TOP: black 2px solid; MARGIN-TOP: 15px; FONT-SIZE: =
90%; COLOR: #999; PADDING-TOP: 15px
}
#footer-copyright A {
	FONT-WEIGHT: normal; COLOR: #000; TEXT-DECORATION: none
}
#footer-copyright .non-copyright {
	DISPLAY: none
}
.print-header {
	MARGIN-BOTTOM: 15px; PADDING-BOTTOM: 15px; BORDER-BOTTOM: black 2px =
solid
}
BODY {
	FONT-SIZE: 12pt; BACKGROUND: #fff; COLOR: #000; FONT-FAMILY: georgia, =
serif
}
H1 {
	FONT-SIZE: 16pt
}
H2 {
	FONT-SIZE: 14pt
}
H3 {
	FONT-SIZE: 12pt
}
H4 {
	FONT-SIZE: 12pt
}
H5 {
	FONT-SIZE: 12pt
}
H6 {
	FONT-SIZE: 12pt
}
A:link {
	FONT-WEIGHT: bold; BACKGROUND: none transparent scroll repeat 0% 0%; =
COLOR: #009; TEXT-DECORATION: underline
}
A:visited {
	FONT-WEIGHT: bold; BACKGROUND: none transparent scroll repeat 0% 0%; =
COLOR: #009; TEXT-DECORATION: underline
}
#content A:link:unknown {
	FONT-WEIGHT: normal; content: " (" attr(href) ") "
}
#content A:visited:unknown {
	FONT-WEIGHT: normal; content: " (" attr(href) ") "
}
#article #content DIV BLOCKQUOTE {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 0.5em; BORDER-TOP: #000 =
1px solid; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; MARGIN: 1.26em =
0px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 0.5em; BORDER-BOTTOM: =
#000 1px solid; TEXT-ALIGN: center
}
#article #content DIV BLOCKQUOTE P {
	MARGIN: 0px
}
#article #content DIV BLOCKQUOTE IMG {
	DISPLAY: none
}
.backtotop {
	DISPLAY: none
}
.back-to-article {
	DISPLAY: none
}
.prevnext {
	DISPLAY: none
}
 HTML #article-related TABLE.data {
	FONT-SIZE: 7pt; WIDTH: 100%
}
#article-related TABLE.data {
	FONT-SIZE: 7pt; WIDTH: 100%
}
#article-related TABLE.data {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #999 1px =
solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; BORDER-LEFT: =
#999 1px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #999 1px solid; =
BORDER-COLLAPSE: collapse; TEXT-ALIGN: left
}
#article-related TABLE.data THEAD {
	FONT-WEIGHT: bold
}
#article-related TABLE.data THEAD TH {
	BORDER-RIGHT: #999 1px solid; BACKGROUND: #f6f6f6; BORDER-LEFT: #999 =
1px solid
}
#article-related TABLE.data THEAD TH.colspan {
	BORDER-RIGHT: #999 1px solid; BORDER-TOP: #999 0px solid; BORDER-LEFT: =
#999 1px solid; BORDER-BOTTOM: #999 1px solid; TEXT-ALIGN: center
}
#article-related TABLE.data THEAD TH.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TD.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY {
	BORDER-TOP: #999 1px solid; BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TR {
	BACKGROUND-COLOR: #f6f6f6
}
#article-related TABLE.data TBODY TR.odd {
	BACKGROUND-COLOR: #fff
}
#article-related TABLE.data TBODY TD {
	BORDER-RIGHT: #999 1px solid; BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TFOOT {
	POSITION: relative
}
#article-related TABLE.data TFOOT TD {
	FONT-SIZE: 7pt; BACKGROUND-COLOR: #fff
}

------=_NextPart_000_0048_01C67920.FE3CF540
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/scripts/minmax.js

// minmax.js: make IE5+/Win support CSS min/max-width/height=0A=
// version 1.0, 08-Aug-2003=0A=
// written by Andrew Clover <and@doxdesk.com>, use freely=0A=
=0A=
/*@cc_on=0A=
@if (@_win32 && @_jscript_version>4)=0A=
=0A=
var minmax_elements;=0A=
=0A=
minmax_props=3D new Array(=0A=
  new Array('min-width', 'minWidth'),=0A=
  new Array('max-width', 'maxWidth'),=0A=
  new Array('min-height','minHeight'),=0A=
  new Array('max-height','maxHeight')=0A=
);=0A=
=0A=
// Binding. Called on all new elements. If <body>, initialise; check all=0A=
// elements for minmax properties=0A=
=0A=
function minmax_bind(el) {=0A=
  var i, em, ms;=0A=
  var st=3D el.style, cs=3D el.currentStyle;=0A=
=0A=
  if (minmax_elements=3D=3Dwindow.undefined) {=0A=
    // initialise when body element has turned up, but only on IE=0A=
    if (!document.body || !document.body.currentStyle) return;=0A=
    minmax_elements=3D new Array();=0A=
    window.attachEvent('onresize', minmax_delayout);=0A=
    // make font size listener=0A=
    em=3D document.createElement('div');=0A=
    em.setAttribute('id', 'minmax_em');=0A=
    em.style.position=3D 'absolute'; em.style.visibility=3D 'hidden';=0A=
    em.style.fontSize=3D 'xx-large'; em.style.height=3D '5em';=0A=
    em.style.top=3D'-5em'; em.style.left=3D '0';=0A=
    if (em.style.setExpression) {=0A=
      em.style.setExpression('width', 'minmax_checkFont()');=0A=
      document.body.insertBefore(em, document.body.firstChild);=0A=
    }=0A=
  }=0A=
=0A=
  // transform hyphenated properties the browser has not caught to =
camelCase=0A=
  for (i=3D minmax_props.length; i-->0;)=0A=
    if (cs[minmax_props[i][0]])=0A=
      st[minmax_props[i][1]]=3D cs[minmax_props[i][0]];=0A=
  // add element with properties to list, store optimal size values=0A=
  for (i=3D minmax_props.length; i-->0;) {=0A=
    ms=3D cs[minmax_props[i][1]];=0A=
    if (ms && ms!=3D'auto' && ms!=3D'none' && ms!=3D'0' && ms!=3D'') {=0A=
      st.minmaxWidth=3D cs.width; st.minmaxHeight=3D cs.height;=0A=
      minmax_elements[minmax_elements.length]=3D el;=0A=
      // will need a layout later=0A=
      minmax_delayout();=0A=
      break;=0A=
  } }=0A=
}=0A=
=0A=
// check for font size changes=0A=
=0A=
var minmax_fontsize=3D 0;=0A=
function minmax_checkFont() {=0A=
  var fs=3D document.getElementById('minmax_em').offsetHeight;=0A=
  if (minmax_fontsize!=3Dfs && minmax_fontsize!=3D0)=0A=
    minmax_delayout();=0A=
  minmax_fontsize=3D fs;=0A=
  return '5em';=0A=
}=0A=
=0A=
// Layout. Called after window and font size-change. Go through elements =
we=0A=
// picked out earlier and set their size to the minimum, maximum and =
optimum,=0A=
// choosing whichever is appropriate=0A=
=0A=
// Request re-layout at next available moment=0A=
var minmax_delaying=3D false;=0A=
function minmax_delayout() {=0A=
  if (minmax_delaying) return;=0A=
  minmax_delaying=3D true;=0A=
  window.setTimeout(minmax_layout, 0);=0A=
}=0A=
=0A=
function minmax_stopdelaying() {=0A=
  minmax_delaying=3D false;=0A=
}=0A=
=0A=
function minmax_layout() {=0A=
  window.setTimeout(minmax_stopdelaying, 100);=0A=
  var i, el, st, cs, optimal, inrange;=0A=
  for (i=3D minmax_elements.length; i-->0;) {=0A=
    el=3D minmax_elements[i]; st=3D el.style; cs=3D el.currentStyle;=0A=
=0A=
    // horizontal size bounding=0A=
    st.width=3D st.minmaxWidth; optimal=3D el.offsetWidth;=0A=
    inrange=3D true;=0A=
    if (inrange && cs.minWidth && cs.minWidth!=3D'0' && =
cs.minWidth!=3D'auto' && cs.minWidth!=3D'') {=0A=
      st.width=3D cs.minWidth;=0A=
      inrange=3D (el.offsetWidth<optimal);=0A=
    }=0A=
    if (inrange && cs.maxWidth && cs.maxWidth!=3D'none' && =
cs.maxWidth!=3D'auto' && cs.maxWidth!=3D'') {=0A=
      st.width=3D cs.maxWidth;=0A=
      inrange=3D (el.offsetWidth>optimal);=0A=
    }=0A=
    if (inrange) st.width=3D st.minmaxWidth;=0A=
=0A=
    // vertical size bounding=0A=
    st.height=3D st.minmaxHeight; optimal=3D el.offsetHeight;=0A=
    inrange=3D true;=0A=
    if (inrange && cs.minHeight && cs.minHeight!=3D'0' && =
cs.minHeight!=3D'auto' && cs.minHeight!=3D'') {=0A=
      st.height=3D cs.minHeight;=0A=
      inrange=3D (el.offsetHeight<optimal);=0A=
    }=0A=
    if (inrange && cs.maxHeight && cs.maxHeight!=3D'none' && =
cs.maxHeight!=3D'auto' && cs.maxHeight!=3D'') {=0A=
      st.height=3D cs.maxHeight;=0A=
      inrange=3D (el.offsetHeight>optimal);=0A=
    }=0A=
    if (inrange) st.height=3D st.minmaxHeight;=0A=
  }=0A=
}=0A=
=0A=
// Scanning. Check document every so often until it has finished =
loading. Do=0A=
// nothing until <body> arrives, then call main init. Pass any new =
elements=0A=
// found on each scan to be bound   =0A=
=0A=
var minmax_SCANDELAY=3D 500;=0A=
=0A=
function minmax_scan() {=0A=
  var el;=0A=
  for (var i=3D 0; i<document.all.length; i++) {=0A=
    el=3D document.all[i];=0A=
    if (!el.minmax_bound) {=0A=
      el.minmax_bound=3D true;=0A=
      minmax_bind(el);=0A=
  } }=0A=
}=0A=
=0A=
var minmax_scanner;=0A=
function minmax_stop() {=0A=
  window.clearInterval(minmax_scanner);=0A=
  minmax_scan();=0A=
}=0A=
=0A=
minmax_scan();=0A=
minmax_scanner=3D window.setInterval(minmax_scan, minmax_SCANDELAY);=0A=
window.attachEvent('onload', minmax_stop);=0A=
=0A=
@end @*/=0A=

------=_NextPart_000_0048_01C67920.FE3CF540--

